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Chapter 1
General Introduction
12 | General Introduction
Purpose and motivation
Due to the aging of the population, Alzheimer’s disease (AD) is a growing socio-
economic problem. The underlying changes associated with this neurodegenerative 
disease start years before clinical manifestation [1]. On a pathological level, AD-
patients show an accumulation of amyloid plaques and neurofibrillary tangles 
which are associated with loss of neurons [2]. Potential disease modifying therapies 
should be given in the earliest stage of the disease, to prevent further neuronal loss. 
To date, no single diagnostic marker is available with sufficiently high predictive 
accuracy rates to provide an accurate diagnosis in a single patient. Consequently, 
there is a need for novel markers to detect the disease at a preclinical stage. 
Magnetic Resonance Imaging (MRI) provides a framework to visualize structural 
and functional changes associated with neurodegenerative diseases in vivo. The 
use of neuroimaging in clinical practice has shifted from exclusion of other diseases 
that may cause the cognitive impairment (e.g. tumor, hemorrhage) to early 
detection (e.g. AD versus healthy aging) and differential diagnosis (e.g. AD versus 
frontotemporal dementia). 
The current thesis aims to expand insight into the use of both conventional (e.g. 
hippocampal volumetry) and novel (e.g. diffusion tensor imaging) MR imaging 
markers for early detection, diagnosis and prognosis of AD. Associations with 
clinical and cerebrospinal fluid (CSF) biomarkers are explored to further disentangle 
the underlying nature and course of the disease.
GENERAL INTRODUCTION 
Alzheimer’s disease and MCI
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting 
approximately 250.000 people in the Netherlands, and 35 million individuals worldwide 
[3]. Despite numerous research, AD is currently incurable and the number of patients 
is expected to exceed 115 million by 2050. The term mild cognitive impairment 
(MCI) has been introduced to describe patients who do not fulfill clinical criteria for 
dementia, but who do have objective evidence of memory deficits without notable 
interference with daily life activities [4]. MCI patients carry an increased risk of 
developing AD, with about 10-15% progressing to AD per year in academic 
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clinical settings. In these subjects, MCI is considered to be a transitional 
phase. However, not all MCI-patients progress to AD: some develop another 
type of dementia, while others improve or remain stable [5]. The course 
of AD is also variable: not all patients progress at the same rate and the 
factors influencing or predicting progression are not well known [6]. Better 
modeling of disease progression in individual subjects will allow us to predict 
when cognitive abilities may break down and when social and behavioral 
disturbances may arise. Staging models based on dynamic biomarkers 
(Figure 1)[7] will furthermore allow us to evaluate treatment effects of novel drugs 
in clinical trials based on the effects of a specific drug in slowing down or stopping 
transition from one stage to the next. 
             
 Figure 1. Hypothetical model of imaging biomarkers in  Alzheimer’s disease [7].
Diagnosing AD
Pathophysiology
The neuropathological hallmarks of AD are extracellular senile plaques 
consisting of amyloid-beta (Ab) and intracellular neurofibrillary tangles 
consisting of hyperphosporylated tau, both associated with neuronal loss. 
Ab is a peptide produced by cleavage of the Ab precursor protein (APP) 
[8] and deposition of amyloid plaques is widely distributed throughout the 
cortex, starting in the posterior association cortices, and showing a relative 
sparing of the medial temporal lobe (MTL) [2]. The ‘amyloid cascade hypothesis’ 
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was recently postulated in which Ab starts to accumulate approximately 15 years 
before the onset of clinical symptoms [7, 9]. Formation of neurofibrillary tangles on 
the other hand, is postulated to start in the MTL and spreads into adjacent lateral 
temporal and association parietal cortices, followed by prefrontal cortices and other 
neocortical areas (e.g. motor and sensory areas) in later stages of the disease [10]. 
Plaques and tangles are associated with regional neuronal loss, cortical atrophy and 
cognitive decline [2, 10]. Both hallmarks of AD can most accurately be quantified 
post-mortem, or in vivo by means of CSF analysis or beta-amyloid Positron Emission 
Tomography (PET) imaging [11]. 
 
Clinical	assessment
A clinical diagnosis of MCI or dementia involves assessing cognitive functions as 
well as the degree of interference in daily life activities, psychological well-being 
and burden of care. These elements can be evaluated by means of an interview 
with both patient and caregiver(s), and neuropsychological assessment. The latter 
one plays a major role in determining the nature and extent of the cognitive 
dysfunction. Additional investigations are needed to clarify the underlying cause of 
the cognitive impairment. Some causes can be identified by means of a blood test 
or neurological examination, but for most neurodegenerative disorders imaging or 
CSF assessment are needed. 
Macrostructural	neuroimaging
MRI or computed tomography (CT) are routinely used to exclude other diseases 
that can cause the cognitive impairment. They can also provide positive evidence 
for AD. Such studies mainly focussed on the MTL, which is affected early in the 
disease process. However, atrophy of the MTL is non-specific for AD [12] and tissue 
loss is not limited to this region [13]. To evaluate the degree of atrophy in the MTL, 
clinicians prefer the use of visual rating scales because these instruments are readily 
available, quick and easy to perform [14]. However, visual rating scales show lower 
predictive accuracy rates and higher inter and intraindividual variability effects [15] 
compared to volumetric (hippocampal) measurements. Manual volumetry is still 
considered gold standard in research practice [16-18], but is time consuming which 
thereby limits routine clinical or large-scale research use. Automated hippocampal 
measurement needs much less rater time and shows no interrater variability effects, 
but might be susceptible to scanner and scan protocol variability. 
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Novel	imaging	markers
Novel imaging markers have now been developed to evaluate changes in gray (GM) 
and white matter (WM), both on a structural (e.g. diffusion tensor imaging (DTI)) and 
functional level (e.g. resting state functional MRI). These markers can be used to test 
structural and functional connectivity between brain regions. Structural markers 
are able to visualize physical connectivity between brain regions, while functional 
connectivity markers display functional connections between brain regions that 
are not necessary directly physically connected. In early AD, both structural and 
functional connectivity are altered [19-24] and there is some evidence that these 
measures become abnormal before macroscopic atrophy is evident. Thus, by means 
of these techniques, structural disconnection may be detected at a stage where 
macrostructural changes such as hippocampal atrophy may not have become visible 
yet, and are linked with neuropsychological performance [25, 26]. 
Structural connectivity markers
DTI measures the random motion of water molecules within tissue, reflecting 
structural organization. Diffusion anisotropy (FA) is often regarded as an index 
reflecting microscopic tissue integrity and correlates with the integrity of the axonal 
membrane [27]. Reduction of FA values suggests a reduction in axon number, 
an impairment of axonal flow, or both. An index of the magnitude of diffusion 
independent of the direction is mean diffusivity (MD). An increase in MD is thought 
to reflect enlargement in the extracellular space due to altered cytoarchitecture 
(i.e. loss of neurons, axons, and dendrites), suggesting immaturity or degeneration 
of the tissue leading to elevated water diffusivity within these regions [28, 29]. 
Alterations in FA or MD could also be due to diffusion changes either parallel or 
perpendicular to the principal direction of the tensor. These measurements are 
referred to as axial (AXD), and radial diffusivity (RAD), respectively. An increase in 
RAD is thought to signify increased space between fibers (suggesting demyelination 
or dysmyelination) [30] whereas increases in AXD suggest axonal damage [31]. 
Functional connectivity markers
Functional connectivity can be tested using the BOLD signal in task-related functional 
or resting-state MRI paradigms [32-34]. Functional connections can be derived from 
their temporal pattern in neurophysiologic change or activation during task-related 
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or task-free research environments [35]. Task-related decreases are found in certain 
regions which remain active in an organized fashion during the resting state of the 
brain [36, 37]. One of these ‘resting state networks’ is the default mode network 
which is particularly relevant for aging and dementia since its vulnerability to 
atrophy, deposition of the amyloid protein, and reduced glucose metabolism [38].
  
Biomarkers	in	cerebrospinal	fluid	(CSF)
CSF biomarkers are increasingly used to detect brain changes associated with AD in 
vivo. In CSF, decreases in levels of beta-amyloid 1-42 (Ab 1-42) are found, together 
with increases in total (t-tau) and phosphorylated tau (p-tau). As the presence of 
these protein levels reflects AD pathology, these CSF biomarkers have been shown 
to differentiate patients with AD from control subjects [39] and to predict conversion 
rate in MCI-patients [40]. Both MRI and CSF are valuable markers of disease [41], 
however, the relation between these markers has been less extensively studied.
To cure or not to cure?
Despite tremendous research, AD is currently incurable. Cholinesterase inhibitors 
are most widely used to reduce the behavioural disorders associated with the 
disease [42]. Non-pharmalogical interventions are often additionally implemented 
to further reduce behavioural disturbances, and to reduce caregiver burden [43, 
44].
Aims and outline    
MR imaging provides more information than macrostructural atrophy and vascular 
abnormalities. However, the added value and exact position of novel imaging 
techniques in the diagnostic field of AD remains unclear. We will investigate 
whether MRI investigation is necessary in the diagnostic process of AD and which 
MRI measurements can incrementally contribute to the early and specific diagnosis 
of Alzheimer disease. The overall aim of this thesis is to evaluate the clinical value 
of novel imaging markers for AD in relation to current (gold standard) methods (i.e. 
hippocampal volumetry, visual rating scale). The first part of the thesis evaluates 
well-known imaging techniques which assess gray matter atrophy in the brain. In 
the second part we will examine the discriminative and predictive value of a novel 
imaging marker for AD: Diffusion Tensor Imaging (DTI). In the third part, we will 
investigate the robustness of structural and functional abnormalities in AD. 
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1. Macrostructural imaging
The current approach in most of Dutch memory clinics consists of cognitive 
examination of patients by means of a neuropsychological test battery, together 
with a neurological investigation, (hetero)anamnesis, a blood test and an MRI scan. 
This clinical protocol forms the starting point of the thesis: 
1. ‘What is the added value of volumetric MRI to neuropsychological test 
performance?’
In Chapter	2, we investigate if MR imaging markers increase predictive accuracy for 
AD relative to a model that only includes demographical and neuropsychological 
information. Furthermore, the importance of MTL atrophy in AD allows us to 
formulate a second question: 
2. ‘Which measurement of MTL atrophy is the most sensitive to predict 
AD-conversion in subjects with MCI?’. 
Chapter 3 investigates the predictive value of four different MTL atrophy 
measurements for conversion to AD in subjects with MCI. Two questions result from 
recent evidence stating that AD pathology is not restricted to the MTL: 
3. ‘Which regions in the brain can discriminate between controls, MCI and 
AD?’ 
&
4. ‘Are different techniques assessing gray matter atrophy in the brain 
leading to the same pattern of abnormalities throughout the same 
dataset?’ 
Chapter	4 describes the discriminative value of several techniques measuring GM 
atrophy in the brain, both in and outside medial temporal lobe regions. 
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2. Connectivity markers
The second part of the thesis examines the discriminative and predictive value of a 
novel imaging marker for AD: DTI. The main questions are: 
5. ‘What is the added value of DTI in discriminating healthy controls, MCI 
and AD?’ 
&
6. ‘Is DTI superior to MTL measurements?’. 
Chapter 5 will assess the value of DTI as imaging marker for AD in relation to MTL 
measurements by means of a meta-analysis. The same question will be addressed in 
chapter 6 by means of a case-control study. Differences in both gray matter atrophy 
and WM integrity are evaluated in a multi-center cohort of healthy old subjects, 
MCI and AD-patients. The predictive value of both volumetry and DTI for cognitive 
decline at 2 years follow-up is furthermore investigated.
3. Methodological issues
The third and last part of the thesis investigates the robustness of structural and 
functional abnormalities in AD. The main question is: 
7. ‘Are structural and functional imaging techniques influenced by internal 
(e.g. patients age) and external (e.g. software, hardware) factors?’
Chapter 7 examines the consistency of FreeSurfer, an automated segmentation 
tool, to detect structural abnormalities under varying processing conditions, and in 
relation to manual volumetry. 
Chapter 8 investigates the validity of resting state fMRI as a marker for disease, by 
evaluating the stability or test-retest reproducibility of resting state networks over 
time in a healthy population. 
Chapter 9 presents our overall conclusions and puts the main findings presented in 
this thesis in the context of our current knowledge about AD.
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Part I
Grey matter atrophy in (early) AD

Lies Clerx,	 Eva	 Dierckx,	 Laura	 van	 de	 Pol,	 Ineke	 van	 Rossum,	
Frans	 Verhey,	 Pauline	 Aalten,	 Frederik	 Barkhof,	 Robin	 Wolz,	 
Daniel	 Rueckert,	 Giovanni	 B.	 Frisoni,	 Magdalini	 Tsolaki,	 
Flavio	Nobili,	Yvonne	Freund-Levi,	Asa	Wallin,	Lutz	Frölich,	Harald	 
Hampel,	Hilkka	Soininen,	Philip	Scheltens	and	Pieter	Jelle	Visser
Chapter 2
The added value of MRI-biomarkers to 
neuropsychological test performance 
for the prediction of AD in subjects 
with MCI
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ABSTRACT
Background. Neuropsychological tests and magnetic resonance imaging (MRI) 
measures can identify Alzheimers’s disease (AD) in the stage of mild cognitive 
impairment (MCI). We aimed to investigate whether measurements of 
medial temporal lobe (MTL) atrophy could increase the predictive accuracy of 
neuropsychological tests for AD-type-dementia. 
Methods.	 We selected 184 MCI-subjects from DESCRIPA and from the 
Alzheimer Dementia cohort of the VU University Medical center in Amsterdam. 
Neuropsychological tests for attention, memory, fluency, executive functioning and 
visuoconstruction were included. MTL atrophy measurements consisted of a visual 
rating scale and an automated hippocampal measurement. Outcome measure was 
the odds ratio for progression to AD-type dementia in 2 years.
Results.	 Among neuropsychological tests the odds ratio was highest for the 
wordlist delayed recall (3.59). The odds ratio was 4.14 for the MTA-score and 7.78 
for hippocampal volume. Hippocampal volume but not MTA-score increased the 
predictive accuracy of delayed recall score for AD-type dementia after 2 years (AUC 
= 0.81; p<.001). Predictive accuracy was increased both in subjects with normal 
and abnormal delayed recall scores at baseline. In the subgroup of subjects with 
an MMSE score >27, both delayed recall and MRI at baseline were predictors of 
conversion. In the group of subjects with a normal MTA-score (<3), only volumetric 
measurements predicted AD. 
Conclusion.	 These results provide further support for the clinical use of MRI 
biomarkers for identification of prodromal AD among MCI-patients. Assessment of 
hippocampal volume together with a delayed recall test may be sufficient for short-
term prediction of AD in subjects with MCI. 
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INTRODUCTION
Due to the aging population, the prevalence and concomitant costs of 
neurodegenerative diseases including Alzheimer’s Disease (AD) are expected to 
increase dramatically [1]. Before entering the phase of dementia, subjects with AD 
experience a period in which they have so called mild cognitive impairments (MCI) 
without encountering interference in daily life activities. Identification of subjects 
with MCI at risk for AD is crucial, as these subjects are useful candidates for drug 
trials which aim to slow down disease progression. 
New criteria for Alzheimer’s disease (AD) recommend the use of cerebrospinal 
fluid (CSF), magnetic resonance imaging (MRI) or positron-emission tomography 
(PET) biomarkers for the diagnosis of AD in subjects with MCI [2, 3]. However, 
in non-academic settings evaluation of AD pathology by means of CSF and PET 
biomarkers is often not feasible. In these settings diagnosis is primarily based upon 
neuropsychological evaluation, anamnestic information and MRI measurements. 
Despite numerous studies evaluating MRI measurements as a candidate biomarker 
for AD, the added value of MRI measures over neuropsychological tests is not clear 
yet.
Neuropsychological tests that can best predict AD-type dementia in subjects with 
MCI are typically episodic memory tasks, such as immediate and delayed recall [4, 
5]. However, according to some studies, assessing other cognitive domains such 
as categorical fluency [6], visuoconstruction [7] and tasks of executive functioning 
[4, 8] may also be useful in predicting AD-type dementia in MCI-patients. MRI is 
routinely used to exclude other diseases or other causes of dementia [9] and medial 
temporal lobe (MTL) atrophy as assessed on structural MRI has furthermore proven 
to be an effective clinical aid in the prediction of AD-type dementia in subjects with 
MCI [10, 11].
Previous studies that examined the added value of MRI over neuropsychological 
tests are inconclusive in nature. In one study, hippocampal and entorhinal cortex 
volumes showed limited added value to memory and measures of functioning [12], 
whereas in other studies [13, 14] was found that a combination of both memory 
and MRI increased predictive accuracy over each measurement alone. In a study 
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of Zhou et al. [15] was found that the combination of the ADAS-Cog with the CDR-
sum of boxes had a slightly better predictive accuracy than the ADAS-Cog with 
cortical thickness of the right temporal lobe (conversion rate 92.7% and 88.8% 
respectively). Another study found that neuropsychological tests and MRI were the 
most informative techniques (compared to Positron Emission Tomography (PET)), 
with 84% and 82% correct classifications [16]. 
The aim of the present study was to evaluate the added value of MRI over 
neuropsychological tests for the prediction of AD in subjects with MCI in a memory 
clinic population. Atrophy of the MTL was assessed using an automated atlas-based 
hippocampal measurement (LEAP) [11, 17] and a qualitative visual rating scale (MTA-
score) [18]. We also investigated whether hippocampal volume had predictive value 
for AD-type dementia in a group of subjects with a high score on the Mini-Mental 
State Examination (MMSE) or with a normal MTA score. Test sequence analyses 
were performed to determine the optimal order of cognitive tests and hippocampal 
volume for the prediction of AD-type dementia [19].
MATERIALS AND METHODS
Subjects
Subjects with MCI were selected from DESCRIPA (Development of Screening 
Guidelines and Clinical Criteria for Predementia AD) [20]. The VUmc center, one 
of the DESCRIPA centers, contributed an additional sample of subjects that were 
seen outside the DESCRIPA inclusion period. Inclusion criteria were: age 54 years 
or older and diagnosis of MCI. Exclusion criteria were diagnosis of dementia 
at baseline or any somatic, psychiatric or neurological disorder (e.g. epilepsy) 
that might have caused the cognitive impairment [20]. For the present study, 
participants were selected from 9 of the 20 participating centers as only in those 
centers both neuropsychological data and MRI measurements were available. Of 
the 270 subjects with MCI in these sites, 204 had MRI data available and, 184 of 
those patients also had complete data for the neuropsychological tests (see below) 
and completed at least 1 follow-up. There were no differences between included 
and excluded subjects with respect to age, gender, educational level, hippocampal 
volume, and cognitive test scores, except for the MMSE-score (included subjects: 
27.47 (2.08) vs. excluded subjects: 26.29 (2.78); p <.001). 
Chapter 2: Added value of MRI-biomarkers | 31 
Clinical assessment and follow-up
All participants underwent a standard diagnostic workup, including clinical history, 
medical and neurological examination, clinical chemistry, functional evaluation 
using the Clinical Dementia Rating scale (CDR) [21], the MMSE, and rating scales for 
depression and neuropsychiatric symptoms. Baseline diagnosis of MCI was made 
according to the criteria of Petersen et al. [22]. Cognitive impairment was defined 
as a z-score <-1.5 SD on any of the following tests: the learning measure or delayed 
recall of a word list learning test or equivalent memory test, the trail making test 
(TMT) part A, TMT part B, categorical fluency, Rey figure copy test or an equivalent 
test [23]. Outcome measure was conversion to AD-type dementia after 2 years. AD 
diagnosis was made according to the DSM-IV [24] and NINCDS-ADRDA criteria, [25]. 
Cognitive testing
A neuropsychological battery was carried out in order to evaluate performance in 
several cognitive domains. In each center a primary test for verbal memory was 
chosen that was identical or at least similar to tests used in the other participating 
centers (memory: Rey Auditory Verbal Learning Test (n=136), Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD, n=28) or Buschke Selective 
Reminding Test (n=20); attention and executive functioning: all TMT-A and TMT-B 
(n=184), categorical fluency animals (n=123) or fluency animals, fruits or cartypes 
(n=61); visuoconstruction: Rey Figure copy test (n=136), CERAD copy figures (n=28), 
Copy figures from the Mental Deterioration Battery (n=20)) [20]. Raw scores on 
neuropsychological tests were corrected for age, education, and sex, in accordance 
with locally collected or published normative data and expressed as z-scores, which 
were used for further analysis.
MRI acquisition and analysis
At each site, patients were scanned according to the routine MRI-protocol. 
Scanners and protocols at different sites varied but all scanning was performed at 
1.0 or 1.5 Tesla. All scans included a three-dimensional T1 weighted gradient echo 
(3DT1) sequence and a fast fluid attenuated inversion recovery (FLAIR) sequence. 
Two measurements of MTL atrophy were included: an automatically measured 
hippocampal volume based on atlas registration (LEAP) [17] and a qualitative visual 
rating scale [18]. Elaborate descriptions of these MRI protocols and measurements 
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are stated in a previous publication [11].
APOE genotype
APOE genotype was determined by polymerase chain reaction of genomic DNA 
extracted from EDTA anticoagulated blood in 154 subjects. Subjects were classified 
as APOE-e4 carriers or non-carriers. 
Statistical analysis
Statistical analyses were performed with IBM SPSS version 20.0 (Chicago, IL, USA) 
and statistical software package R (R foundation, Vienna, Austria). Differences 
between groups were analyzed using an independent sample t-test for continuous 
variables and chi-square test for categorical variables. Area under the curve 
(AUC) for AD-type dementia after 2 years follow-up was calculated using a time-
dependent ROC curve in R [26]. Sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV) and odds ratio (OR) for conversion to AD-
type dementia after 2 years were calculated using data-driven cut-points based on a 
time dependent ROC. Cut-points were determined by maximizing the Youden Index 
(sensitivity+specificity-1) for prediction of AD-type dementia at 2-years follow-up. 
Significance was set at p<0.05 and 95% confidence intervals (CI) were calculated. 
Data for each neuropsychological test and MRI-measurement were dichotomized 
into separate variables according to these cut-points. Univariate and multivariate 
logistic regression analyses were performed for dichotomized variables to assess 
whether a combination of markers was more predictive for AD than each of these 
measurements alone. Demographic variables and MMSE score were added in 
the first step, univariate significant cognitive test scores in the second step and 
hippocampal volume or MTA score in the third step. After each step we only retained 
statistically significant predictors in the model. Sensitivity and specificity values 
were calculated based on the results of the regression model. To assess whether 
the model improved after each step, the increase in c2 was tested. A predicted 
value of 0.5 assumed presence of the disease.
RESULTS
Subject characteristics
From the total group of MCI-patients included in this study 40% were non-amnestic 
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MCI (74% single-domain and 26% multi-domain) and 60% amnestic MCI (45% single-
domain and 55% multi-domain). Subject characteristics at baseline are shown in 
Table 1. Subjects who converted to AD-type dementia at 2-years follow up were older, 
had lower baseline scores on the MMSE, the immediate and free delayed recall, the 
TMT-B and categorical fluency task compared to those who did not progress, and 
were often carrier of the APOE-e4 allele. Baseline hippocampal volumes were lower 
and MTA scores higher in converters compared to non-converters. 
Table 1. Subject characteristics.
Non-converters Converters
N 148 36
Age 69.4 (7.9) 72.9 (6.8)**
Female (%) 57 60
Years education 9.1 (4.1) 9.7 (4.3)
MMSE score 27.7 (2.1) 26.6 (1.9)**
Z-score wordlist (free delayed recall) -1.17 (1.20) -1.91 (0.82)***
Z-score wordlist (immediate free 
recall) -1.03 (1.04) -1.42 (0.85)*
Z-score Fluency -0.96 (0.91) -1.20 (0.72)
Z-score TMT-A -1.09 (1.56) -0.69 (1.25)
Z-score TMT-B -1.45 (1.96) -1.44 (1.71)
Z-score Rey Complex Figure -0.08 (1.23) -0.03 (1.16)
ApoE-e4-carrier (%) 42 59*
Hippocampal volume (mm3) 6016 (747) 5291 (656)***
MTA-score 2.5 (1.5) 3.5 (1.5)**
Average FU (year) 2.37 (0.79) 1.51 (0.58)***
Average time to AD (year) - 1.38 (0.55)
All volumetric measurements are corrected for intracranial volume. Values are mean (SD). 
Abbreviations: MMSE = Mini-Mental state examination; TMT: Trial-making test; ApoE = 
apolipoprotein E genotype; LEAP: learning embeddings for atlas propagation; MTA: medial 
temporal lobe atrophy; FU = follow-up; AD = Alzheimer’s disease. 
* p < .05, ** p	< .01, *** p < .001 for differences between groups.
Univariate predictive accuracy 
The AUC for prediction of AD-type dementia at 2 years follow-up was around 0.70 
for the MRI measurements, the MMSE and the delayed recall score, while it was 
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below 0.61 for the other neuropsychological measurements (0.52-0.61) (Table 2). 
When scores were dichotomised based on a cut-point that maximised the Youden 
index, the overall predictive accuracy (odds ratio) was highest for hippocampal 
volume (OR=7.8), followed by MTA-score (OR=4.1) and the free delayed recall 
test (OR=3.6), the MMSE-score (OR=2.9), the immediate free recall test (OR=2.5), 
categorical fluency (OR=2.3) and TMT-B (OR=1.9). TMT-A and Rey complex figure 
test did not predict AD conversion. When MRI-measurements were investigated 
for both hemispheres separately, it was found that the predictive accuracy was 
somewhat higher for the left hippocampus compared to the right hippocampus. 
Differences in odds ratio for left and right MTA-score were negligible (Table 2). 
Multivariate predictors 
Neuropsychology
When age, MMSE score and neuropsychological tests were entered together, only 
age and delayed recall score independently predicted AD conversion (Table 3). 
Neuropsychology	combined	with	MRI-markers
When age, MMSE score and delayed recall score were combined with MRI 
measurements, hippocampal volume (change in c2 = 16.57; df = 1; p < .001) but 
not the MTA-score (p= .06) increased the likelihood of conversion (Table 3). Both 
left and right hippocampal volume increased predictive accuracy (left: c2 = 18.47 df 
= 1; p < .001; right: c2 = 8.90 df = 1; p	< .001) (Table 3). The increase of predictive 
accuracy was due to an increase in both sensitivity and specificity. 
Test sequence
Figure 1 shows probability plots of AD-type dementia for different sequences of 
delayed recall test and hippocampal volume in which the change in probability 
of AD-conversion is visualized after adding the result of each individual test. If 
hippocampal volume was analyzed first, assessment of the delayed recall task 
increased predictive accuracy in subjects with a normal hippocampal volume 
(OR=4.3,	p	= 0.02) but not in subjects with abnormal hippocampal volumes (OR=1.3, 
p	= 0.7) (Figure 1A). If the delayed recall task was administered first, assessment of 
hippocampal volume increased predictive accuracy for AD-type dementia both in 
subjects with a normal delayed recall score (OR=16.4, p < 0.001) and in subjects 
with an abnormal delayed recall score (OR=5.0, p < 0.001) (Figure 1B). 
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Predictive value in subjects with a a MMSE or MTA score above cut-off
If subjects with an MMSE-score >27 were selected, (n=106, of which 14 converted) 
both delayed recall and MRI measurements at baseline predicted AD-type dementia 
at follow-up (Table 5). In subjects with a normal MTA-score (summed left and right 
score <3)  (n=105, of which 12 converted), hippocampal volume but not delayed 
recall or MMSE score predicted progression (Table 5).
Table 4. Univariate predictive accuracy in cases with MMSE>27 or MTA-score<3
 
Data-selection based on A. MMSE >27 or B. MTA-score below 3. OR = odds ratio; CI 
= confidence interval; df = degrees of freedom; DR = free delayed recall score; MMSE = 
mini-mental state examination score. *Baseline MMSE > 27 and AD at follow-up (n=14); 
**Baseline MTA < 3 and AD at follow-up (n=12). 
DISCUSSION
Our main finding is that hippocampal volume but not MTA-score increases the 
predictive accuracy of the delayed recall score for the prediction of AD-type 
dementia after 2 years. Predictive accuracy was increased both in subjects with 
normal and abnormal delayed recall scores at baseline. In the subgroup of subjects 
with an MMSE score >27, both delayed recall and MRI measurements at baseline 
were predictors of conversion at follow-up. In the group of subjects with a normal 
MTA-score (<3), only volumetric measurements predicted AD. 
Measure OR (CI) p X2 df p
A. Predictive accuracy MMSE >27*
DR 9.17 (1.94-43.40) 0.005 11.14 1 0.001
Hippocampal volume 5.87 (2.40-14.30) 0 14.9 1 0
MTA 2.71 (1.16-6.34) 0.02 5.44 1 0.02
B. Predictive accuracy MTA<3**
MMSE-score 2.45 (0.71-8.52) 0.16 1.88 1 0.17
DR 2.04 (0.56-7.46) 0.28 1.21 1 0.27
Hippocampal volume 6.53 (2.84-14.98) 0 19.59 1 0
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Neuropsychological predictors   
In line with previous studies, delayed recall appeared the best neuropsychological 
predictor [27-31]. We found that categorical fluency and TMT-B had a moderately 
high predictive accuracy for AD. Previous studies also found that the TMT-B task 
predicted AD in amnestic MCI [32, 33] and that categorical fluency was the second 
most sensitive test in the detection of cognitive changes due to prodromal AD [34]. 
Important to note however is that other disorders may cause low performance 
on delayed recall tests. Disorders which can impair attentional processes (e.g. 
depression, anxiety) may result in poor registration and encoding of information [35] 
and disorders of executive functioning may moreover result in retrieval problems 
[36]. The same pattern can be identified in our data, whereas a cut-point of -1.31 
(Z-score) on the delayed recall task shows a high sensitivity together with a low 
specificity. Cued recall techniques on the other hand are thought to minimize the 
effect of attentional deficits and thus be more specific for AD [5, 35, 37].
MRI predictors
In line with previous studies, it was found that visual rating scales show lower 
predictive accuracy compared to volumetric measurements [11]. The present study 
furthermore confirmed that in a group of subjects with a normal MTA-score (<3), 
volumetric measurements still independently predicted AD-conversion, indicating 
that hippocampal volume is more sensitive for AD than a visual rating scale. Our 
finding of left>right is in line with one study investigating a large ADNI cohort 
stating that left hippocampal volume at baseline was the best single predictor of 
AD-conversion [38]. Another study in cognitively normal subjects reported that left 
hippocampal volume was a predictor for verbal memory function [39]. 
Neuropsychology and MRI-measurements 
The present study found that hippocampal volume increased predictive accuracy 
relative to a model with only neuropsychological information. Furthermore, test 
sequence analysis found that assessment of hippocampal volume increased 
predictive accuracy both in subjects with a normal and abnormal delayed recall 
score. In line with these findings, a recent study found the highest predictive 
accuracy for a model that combined a delayed recall test, functional measures and 
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hippocampal and entorhinal cortex volumes with age and MMSE-score [12]. Unlike 
hippocampal volume, visual MTA-ratings did not increase the predictive accuracy for 
conversion in a model with the delayed recall task.  In line with the added value of 
hippocampal volume in subjects with normal memory scores, hippocampal volume 
also predicted conversion in subjects with a normal MMSE-score. These findings 
indicate the necessity of adding volumetric measurements of the hippocampus to 
standard neuropsychological investigation in order to increase the certainty that 
the MCI syndrome is due to AD-pathology.
Limitations
We determined cut-offs within a study population that also included subjects from the 
present analyses. This could have led to an overestimation of the predictive accuracy. 
However, it is unlikely that it influenced our findings with respect to the differences in 
predictive accuracy between measurements, as the same method was used to define 
the cut-point for each measurement. The diagnosis of AD at follow-up was not validated 
neuropathologically which may have possibly led to a misclassification of some cases. 
Follow-up data with AD diagnosis for all subjects was only available for relatively 
short follow-up intervals (2 years). A recent meta-analysis found that predictive 
accuracy for MTL atrophy decreased when follow-up was longer [40]. Still, short-
term prognosis may be important for selection of subjects for trials. Recent studies 
point out the importance of cued recall tasks as specific marker for AD-conversion 
[5, 29, 35, 41, 42]. One could suggest using free delayed recall tasks for diagnosing 
MCI, and cued recall tasks to predict which MCI patients are likely to convert, and 
thus represent a group of prodromal AD-patients  [35, 42]. A recent study found 
biological evidence for the role of cued recall as neuropsychological marker for early 
AD [41]. Unfortunately, in our study no cued recall task was available. Candidate 
tests which can be considered in future studies are the Visual Association Test 
(VAT) [43] and the Memory Impairment Screen (MIS) [44]. A recent study found 
that the MISplus showed highest predictive accuracy values in predicting future AD-
conversion in subjects with MCI [5].Scanners with different field strengths (1T and 
1.5T) were used, reflecting real-life situations in which scanners and magnetic field 
strengths do vary. A previous study showed that it is unlikely that a small difference 
in field strength has a major impact on volumetric measurements [11]. It can be 
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considered a strength that a population from a memory clinic setting was used 
for this study. Conversely, findings may not be readily generalised to community 
populations.  
Implications for clinical practice
Our findings indicate that a combination of neuropsychological data, especially the 
administration of delayed recall tasks, together with hippocampal volume is preferred. 
Sensitivity and specificity increases when hippocampal volume is added to a model 
which only includes neuropsychological data. In addition, structural MRI assessment 
is useful to rule out specific causes of cognitive impairment (e.g. stroke, tumor) [12]. 
The added value of performing a visual rating scale on top of neuropsychological 
testing is however limited in terms of sensitivity and specificity (no increase in 
overall predictive accuracy).Although a combination of both neuropsychology and 
volumetry is preferred, predictive accuracy values of hippocampal assessment 
alone are comparable. Since the likelihood to detect MCI patients at risk for AD-
conversion is highest for volumetric measurements, volumetric assessment of MTL 
atrophy together with a delayed recall task may be sufficient for the diagnostic 
investigation of MCI-patients. In addition, one could consider adding elaborate 
neuropsychological investigation in subjects with normal hippocampal volumes. 
 
Assessing disease progression by means of episodic memory tests (delayed recall) 
and MMSE-score is an alternative at the cost of a lower sensitivity and specificity. 
For example, subject may progress to AD but still perform relatively well on cognitive 
tests (low sensitivity). Moreover, not all subjects with memory impairment progress 
to AD (low specificity). Free recall is moreover dependent on retrieval mechanisms, 
motivational and attentional processes. In line with recent criteria, however, one 
should additionally assess whether free recall deficits can be normalized with 
cueing. Failure to recall words after the presence of cues is indicative of prodromal 
AD [3]. When applying a more extensive neuropsychological test battery one should 
consider including MMSE-score, a verbal wordlist test (including immediate and free 
delayed recall), a fluency test and a test for executive functioning (e.g. TMT-B task), 
which are all shown to be independent predictors of AD-conversion in subjects with 
MCI. 
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We previously showed that CSF markers further improved predictive accuracy over 
hippocampal atrophy by increasing the sensitivity [21]. Combined use of both CSF 
and imaging biomarkers is highly accurate for either early diagnosis or exclusion of 
AD in patients with MCI [21, 32, 39-41]. Future studies could add both MRI and CSF 
measurements to neurospychological data in order to further increase predictive 
accuracy.
CONCLUSION
The present study found that volumetric measurements are the best predictors of 
AD-conversion after 2 years in a group of MCI-subjects. Assessment of hippocampal 
volume together with a delayed recall test may be sufficient for short-term prediction 
of AD in subjects with MCI. 
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ABSTRACT   
Our aim was to compare the predictive accuracy of four different medial temporal 
lobe measurements for Alzheimer’s disease (AD) in subjects with mild cognitive 
impairment (MCI). Manual hippocampal measurement, automated atlas based 
hippocampal measurement (LEAP), a visual rating scale (MTA-score), and lateral 
ventricle measurement were compared. Predictive accuracy for AD 2 years after 
baseline was assessed by ROC analyses with area under the curve (AUC) as outcome. 
Annual cognitive decline was assessed by slope analyses up to 5 years after baseline. 
Correlations with biomarkers in cerebrospinal fluid (CSF) were investigated. Subjects 
with MCI were selected from the DESCRIPA multicenter study (n=156) and the single-
center VU medical center (n=172). At follow-up, AUC was highest for LEAP (0.71) 
and manual hippocampal measurement (0.71), while lower for MTA-score (0.65) 
and lateral ventricle (0.60). Slope analysis yielded similar results. Hippocampal 
measurements correlated with CSF total tau (t-tau) and phosphorylated tau (p-tau), 
not with beta-amyloid (Ab)1-42. MTA-score and lateral ventricle volume correlated 
with CSF Ab1-42. We can conclude that volumetric hippocampal measurements are 
the best predictors of AD conversion in subjects with MCI. 
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INTRODUCTION
Alzheimer’s disease (AD) is the leading cause of dementia in the elderly affecting 
more than 27 million people worldwide. Early detection of AD may prevent 
irreversible damage by enabling preventative treatment [1, 2].  A primary focus 
of research in this area is identifying which biomarkers are clinically useful for the 
early diagnosis of AD. 
Medial temporal lobe (MTL) atrophy as assessed on structural MRI has proven to 
be an effective clinical aid in the early diagnosis of AD [3], and this method predicts 
AD in subjects with mild cognitive impairment (MCI) [3-7]. There are several ways 
to determine the degree of MTL atrophy in the brain including manual delineation, 
(semi-) automated techniques to measure hippocampal volume, qualitative ratings 
of MTL atrophy (MTA-score), and assessment of lateral ventricular volume [8-18]. 
Each of these methods has its strengths and limitations. 
Manual volumetry is considered the gold standard [19-21] but is time consuming, 
limiting routine clinical or large-scale research use. Automated measurements are 
quick and widely applicable, but may be susceptible to scanner and scan protocol 
variability. Volumetric measurements of the lateral ventricle require a minimum 
of rater time with robust automatic segmentations but show a lot of variability 
and asymmetry between subjects [14]. Qualitative ratings are quick to perform 
but sensitive to interrater variability and show lower accuracy rates compared to 
volumetric analysis [22, 23]. Visual rating scales are furthermore insensitive to 
detect atrophy progression over time [24].
A number of studies have examined differences between various techniques 
to measure atrophy of the MTL, mostly comparing manual with automated 
hippocampal volumetry [25-27] or volumetric hippocampal measurements to a 
visual rating scale [15, 24, 28-30]. These studies typically evaluate the diagnostic 
accuracy of different MRI techniques by comparing AD patients with healthy control 
subjects. Most studies found that manual hippocampal measurement shows 
similar performance as automated hippocampal segmentation [25, 31]. However, 
the performance of automated techniques may be less precise when applied in 
AD patients suffering from moderate to severe brain atrophy and/or white matter 
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hyperintensities which may lead to false allocations of gray matter, white matter 
or cerebrospinal fluid (CSF) [32-34]. One author stated that visual rating of MTL 
atrophy is a quick and clinically useful technique for differentiating AD from controls 
and is quicker and more accurate than volumetry [29]. 
To our knowledge, no study has compared the diagnostic performance of manual 
and atlas-based hippocampal segmentation, lateral ventricle volume and a 
qualitative rating. Moreover, no comparative studies have been performed on 
the predictive accuracy of these different methods to predict AD in subjects with 
MCI, their relation with CSF biomarkers of AD, and the of multi-center settings on 
diagnostic performance.
The aim of the present longitudinal study was to compare the predictive accuracy 
of four different MTL measurements for the progression to AD-type dementia 
in patients with MCI over a 2-year follow up period. Atrophy of the MTL was 
assessed using manual measurement of the hippocampus, automatically measured 
hippocampal volume based on atlas registration (LEAP), volumetric measurement 
of the expansion of the lateral ventricle and a largely used qualitative rating scale. 
Since subjects may convert at a later point in time, slope analyses were additionally 
performed with annual cognitive decline up to 5 years as outcome measure. The 
correlation of MTL measures with AD biomarkers in CSF was also investigated and 
the predictive accuracy was tested both in a multicenter study with different scan 
protocols and in a single-center study. 
MATERIALS AND METHODS
Subjects
We selected participants with MCI from the DESCRIPA (Development of Screening 
Guidelines and Clinical Criteria for Predementia AD) study and the Alzheimer 
Center of the VU University Medical center (VUmc) in Amsterdam. DESCRIPA is 
a multicenter prospective cohort study from the European Alzheimer’s Disease 
Consortium (EADC) aimed at developing clinical criteria and screening guidelines 
for predementia AD [35]. For this study participants were selected from 9 of the 20 
participating centers where MRI scanning was performed as part of clinical practice 
or as research protocol. The VUmc cohort in the present study included the VUmc 
subjects enrolled in the DESCRIPA study and an additional sample of subjects that 
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were seen outside the DESCRIPA inclusion period. (Appendix S1).
Inclusion criteria for both cohorts were: age 54 years or older, diagnosis of MCI and 
availability of results for each MRI measure and outcome at follow-up. Exclusion 
criteria were diagnosis of dementia at baseline or any somatic, psychiatric or 
neurological disorder (e.g. epilepsy) that might have caused the cognitive impairment 
[35]. At baseline scans were available for 456 subjects. Visually rated MTL atrophy 
was available for all subjects. Of these, 54 had no FU data and were excluded. 
Of the remaining 402 subjects, scans were not available in digital format for 21 
subjects. Of the remaining 381 scans, manual segmentation of the hippocampus 
could be performed on 341 scans (reason missings: technical problem volumetric 
measurement [n=5], technical problem automated intracranial volume estimation 
[n=25] and logistics [n=10]), LEAP based volumetry on 357 scans (reason missings: 
technical problem volumetric measurement [n=11] and logistics [n=13]), and lateral 
ventricle volumetry on 335 scans (reason missings: technical problem volumetric 
measurement [n=37], and logistics [n=9]). Data for all four medial temporal lobe 
measurements was available for 328 subjects, 156 from DESCRIPA and 172 from 
VUmc.  There were no differences between included and excluded subjects with 
respect to age, gender, educational level and cognitive test results. 
Clinical and cognitive assessment
All participants underwent a standard diagnostic workup, including clinical 
history, medical and neurological examination, clinical chemistry, functional 
evaluation using the Clinical Dementia Rating scale (CDR) [36], the Mini-Mental 
State Examination (MMSE), and rating scales for depression and neuropsychiatric 
symptoms. A neuropsychological battery was performed to evaluate performance 
in several cognitive domains. In each center a primary test for verbal memory, 
language, attention, executive functioning, and visuoconstruction was chosen 
that was identical or similar to tests used in other centers [35]. Raw scores on 
neuropsychological tests were corrected for age, education, and sex, in accordance 
with locally collected or published normative data and expressed as z-scores, which 
were used for further analysis. Baseline diagnosis of MCI was made according to 
the criteria of Petersen et al. [37, 38]. MCI was defined as a z-score <-1.5 SD on 
any of the following tests: the learning measure or delayed recall of a word list 
learning test or equivalent memory test, the trail making test (TMT) part A, TMT 
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part B, verbal fluency, Rey figure copy test or an equivalent test [39]. We calculated 
a composite score as the average z-score of the 6 tests if scores were available for 
at least 3 tests [40].
Follow-up was conducted annually for up to 5 years. The primary outcome measure 
was conversion to AD-type dementia after 2 years. AD diagnosis was made according 
to the DSM-IV [41] and NINCDS-ADRDA criteria, [42]. Secondary outcome measures 
were annual cognitive decline on the MMSE and the cognitive composite score. 
MRI acquisition and image analysis
Scan	protocol	
At each site, patients were scanned according to the routine MRI-protocol. Scanners 
and protocols at different sites varied but all scanning was performed at 1.0 or 1.5 
Tesla (Appendix S1). All scans included a three-dimensional T1 weighted gradient 
echo (3DT1) sequence and a fast fluid attenuated inversion recovery (FLAIR) 
sequence. 
MRI-measurements	
MTL atrophy was assessed using manual measurement of the hippocampus, 
automatically measured hippocampal volume using multi-atlas segmentation 
(LEAP), volumetric measurement of the expansion of the lateral ventricle and a 
qualitative rating. All volumetric measurements were corrected for intracranial 
volume (ICV). The LEAP measurement was ICV corrected by means of a scaling 
factor from MNI (Montreal Neurological Institute), the manual hippocampal 
measurement and the lateral ventricle measurement were ICV corrected by means 
of a scaling factor derived from FSL software. The total rating time of each method 
can be found in Supplementary Table S1. Rater time needed for analysis was lowest 
for LEAP hippocampal measurement (4 minutes) followed by the qualitative rating 
(5 minutes). Rater time was 30 minutes for lateral ventricle measurement and 150 
minutes for manual hippocampal volumetry. 
For the manual segmentation of the hippocampus, the baseline 3DT1-weighted 
volume sequence was reformatted in 2-mm slices (in-plane resolution: 1x1 mm) 
and oriented perpendicular to the long axis of the left hippocampus [21]. Regions 
of interest (ROIs) of the hippocampus were constructed by manual delineation of 
hippocampal borders on both sides on the reformatted slices, using the in-house–
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developed software package Show_Images 3.7.0 (VU University Medical Center, 
Amsterdam, The Netherlands). Delineation of the hippocampus was performed 
using previously described criteria [43-45] by 3 trained technicians (coefficients 
of variation: interrater <8%, intrarater <5%) blinded to diagnosis. ROIs included 
the dentate gyrus, cornu ammonis, subiculum, fimbria, and alveus. Baseline 
hippocampal volume was calculated by multiplying the total area of all ROIs of each 
hippocampus by slice thickness. Baseline hippocampal volumes were adjusted for 
intracranial volume (ICV), using the scaling factor derived from SIENAX (FSL, FMRIB, 
Oxford, UK) [46]. 
Automated hippocampal volumetry was performed using the Learning embeddings 
for atlas propagation (LEAP) method [17]. In this method, multi-atlas registration is 
applied to a cohort of brain images after representing the whole population together 
with an initial set of atlases. The initial set is propagated to a number of unlabeled 
images in their local neighbourhood which are used to label them. Images labeled 
in this way become atlases themselves and are, consequently, further propagated 
throughout the whole dataset. In this way, each image is labeled using a number of 
atlases in its close vicinity, which has been shown to perform more robust on diverse 
datasets than other multi-atlas registration techniques [17]. A brief visual inspection 
of the segmented hippocampi was performed in order to identify clear failures of 
the automated method. Except for technical failures listed below, no subjects were 
excluded after this inspection and no manual correction was performed.
Measurement of the lateral ventricle was executed with an extension of SIENAX 
[47, 48], part of FSL [49]. SIENAX starts by extracting brain and skull images from 
the single whole-head input data [50]. The brain image is then affine-registered to 
MNI152 space [51, 52] using the skull image to determine the registration scaling. 
This is primarily in order to obtain the volumetric scaling factor, to be used as a 
normalisation for head size. Next, tissue-type segmentation is carried out [53] in 
order to calculate total volume of brain tissue (including separate estimates of 
volumes of grey matter, white matter, peripheral grey matter and ventricular CSF). 
After the tissue segmentation, a registered mask is used to exclude the CSF on the 
outer side of the brain. The resulting ventricular structure is manual edited when 
the segmentation or the mask did not take the whole ventricle into account or did 
contain CSF pixels not belonging to the ventricles (CSF found outside the ventricles).
The visual rating of MTL atrophy was performed using a qualitative scale [15]. Rating 
was performed on coronal T1-weighted images using a 5-point visual scale (MTA-
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scores), ranging from 0 (no atrophy) to 4 (severe atrophy) based on the height of 
the hippocampal formation and the surrounding CSF spaces. In the analysis, the 
sum of both sides (left and right) was used. All visual rating was performed at VUmc 
by a number of trained raters. Scans from VUmc were rated by a group of 3 raters 
supervised by a neuroradiologist  (intrarater weighted Cohen k > 0.80; interrater 
weighted Cohen k > 0.80) [54]. The Descripa scans were rated by a single rater from 
VUmc (intrarater weighted Cohen k =0.68) [45].
CSF analyses 
CSF was collected by lumbar puncture and levels of beta amyloid (Ab)1-42, total tau 
(t-tau) and phosphorylated tau (p-tau) in CSF were measured using commercially 
available sandwich ELISAs (Innotest b-amyloid 1-42; Innotest hTAU-Ag; Innogenetics, 
Ghent, Belgium), specially constructed to measure Ab1-42 and t-tau [55, 56] by 
experienced technicians at the lab in Gothenburg for the DESCRIPA cohort and in 
Amsterdam for the VUmc cohort. CSF was available for 147 subjects. We corrected 
for interlaboratory ELISA differences by analyzing 33 samples at both labs and we 
adjusted VUmc values to those of DESCRIPA using the following equating formula: 
Gothenborg= average Gothenborg + (SD Gothenborg/SD VUmc)*(VUmc - average 
VUmc) [57]. Abnormal values for CSF measures were a concentration ≤ 550 pg/mL 
for Ab1-42, >52 pg/mL for p-tau and >375 pg/mL for t-tau [58].
APOE genotype
APOE genotype was determined by polymerase chain reaction of genomic DNA 
extracted from EDTA anticoagulated blood in 262 subjects. Subjects were classified 
as APOE-e4 carriers or non-carriers. 
Statistical analysis
Statistical analysis was performed with IBM SPSS version 19 (Chicago, IL, USA) and 
statistical software package R (R foundation, Vienna, Austria). Correlations between 
the different methods for MTL assessment and between MTL and other biomarkes 
(CSF, APOE-e4 allele) were analyzed by the Pearson’s correlation coefficient for 
continuous data, and the Spearman rank test for correlations including the MTA-
score. Intraclass correlation coefficient (ICC) and paired t-test were performed to 
investigate the agreement between MTL measurements. 
The main outcome measure was the area rereareunder the curve (AUC) for AD-
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type dementia after 2 years follow-up, calculated using a time-dependent ROC 
curve in R [59]. Differences in AUC between methods were tested as described 
elsewhere [60]. We calculated the sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), odds ratio (OR) and hazards ratio (HR) for 
AD-type dementia at 2- year follow-up using data-driven cut-points based on a time 
dependent ROC. First we calculated the cut-point that maximized the Youden Index 
(sensitivity+specificity-1) for predicting AD-type dementia after 2 years. Second, we 
selected cut-points that predicted AD-type dementia with a sensitivity of 85%. Cut-
points were calculated in the whole sample and in each cohort separately. Spline 
analyses were performed to determine AD-free survival after 2 year as a function 
of each MRI-measurement in the total cohort. Slope analyses with mixed models 
were performed to investigate whether MTL atrophy was associated with change 
on the MMSE and a cognitive composite score at follow-up. The analyses included 
the baseline score and available follow-up scores up to 5 years after baseline and 
were corrected for age and education. An unstructured covariance structure with 
center as a random effect was used as this model provided the best -2 log likelihood 
compared to models with simpler covariance structures [40]. 
RESULTS
Subject characteristics
From the total group of MCI-patients included in this study 37% were non-amnestic 
MCI (73% single-domain and 27% multi-domain) and 63% amnestic MCI (44% 
single-domain and 56% multi-domain). Baseline and follow-up characteristics are 
shown in table 1. Both cohorts were comparable for age and APOE-e4 status. The 
DESCRIPA cohort included more females and education was lower compared to the 
VUmc cohort. Scores on the MMSE and a delayed recall task were lower in the VUmc 
cohort. At follow-up, ninety-one subjects were diagnosed with probable Alzheimer 
type dementia (28%). Conversion rate was higher in the VUmc cohort (35.5%) than 
in the DESCRIPA cohort (19.2%), p<.001. Twelve subjects converted to a different 
type of dementia at follow-up: 4 subjects converted to frontotemporal dementia, 
6 to dementia with Lewy bodies, one to vascular dementia and one to another 
form of dementia. These subjects were included in the no-AD group. The follow-up 
length was slightly higher in the VUmc cohort. Characteristics of subjects with and 
without AD-type dementia at FU in each cohort are shown in supplementary table 
S2.
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Table 1. Subject characteristics.
All volumetric measurements are corrected for intracranial volume. Values are mean (SD). 
Abbreviations: MMSE = Mini-Mental state examination; ApoE = apolipoprotein E genotype; 
Descripa cohort VUmc cohort Combined cohort
N 156 172 328
Age 70.3 (7.9) 70.9 (7.3) 70.6 (7.6)
Female (%) 59.6 44.2 ** 51.5
Years education 8.5 (3.9) 11.2 (3.3)*** 10 (3.8)
MMSE score 27.2 (2.3) 26.6 (2.6)* 27.0 (2.5)
Z-score wordlist (delayed 
recall)
-1.23 (1.20) -1.58 (1.10)* -1.38 (1.20)
ApoE-e4-carrier (%) 45 56 51
Homo/heterozygous  
ApoE-e4-carriers (%)
38/7 38/18 38/13
Manual hippocampus 
(mm3)
7874 (1294) 7462 (1097)** 7657 (1211)
LEAP hippocampus 
(mm3)
5897 (798) 5446 (632)*** 5661 (749)
MTA-score 2.8 (1.7) 2.3 (1.7)** 2.5 (1.7)
Lateral ventricle (mm3) 53409 (26105) 57374 (28042) 55488 (27170)
CSF Ab1-42, pg/ml 561 (256) 604 (283) 594 (277)
Abnormal CSF Ab1-42 
(%) 
49 52 51
CSF t-tau, pg/ml 418 (298) 558 (347)* 525 (351)
Abnormal CSF t-tau (%) 51 68 64
CSF p-tau, pg/ml 64 (33) 80 (47) 77 (45)
Abnormal CSF p-tau (%) 54 71 67
CSF Ratio Ab1-42/t-tau 2.2 (2.2) 1.6 (1.5) 1.8 (1.6)
Outcome at last FU (%)
- No AD 80.8 64.5 72
- AD 19.2 35.5*** 28
Average FU non-de-
mented subjects (year)
2.35 (0.84) 2.67 (1.31)* 2.47 (1.09)
Average time to AD 
(year)
1.51 (0.71) 2.29 (1.39)** 2.07 (1.28)
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Ab1-42 = beta amyloid 1-42; t-tau = total tau, p-tau = phosphorylated tau; FU = follow-
up; AD = Alzheimer’s disease. * p < .05, ** p	< .01, *** p < .001 for differences between 
cohorts.
Correlations between MTL-measures
Manual and automated LEAP hippocampal volumes correlated highly (Pearson’s r: 
0.71, p<.001) with intermediate agreement (ICC: 0.38, p<.001, Bland-Altmanplot 
(Supplementary Figure S2)). Paired t-test showed significant differences between 
the two techniques (t: 42.27, p<.01) with LEAP hippocampal measurement showing 
lower volumes. Using the cut-point based on the Youden index, the kappa and 
the overlap between manual and LEAP hippocampal volume were 0.60 and 0.80 
respectively.
 The correlation between the MTA-score and the manual and LEAP 
hippocampal volume was -0.36 and -0.27 respectively (p<.01). Using the cut-point 
based on the Youden index, the kappa was 0.29 and the overlap between scores 
0.69 for manual vs MTA-score and 0.37 (kappa) and 0.65 (overlap) for LEAP vs 
MTA-score. The lateral ventricle measurement strongly correlated with MTA-score 
(r=0.60, p<.001) and showed weak correlations with both manual (r=-0.20, p<.01) 
and LEAP hippocampal volume (r=-0.20, p<.01).
Correlations with AD biomarkers
Manual and LEAP hippocampal volume significantly correlated with CSF t-tau, p-tau 
and Ab/t-tau ratio (all p<.01, Table 2). The MTA-score correlated with Ab1-42 (p<.05) 
and the ratio Ab/t-tau (p<.01). The lateral ventricle volume correlated with Ab1-
42 (p<.01) and p-tau (p<.05). Only the LEAP hippocampal volume at baseline was 
associated with APOE-e4 allele status (LEAP volume APOE-e4 carriers 5516 mm3 vs 
5852 mm3 for APOE-e4 non-carriers, t=2.72, p<.001).
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Ab1-42 T-tau P-tau Ab/t-tau
Manual hippocampus 0.09 -0.28** -0.23** 0.29**
LEAP hippocampus 0.05 -0.32** -0.27** 0.33**
MTA-score -0.20* 0.11 0.06 -0.24**
Lateral ventricle -0.30** 0.12 0.16* -0.1
Table 2. Correlation with CSF measurements.
 
Shown are Pearson correlation coefficients or Spearman-rank correlation coefficients 
(correlations with MTA score).  Abbreviations: Ab1-42 = beta amyloid 1-42; t-tau = total tau; 
p-tau = phosphorylated tau; MTA = medial temporal lobe atrophy. * p<.05, ** p< .01.
Predictors of AD-type dementia in combined sample
In the total sample, the AUC for prediction of AD-type dementia at 2 years follow-up 
was highest for the LEAP hippocampal measurement (0.71) and manual hippocampal 
measurement (0.71), while it was substantially lower for the MTA-score (0.65) and 
lateral ventricle (0.60) (Figure 1). If measurements were dichotomised using the cut-
point that maximised the Youden Index, the overall predictive accuracy for AD after 
2 years was best for the manual and LEAP hippocampal volumetric measurements 
(OR 6.4-6.5, HR 4.4-4.5), and lowest for the qualitative rating and lateral ventricle 
volume (OR <4, HR <3) (Table 3). Figure 2 shows the 2-year dementia risk according to 
baseline MTL score based on spline analysis. The x-axis shows the degree of atrophy 
and the y-axis depicts the risk for AD at follow-up associated with the degree of 
atrophy. Both manual and LEAP hippocampal volume had a non-linear relation with 
dementia risk indicating that the risk for dementia did not change much with very 
large or very small volumes. The optimal cut-point based on the Youden index for 
these measures was found halfway through the linear part of the plot. 
If measurements were dichotomised using the cut-point that provided 
a sensitivity of 85% similar results were obtained. These analyses also showed 
that the specificity was higher for manual and LEAP volumetric measurements of 
hippocampal volume than for MTA-score and lateral ventricle volume. 
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Predictors of cognitive decline
Since subjects with MCI may convert to AD-type dementia after the 2-years 
follow-up, we performed slope analyses with annual cognitive decline up to 5 
years as outcome measure. Subjects with abnormal scores for manual and LEAP 
hippocampal measurement and MTA-score at baseline declined 2 times as fast on 
the MMSE (p<.001) and declined 2.6 to 4 times as fast on the cognitive composite 
score (p<.01) compared to subjects with normal MTL scores (Table 4, Figure 3). The 
lateral ventricle volume only predicted decline on the cognitive composite score 
(p<.01) (Table 4, Figure 3).
Multicenter versus single-center cohort  
In the DESCRIPA multicenter cohort, AUC analysis showed best predictive accuracy 
values for LEAP (0.74) followed by manual hippocampus volume (0.71). In the 
single-center cohort, manual hippocampus was the best predictor for AD (AUC: 
0.69) followed by LEAP (AUC: 0.68) and MTA-score (AUC: 0.65) (Figure 1). In 
order to investigate whether optimal cut-points for predicting AD-type dementia 
differed between the multicenter and single center cohort, we calculated within 
each cohort the cut-point that maximised the Youden index and the cut-point that 
provided a sensitivity of 85% for the prediction of AD-type dementia after 2 year 
(Table S3). These analyses showed that the optimal cut-points for the manual and 
LEAP hippocampal measurement were similar between the multicenter and the 
single-center cohort with relative differences of less than 2.5% for the cut-points 
based on the Youden index and less than 5.5% for the cut-points that provided a 
sensitivity of 85%.
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Fig. 1. Area under the curve (AUC) of a ROC-curve for MRI-measurements for A) 
total sample, B) DESCRIPA cohort and C) VUmc cohort. All volumetric measurements 
are corrected for intracranial volume. Abbreviations: ROC = receiver operating 
characteristics; MTA = medial temporal lobe atrophy.
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Fig. 2. Spline analyses showing AD-free survival after 2 year as function of MRI-
measurement in total cohort for A) Manual hippocampal volume, B) LEAP 
hippocampal volume, C) MTA-score and D) Lateral ventricle volume. Red line 
indicates cut-point that maximised the Youden index. All volumetric measurements 
are corrected for intracranial volume. Abbreviations: AD = Alzheimer’s disease; MTA 
= medial temporal lobe atrophy.
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Fig. 3. Slope analyses showing annual cognitive decline on A) the MMSE and B) a 
cognitive composite score as predicted by baseline MTL measurements. Abnormal 
MRI-values at baseline were defined as manual hippocampal volume <7559 mm3, 
LEAP hippocampal volume <5374 mm3, MTA-score ≥3 and lateral ventricle volume 
≥58491 mm3. Figure A+B: the solid line indicates the subjects with normal values. The 
dotted line indicates subjects with abnormal values. Abbreviations: MAN = manual 
hippocampal volume; LEAP = LEAP hippocampal volume; MTA = medial temporal 
lobe atrophy score; LATVEN = lateral ventricle volume; MMSE = Mini-Mental State 
Examination. All volumetric measurements are corrected for intracranial volume. 
The cognitive composite score = average z-score of learning or delayed recall of a 
word list learning test or equivalent memory test, the trail making test (TMT) part A, 
TMT part B, verbal fluency, Rey figure copy test or an equivalent test. 
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Table 3. Predictive accuracy for AD-type dementia after 2-years. 
Cut-point based on 
Youden index
Cut-off Sens Spec PPV NPV OR HR
Manual hippocampus 7559 0.78 0.65 0.46 0.88 6.47 4.55
LEAP hippocampus 5374 0.66 0.77 0.52 0.85 6.4 4.43
MTA-score 3 0.66 0.64 0.41 0.83 3.4 2.77
Lateral ventricle 58491 0.53 0.68 0.39 0.79 2.36 2.01
Cut-point for a 
sensitivity of 85%
Manual hippocampus 8379 0.88 0.37 0.35 0.89 4.22 3.15
LEAP hippocampus 5901 0.87 0.42 0.36 0.89 4.72 3.34
MTA-score 2 0.86 0.3 0.32 0.85 2.57 2.03
Lateral ventricle 34859 0.84 0.27 0.31 0.81 1.87 2
All volumetric measurements are corrected for intracranial volume. Cut-off in mm3 for 
volumetric measurements. Abbreviations: Sens = sensitivity; Spec = specificity; PPV= 
positive predictive value; NPV = negative predictive value; AUC = area under the curve; OR 
= odds ratio; HR = hazard ratio; LEAP = Learning Embeddings for Atlas Propagation; MTA = 
Medial temporal lobe atrophy.
DISCUSSION
The present study showed that volumetric measurements of the MTL are better 
predictors for AD-type dementia in subjects with MCI than a qualitative rating or 
the assessment of the lateral ventricle volume. 
This is to our knowledge the first study comparing four different measures for 
MTL atrophy in a large sample of MCI-subjects from a memory clinic population. 
Furthermore this is the first study to compare the predictive accuracy of these 
measurements in single-center and multicenter settings and to investigate the 
correlations between these measurements and other AD biomarkers.
Comparison of MTL assessment methods
Predictive	accuracy
The degree of neurodegeneration in MTL structures is the best MRI marker of 
imminent conversion to AD, with decreased hippocampal volume being the most 
robust structural MRI feature [61].
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Table 4. Annual cognitive decline over 5 years of follow-up. 
MMSE score Cognitive composite score
Baseline 
score
Slope Baseline 
score
Slope
Manual 
hippocampus
Normal 27.6 (0.47)a -0.45 (0.09)a,b -0.90 (0.08) -0.05 (0.02)c,d
Abnormal 26.7 (0.47) -1.04 (0.10)e -1.00 (0.09) -0.17 (0.03)e
LEAP 
hippocampus
Normal 27.4 (0.42)c -0.54 (0.09)a,b -0.92 (0.07) -0.07 (0.02)b,c
Abnormal 26.5 (0.46) -1.13 (0.12)e -1.01 (0.09) -0.18 (0.04)e
MTA-score Normal 27.4 (0.43)f -0.49 (0.08)a,e -0.84 (0.07)c -0.05 (0.02)a,b
Abnormal 26.9 (0.43) -1.14 (0.11)e -1.05 (0.08) -0.20 (0.03)e
Lateral 
ventricle
Normal 27.4 (0.46) -0.70 (0.09)e -0.96 (0.07) -0.01 (0.03)c
Abnormal 27.0 (0.48) -0.94 (0.13)e -1.00 (0.09) -0.22 (0.05)c,e
Data are mean (SD). Slope refers to annual change on the test. A negative slope indicates 
cognitive decline. Scores dichotomised based on Youden cut-offs.  
Key: MMSE=Mini-Mental State Examination; MTA = medial temporal lobe atrophy
a p	< 0.001 for baseline score or slope compared with the abnormal biomarker group.
b p	< 0.01 for slope different from 0 (=a statistically significant change over time in test score).
c p < 0.01 for baseline score or slope compared with the abnormal biomarker group.
d p < 0.05 for slope different from 0 (=a statistically significant change over time in test score).
e p < 0.001 for slope different from 0 (=a statistically significant change over time in test 
score). f p < 0.05 for baseline score or slope compared with the abnormal biomarker group.
In our study, predictive accuracy of both volumetric hippocampal measurements 
for AD-type dementia was indeed higher than that of the qualitative rating and 
lateral ventricle measure. This is in line with current evidence stating that manual 
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and automated volumetric methods show similar performances in diagnosing AD 
[25, 31, 62, 63] and that qualitative rating scales or lateral ventricle measurements 
are less accurate predictors than volumetric methods [24, 28, 30]. 
The slope analyses of cognitive decline over 5 years again yielded similar results 
with LEAP and manual hippocampal volume at baseline predicting cognitive decline 
on both the MMSE and a cognitive composite score. Slope analysis for the MTA-
score predicted cognitive decline equally well as the volumetric measures. This is 
again in line with previous findings showing that automatically measured volume 
change in the hippocampus is correlated with decline of performance on the MMSE 
[64] and that manually measured hippocampal volume reduction is correlated with 
the severity of impairment on neuropsychological tests [65]. Another study found 
that performance on the MMSE was directly correlated with hippocampal volume 
[66]. 
Relation	with	other	AD-biomarkers
Manual and LEAP hippocampal volume significantly correlated with CSF t-tau 
and p-tau but not with Ab1-42. The correlation of hippocampal volumetric 
measurements with CSF tau but not with CSF Ab is in line with previous studies 
conducted in subjects with MCI [67, 68] and subjects with prodromal AD or AD 
[69]. It may be explained by the obervation that antemortem hippocampal volume 
significantly correlated with the density of neurofibrillary tangles at autopsy [70, 71] 
but not with amyloid beta plaque load [70]. The qualitative MTA-score and lateral 
ventricle volume correlated with CSF Ab1-42. This correlation may indicate that 
these MTL measures in part reflect generalised brain atrophy as previous studies 
showed that lower Ab1-42 levels but not t-tau levels were associated with total 
brain atrophy and ventricular volume [72]. 
Overlap	between	measurements
Although the LEAP and manual hippocampal measurement correlated highly 
(r=0.71) and scores showed 80% overlap, the intraclass correlation coefficient (ICC) 
of 0.38 indicated a moderate agreement. This might be due to the fact that the 
LEAP volume was consistently lower, since the ICC is sensitive for absolute sizes. 
A previous study that compared LEAP with manual measurements found a much 
higher ICC of 0.89 [17]. Although in this study LEAP volume was systematically lower 
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than the manual volumetric measurement, this difference was smaller than in our 
study. Differences in absolute volumes may be due to the use of different borders 
for hippocampal delineation. Major parts of the hippocampus are included in both 
volumetric methods with the only difference that the LEAP method misses some 
of the hippocampal head, some of the alveus and some of the fimbria, and ends a 
few slices earlier than manual hippocampal outlining. Despite the differences in raw 
volume, both methods have a comparable diagnostic accuracy indicating that these 
parts are less important for AD pathology. It is also likely that the cut-off points for 
each hippocampal method likely reflected a similar degree of abnormality. Namely, 
if we defined the cut-off that provided a sensitivity of 0.85, the specificity of each 
method was equal. When the cut-off was used that optimised the Youden index, 
small differences in sensitivity and specificity were found but the combination of 
sensitivity and specificity expressed as odds ratio was the same. Differences in 
absolute volumens between different measurements protocols may be reduced in 
the future as efforts are made towards the harmonization of an MRI segmentation 
protocol for hippocampal delineation [20]. Since manual volumetry is used as the 
standard against which automated segmentation algorithms are assessed, future 
synchronization and comparison of both techniques will be facilitated. Correlations 
between manual and LEAP volumetric measurements and MTA-score were low 
with a moderate overlap between both methods. The same pattern was found for 
correlations and overlap between both volumetric hippocampal measurements 
and expansion of the lateral ventricle. 
The findings above indicate, in line with previous studies, that volumetric and 
qualitative measures of MTL atrophy measure different aspects of AD pathology 
[73, 74].  Manual and LEAP hippocampal volume correlated with each other, both 
showed high predictive accuracy values and both correlated with t-tau and p-tau 
but not with Ab1-42. In contrast, visually rated MTA-score and expansion of the 
lateral ventricle correlated highly with each other but not with the volumetric 
measures. They showed lower predictive accuracy for AD-conversion than the 
volumetric measures and correlated highly with amyloid beta in CSF rather than CSF 
tau. As discussed above, it is possible that both the MTA-score and lateral ventricle 
volume reflect a widening of ventricular spaces i.e. the temporal horn, which may 
be indicative of generalised atrophy rather than atrophy of the hippocampus alone. 
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Comparison of cohorts
None of the MTL measures showed major differences in predictive accuracy between 
the single and multicenter cohort. When optimal cut-points for each measure were 
calculated for each cohort separately these cut-points only slightly differed between 
the cohorts for the volumetric hippocampal measurements, which shows that 
volumetric measurements display stable cut-points across different cohorts Some 
differences were noted between the cohorts on cut-points for the MTA-score and 
lateral ventricle, suggesting that MTA-score and lateral ventricle are more sensitive 
for cohort differences.
Technical considerations
In general automated measurements are more susceptible to scanner and scan 
protocol variability. In our study, no significant differences between both methods 
were found with LEAP showing similar or even slightly better performance than 
manual volumetry. This suggests that automated measurements can be performed 
in multi-centre studies without strict standardisation of scan protocols. The 
percentage of technical failures was small for manual hippocampal measurement 
(0.07 %) and LEAP hippocampal measurement (0.03 %). All failures were observed 
in 2 DESCRIPA sites that apparently used scan frequencies which occasionally 
led to technical errors during the pre-processing phase (e.g. intensity problems), 
making these particular scans unsuitable for applying subsequent volumetric 
measurements. SIENAX related measurements (ICV measure and lateral ventricular 
volume) yielded a higher technical failure rate (1% for lateral ventricle) and were 
observed across all sites. These were due to calculation errors or a combination 
of software and image quality problems. These findings indicate that the lateral 
ventricle measurement is more sensitive for specific differences in image quality 
than a manual or automated hippocampal measurement. It should be noted than 
scan sequences were designed for routine clinical practice and not for automated 
measurements and it is likely that failure rate could be reduced by using protocols 
optimised for automated measurements.
Limitations
The present study had several limitations. There were differences in subject 
characteristics between the single-center and multicenter cohort. Subjects from 
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the single-center VUmc cohort were more severely impaired and had lower 
baseline MMSE scores, more severe memory impairment, a lower hippocampal 
volume, higher CSF tau, and a higher conversion rate to dementia. Despite these 
differences, however, the predictive accuracy was similar in each cohort. Another 
limitation is that the cut-offs of all MRI measurements were determined within a 
study population that also included the subjects from the present analyses. This 
could have led to an overestimation of the predictive accuracy. However, it is 
unlikely that it influenced our findings with respect to the differences in predictive 
accuracy between MRI measurements, as we used the same method to define the 
cut-point for each measurement. Follow-up data with AD diagnosis for all subjects 
was only available for relatively short follow-up intervals (2 years). For clinical trials, 
however, short-term prognosis may be important. For those subjects of whom long-
term follow-up data was available, predictive accuracy for annual cognitive decline 
up to 5 years was additionally investigated. The diagnosis of AD at follow-up was not 
validated neuropathologically which may have possibly led to the misclassification 
of some cases.  We used scanners with different field strengths (1T and 1.5T) which 
reflected real-life situations in which scanners and magnetic field strengths do vary. 
However, these differences may have introduced bias. We therefore compared the 
hippocampal volume between subjects scanned on a 1.0T scanner (n=127) and a 
1.5T scanner (n=201) after correction for age, gender, educational level, baseline 
MMSE score and follow-up diagnosis. The difference in volume between 1.0 and 
1.5 T scanners was 0.2% for the LEAP method (p = 0.9, [75]), 0.9% for manual 
hippocampal volume (p = 0.6), and 1.5% for the lateral ventricle volume (p = 0.8). We 
also tested whether field strength modulated the effect of the volumetric measures 
on conversion to AD-type dementia. For none of the measures the interaction 
between field strength and volumetric measure was statistically significantly 
associated with conversion (p > 0.15). A recent study also found a limited effect 
of fieldstrength on hippocampal volume. This study compared the hippocampal 
volume measured by the LEAP method between subjects scanned both on a 1.5T 
and  3T scanner (Wolz 2013, under review). This study found a very high correlation 
between the measurements on each scanner (r=0.98). The volumes measured 
on 3T were on average 24.4mm3 or 1.17% larger than on 1.5T (Wolz 2013, under 
review). This variability was similar to that for volumes rescanned on scanners 
with the same field strength (1.5%) (Wolz 2013, under review). Taken together, it 
is unlikely that the small difference in field strength in our study had a major effect 
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on the volumetric measurements in our study. Different methods were used for 
ICV correction of both hippocampal measurements (see 2.3.2). Both correction 
methods were thoroughly compared and showed high correlations (ICC: 0.93 for 
LEAP with MNI versus FSL scaling and 0.95 for manual volumetric measurement 
with MNI versus FSL scaling) and similar results regarding predictive accuracy. As a 
result of this analysis, ICV correction of each individual method was applied. It can 
be considered a strength that for this diagnostic study a population from a memory 
clinic setting was used. A consequence however is that these findings may not be 
applicable to other settings, including the general population. 
Clinical implications
Volumetric measurements of the MTL are the best predictors for AD-type dementia 
in subjects with MCI. Both volumetric measurements strongly correlate with CSF 
markers of neuronal injury (CSF t-tau and p-tau), are able to predict cognitive 
decline and show consistent cut-off values between different cohorts. LEAP 
hippocampal volume has the advantage over manual volumetry that it needs much 
less rater time and shows no interrater variability effects. In addition, LEAP has a 
low technical failure rate. Visual rating scales are also quick and easy to perform but 
show lower predictive accuracy rates and higher inter and intraindividual variability 
effects [23] compared to LEAP volumetric measurement. Another disadvantage of 
visual rating scales, although outside the scope of this study, is that they cannot 
detect subtle atrophy progression and are thus insensitive to change over time [24, 
28]. Since the hippocampus is among the first areas affected by the disease [76, 
77], repeated measurement of its volume is clinically important. LEAP hippocampal 
measurement is suitable for implementation in clinical practice with on average 
four minutes control time on a standard computer. Cut-points that maximised the 
balance between sensitivity and specificity as expressed by the Youden index or that 
provided a sensitivity of 85% were defined. The cut-point based on the Youden index 
may be preferred since it has shown to be more consistent between the multi and 
single centre cohort (Supplementary Table S3). Depending on the clinical needs also 
other cut-points may be chosen, that for example maximize the positive or negative 
predictive value [78]. Any choice for a specific cut-point has a trade-off between 
the chance of missing the disease (false negative rate, 1-sensitivity) or incorrectly 
diagnosing someone as having the disease (false positive rate, 1-specificity). The 
choice will therefore depend on its clinical use. For example, if a treatment for MCI 
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due to AD would be available the choice may depend on the safety profile of the 
treatment. If a treatment has many or severe side-effects, high specificity is more 
important than a high sensitivity and the opposite is true for treatments with little 
side-effects. In the situation that treatment is not available and biomarkers are 
used for diagnosis, one may prefer to use a cut-point with a low false positive rate 
as an incorrect diagnosis of AD may have a major negative impact on the patient. 
Future directions
Future MRI-studies need to investigate abnormalities in AD signature regions in and 
outside the MTL. A recent study found that subjects with future cognitive impairment 
(preclinical AD and MCI) also showed reduced brain volume in posterior cingulate/
precuneus and orbitofrontal cortex, at least 4 years before any cognitive symptoms 
[79]. Other structural MR studies also found abnormalities in AD or MCI outside the 
MTL region such as the corpus callosum [80-83], cingulum [84-86], parietal [87], 
temporal lobe other than MTL [88] and frontal lobe [89]. Future MRI-studies need 
to investigate abnormalities in AD signature regions in and outside the MTL. 
CONCLUSION
Volumetric hippocampal measurements are the best predictors of conversion to AD-
type dementia in subjects with MCI after 2 years follow-up and are able to predict 
annual cognitive decline. For the limited rater time, LEAP automated hippocampal 
measurement may be preferred.
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SUPPLEMENTARY DATA
Table S1. Measurement logistics MRI.
Rater time Computer calculation time
Manual hippocampal measurement 150 -
ICV measurement* 10 -
Segmentation with SIENAX** - 75
LEAP hippocampal measurement 4 250
MTA-score 5 -
Lateral ventricle 30 -
Time in minutes per scan. *ICV measurement time should be added to manual hippocampal 
measurement. ** Segmentation time should be added to time needed for lateral ventricle 
measurement. ICV: intracranial volume, LEAP: learning embeddings for altas propagation, 
MTA: medial temporal lobe atrophy. 
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Table S2. Differences between AD (AD+) and non-AD (AD-) in both cohorts.
Descripa VUmc
AD – (1) AD + (2) AD – (3) AD + (4)
N 126 30 111 61
Age 69.4 (55.2-89) 74.1 (63-90)** 70.4 (54-87) 72 (56-81)
Female (%) 60.3 56.7 38.7 54.1
Years education 8.4 (3-18)^^ 8.9 (3-22) † 11 (6-18) 11 (6-17)
MMSE score 
baseline
27.5 (18-30) 26 (21-29)** 27 (19-30) 26 (18-30)**
Z-score wordlist – 
delayed recal
-1.07 (-4.06;1.96)
-1.9  
(-3.16;-0.21)***
-1.43  
(-3.16;2.35)
-1.94  
(-3.46;-0.05)*
% ApoE 4 43.3 53.8 50 68.2
Manual hippo-
campus 
8107  
(5318-12882)^^
6891 
(5054 – 9149)***
7714  
(5454-10455)
7003  
(4850-9892)***
Leap hippocam-
pus
6033  
(3684-8281) ^^^
5324  
(4297-7254)***
5601  
(4088-7061)
5162  
(3327-6487) ***
MTA-score 2.5 (0-6) ^^^ 3.9 (0-7)*** † 1.8 (0-6) 3 (0-8) ***
Lateral ventricle
51446  
(12128-126853)
61652  
(25330-144640)
53474  
(10786-162353)
64470  
(8587-167163) *
All volumetric measurements are corrected for intracranial volume. 
AD: Alzheimer’s disease, MMSE: Mini-Mental State Examination score, APOe4: apolipoprotein 
E4, LEAP: Learning Embeddings for Atlas Propagation, MTA: Medial temporal lobe atrophy.
Differences between converters and non-converters in each separate cohort (group (1) vs 
group (2) and group (3) vs group (4): * p	< .05, ** p < .01, *** p < .001. 
Differences between non-converters (group (1) vs group (3)): ^^ p < .01, ^^^ p < .001. 
Differences between converters (group (2) vs group (4)): † p	< .05.
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Table S3. Cut-off points.
Youden Sensitivity 85%
Descripa VUmc Both Descripa VUmc Both 
Manual HC <7427 <7590 <7559 <8647 <8173 <8379
LEAP HC <5374 <5431 <5374 <6043 <5794 <5901
MTA-score (L+R) ≥3 ≥3 ≥3 ≥3 ≥1 ≥2
Lateral ventricle ≥58491 ≥45045 ≥58491 ≥31494 ≥38763 ≥34859
All volumetric measurements are corrected for intracranial volume and presented in mm3. 
HC: hippocampus, LEAP: Learning Embeddings for Atlas Propagation, MTA: Medial temporal 
lobe atrophy, L: left, R: right.
	  Fig. S1. Image of hippocampal LEAP segmentation. This figure shows an example of an 
image of hippocampal volume segmentation for horizontal, coronal, and sagittal sections 
using the atlas-based LEAP method.
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Fig. S2. Bland-Altman Plot displaying the agreement between both volumetric 
hippocampal measurements (values are log-transformed). Both measures are 
corrected for intracranial volume. 
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Appendix S1. Scan parameters and MRI protocols used at each center.
DESCRIPA
CENTER HUDDINGE
Siemens Avanto 1.5 T, 21 slices, FOV 220 mm, FOV phase 87.1, distance factor 30, 
phase R>L, slice thickness 5.0 mm, TE: 96 ms, TR: 4000 ms, flip angle 150◦, number 
of averages 1.
Siemens Symphony 1.5 T, 21 slices, FOV 220 mm, FOV phase 75.0, distance factor 
30, phase R>L, slice thickness 5.0 mm, TE: 99 ms, TR: 4100 ms, flip angle 150◦, 
number of averages 2.
CENTER KUOPIO
Siemens Vision 1.5 T, T1 3D-scan, MPRAGE OBL; COR>TRA, FOV 250, mat 256x256, 
128 slices, TR 9.7ms, TE 4 ms, Slice th 2.0mm, no slice gap, flip angle 12◦
CENTER MALMO 
Siemens Sonata 1.5 T, MPRAGE + lmpr-cor, 144 slices, FOV 250 mm, phase R>L, TR 
1970, TE 3.93, distance factor 50, slice thickness 1.5 mm, flip angle 15◦.
CENTER MUNICH 
Siemens Magnetom Vision; 1.5 T; MPRAGE; Slice thickness 1.05 mm, TR 11.4, TE 
4.4, TI 300; FOV 256*256; Flip angle 8 graden; number of averages 1.
CENTER THESSALONIKI 
Siemens Expert Plus unit 1.0 T, 3D-MPR: 15 (TR) ,7 TE ,8 FLIP ANG., 250 (Slabth), 
1,49Ef thick, 168 Partitions, 250 FOV,256x192 Matrix, 1 Aquis. ,ACQ TIME 10,21min
CENTER BRESCIA 
Philips Gyroscan PG 1.0 Tesla: sagittal 3D T1 scan: TR= 20 ms, TE= 5 ms, flip angle= 
30°, field of view= 220 mm,  acquisition matrix 256 × 256, number of slices= 100/130, 
slice thickness 1,3 mm.
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CENTER GENOA 
Philips Intera 1.5 Tesla: Sagittal MP RAGE : t1w/3d/tfe, TR 8.5, TE 3.9, Flip 8, thickness 
1,no overcontiguous, no gap, matrix 100% 256, fov 256, reconstructed voxel size 
1.00/1.00/1.00, rfov 100%, T1  t1w/se, TR 580, TE 15, flip 69, slices 22, thick 5mm, 
matrix 80% 240, fov 240, rfov 75%,  pre (tra)- and postGD-GDPA (tra, sag, cor)
CENTER MAASTRICHT 
Philip NT, 1.5 T Gyroscan: T1-weighted images obtained in the coronal plane using a 
3D-gradient fast field echo (FFE) sequence. TR = 35 ms, TE = 7 ms, FA= 35, FOV= 240 
mm,slice thickness = 1.5 mm, matrix size = 256x256, voxelsize = 0.94mm x 0.94mm 
x 1.5 mm.
CENTER MANNHEIM 
Siemens Medical solution Magnetom, Vision plus  1.5 Tesla: T1 MPR 30, TR=11.4 
ms, TE=4.4 ms, flipangle=15, FoV=256mm, format 8/8, slices=162, no gap.
 
 
CENTER VUmc  (VUmc data from DESCRIPA + an additional sample)
Siemens Magnetom Impact Expert 1.0 T, 3D scan, 168 slices, FOV 250 mm, matrix 
256 × 256; slice thickness 1.5 mm, TE: 7 ms, TR: 15 ms, TI 300 ms, flip angle 15◦.
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ABSTRACT
The present study compares four different structural magnetic resonance imaging 
techniques used to measure gray matter (GM) atrophy in Alzheimer’s disease 
(AD): manual and automated volumetry, cortical thickness (CT) and voxel-based 
morphometry (VBM). These techniques are used interchangeably in AD research 
and thus far it is unclear which technique is superior in detecting abnormalities early 
in the disease process. 18 healthy participants without any memory impairment, 
18 patients with MCI, and 17 patients with mild AD were included and between-
group differences were investigated in AD signature regions (areas in the prefrontal 
cortex (PFC), medial temporal lobe (MTL) and posterior parietal cortex (PPC)). Both 
manual volumetric measurements and VBM were able to detect GM atrophy in 
the early stages (differentiation controls and MCI), mainly in the MTL. In the early 
phase, automated volumetric measurements showed GM differences in the PPC 
but not in the MTL. In our sample, CT measurements were not sensitive for group 
differences in the early stages. PFC regions showed abnormalities in the later stages 
(controls vs AD) when manual volumetric measurements or VBM are employed. 
Manual volumetric measurements together with VBM are preferred techniques 
for assessing GM differences showing abnormalities in most of the investigated 
regions, with a predominance of the MTL in the early phase. Automated FreeSurfer 
volumetric measurements show similar performances in the early phase, displaying 
group differences in the PPC but not in MTL regions. Measurements of CT are less 
sensitive in the MCI stage and it’s sensitivity is restricted to the MTL and PPC regions 
in later stages of the disease (AD). 
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INTRODUCTION
Since the prevalence of Alzheimer’s disease (AD) is expected to increase rapidly 
in the following decades, early detection and intervention in persons who are at 
risk for developing AD is an important public health goal. Clinical and pathological 
evidence indicates that older individuals who have significant memory impairment 
but are not demented may be in a transitional phase between normal aging and AD, 
a state often referred to as as ‘mild cognitive impairment’ (MCI) [1]. A large part of 
the patients with MCI have a high likelihood of progressing to probable AD within 
a few years [2-4]. Brain imaging can aid the early diagnostic process, ultimately by 
detecting neurodegenerative abnormalities at an earlier stage than the standard 
neurological examination or before objective signs are present [5, 6]. Imaging can 
furthermore help to select MCI-subjects for AD-trials by detecting differences in 
an early stage and is able to monitor disease progression.Within the domain of 
magnetic resonance imaging (MRI), the major focus lies on manual segmentation 
of structures known to be involved in dementia, especially the parahippocampal 
gyrus and the hippocampus [7-9].
The present study compares four different structural MRI techniques used to assess 
gray matter (GM) atrophy in AD. Manual volumetry, still considered gold standard 
[10-12], is however time-consuming, making it difficult to implement in routine 
clinical practice or for large-scale research use. To overcome the disadvantages of 
manual volumetry, techniques to perform automated (whole brain) analyses have 
been designed, e.g. Voxel based morphometry (VBM), automated segmentation 
methods (e.g. FreeSurfer) and cortical thickness (CT). Automated measurements 
are widely implemented and fast, but may underestimate atrophy status and thus 
lead to false negatives results [13]. CT analysis in AD patients has revealed cortical 
thinning in several brain regions known to be affected in AD [14-16] and this thinning 
has furthermore shown to be related to the severity of AD, even in early stages [17]. 
The main disadvantage of the method is its inaccuracy in medial cortical areas (e.g. 
parahippocampal gyrus) and the impossibility to determine cortical thickness in the 
hippocampal region.
Another widely used technique to study brain atrophy in-vivo is voxel-based 
morphometry (VBM), a method to calculate voxel-wise gray matter concentration of 
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brain areas based on a whole-brain analysis [18, 19]. Volume changes of GM, white 
matter (WM) and cerebrospinal fluid (CSF) are examined separately. The automated 
computational procedures of VBM are unaffected by inter-rater differences and 
anatomical boundary shifts are minimized by the utilization of statistical maps 
and segmentation techniques [20]. VBM can be applied as a first-pass strategy, to 
generate hypotheses [21]. Disadvantages of VBM can be found in the pre-processing 
phase, when warping and smoothing of MRI data is applied. Warping algorithms may 
not always succeed in matching the anatomical characteristics across participants 
and smoothing furthermore reduces the individual variability of gyrus and sulcus 
features [22]. Especially when degenerated brains are studied, these steps might 
induce both type I and II errors in the outcome. VBM furthermore does not provide 
information of brain atrophy at a single-subject level, it only permits group-level 
analysis, limiting its diagnostic employability in the clinical setting.  
The four techniques mentioned above are used interchangeably in AD research 
and thus far it is unclear which technique is superior in detecting abnormalities 
early in the disease process. Since manual volumetric measurements of the medial 
temporal lobe (MTL) are hard to implement in everyday clinical practice, possible 
alternatives to measure GM atrophy in AD are evaluated. It is furthermore known 
that AD pathology is not restricted to the MTL lobe and that prefrontal [23] and 
posterior parietal regions [24] also show abnormalities early in the disease process. 
In this study, regions were selected based on their relevance for AD. 
This is, to our knowledge, the first study directly comparing four techniques which 
measure gray matter atrophy in a group of healthy controls, patients with MCI 
and patients suffering from mild AD. We evaluated which technique is superior in 
detecting abnormalities early in the disease process. In addition, we investigated 
whether atrophy of prefrontal cortex (PFC), posterior parietal cortex (PPC) or medial 
temporal lobe (MTL) regions is most indicative of (preclinical) AD.
MATERIALS AND METHODS
Subjects
Three groups of older male participants were included: 20 healthy participants 
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without any objective memory impairment (controls), 20 patients with amnestic 
MCI, and 20 patients with mild AD. Controls were recruited by means of an 
advertisement in local newspapers. An extensive neuropsychological test battery 
was administered and subjects were included when their performance did not 
deviate from normal on the Verbal Learning Test [25, 26]. Patients with MCI and mild 
AD were recruited from the Memory Clinic of the Maastricht University Hospital. 
Diagnosis was made according to the Petersen criteria for MCI (with at least an 
impairment in the memory domain) [27, 28], and the DSM-IV [29] and NINCDS-
ADRDA criteria for AD [30]. Diagnosis was based on medical history, co-morbidity, 
course, and MRI scanning. The MRI scan was only acquired to exclude neurosurgical 
lesions vascular pathology; levels of atrophy were not used for the diagnosis of MCI 
and AD.
Exclusion criteria were: MRI-contraindication, abuse of alcohol and drugs, other 
past or present psychiatric or neurological diseases or serious system diseases, and 
structural abnormalities in the brain that could account for the cognitive decline. 
Two participants in the control group were excluded because a brain infarct was 
detected on the MRI scans. Two participants in the MCI group, and three in the AD 
group were excluded because their MRI images showed motion artefacts. The study 
was approved by the local Medical Ethics Committee of the Maastricht University 
Medical Centre. Written informed consent was obtained from all participants and 
from the primary caregiver of the AD patients in accordance with the committee’s 
guidelines and with the Declaration of Helsinki [31]. 
Image acquisition and analysis  
MRI scans were acquired with a 3 Tesla Gyroscan NT MRI scanner (Philips, Best, 
The Netherlands). Structural T1 images were acquired in the sagittal plane using an 
MPRAGE sequence (TR=8 , TE= 3.7 msec, FA= 8°, FOV= 240 X 240, matrix size= 240 
x 240, number of slices= 180). Regions of interest were selected in the prefrontal 
cortex (inferior prefrontal cortex, orbitofrontal cortex), posterior parietal cortex 
(precuneus, posterior cingulate cortex) and medial temporal lobe (hippocampus, 
parahippocampal gyrus). For each technique, left and right side of each selected 
region were analyzed separately.
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Manual	volumetry
For the manual tracing we used GIANT (General Image Analysis Tools; [32]), a 
customized software program which allows tracing of regions of interest (ROI) in a 
triplanar and rotatable 3D surface-rendered view, and calculation of  GM volumes 
of interest. Boundaries of selected frontal and temporal structures were set 
according to criteria described in a previous publication [33] (Supplementary Table 
S1). Boundaries of the posterior cingulate and precuneus cortex were adapted from 
Jones et al. [34] and Ryu et al. [35] respectively (Supplementary Table S1).
Both raters (LC, CE) were blind to the demographic and cognitive 
characteristics of the participants. Intra-rater reliability was determined by the 
Intraclass Correlation Coefficient (ICC) [36]. To account for age-related cortical 
shrinkage we measured the intracranial volumes (ICV) with the FSL Brain Extraction 
Tool [37]. Our analyses were corrected for ICV, which partials out individual variability 
in maximal total brain volume achieved in adulthood independent from possible 
brain atrophy at later ages  (Supplementary Table 1). To control for Type I errors, 
we performed the false discovery rate (FDR) controlling procedure, a correction 
for multiple comparisons [38]. This method differs from the classical Bonferonni 
approach in that it is less stringent and as such also reduces the increased probability 
of making Type II errors.
Automated	volumetry  
In accordance with Gronenschild et al. [39], a Macintosh with OSX 10.5.8. was used 
for analysis. Cortical reconstruction and volumetric segmentation was performed 
with FreeSurfer version 4.5.0, which is freely available (http://surfer.nmr.mgh.
harvard.edu). In this approach, brain areas are segmented using a nonlinear 
template matching [40]. After linearly registering the test image to the template, 
the algorithm estimates the nonlinear transformation between a given MRI and a 
probabilistic atlas of the selected brain structure constructed from a cohort of 14 
young and middle-aged subjects using a maximum likelihood criterion. Probabilistic 
labels are warped back to the individual MRI using the inverse of this transform. 
The final segmentation is accomplished by maximizing the a posteriori probability in 
the Bayes formula at each voxel. Voxel-wise probabilistic labels and their predicted 
image intensities serve as the prior term, while the intensity similarity between the 
target image and the template serves as the likelihood term.
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In this study, FreeSurfer voxel volumes were used (not the tabulated volumes 
corrected for partial volume effects) in order to obtain a proper comparison with the 
manual volumetric measurement. The borders of the FreeSurfer ROI of the isthmus 
fits best with our definition of the posterior cingulate cortex as adopted for the 
manual segmentation and were subsequently used. The posterior cingulate cortex 
ROI included in the FreeSurfer automated measurement is more rostral compared 
to our definition.
Cortical	thickness	(CT)	
The FreeSurfer CT pipeline has been described and validated in previous publications 
(Dale et al., 1999; Fischl et al., 1999; Fischl and Dale, 2000; Han et al., 2006). To 
summarize, processing involves intensity normalisation, registration to Talairach 
space, skull stripping, segmentation of WM, tesselation of the WM boundary, 
smoothing of the tesselated surface and automatic topology correction. The 
tesselated surface is used as the starting point for a deformable surface algorithm 
to find the WM and then the pial boundary. For each point on the tesselated WM 
surface, the CT is calculated as the average of the distance from the WM surface 
to the closest point on the pial surface and from that point back to the closest 
point on the WM surface [41]. The cortex of the brain was automatically subdivided 
into gyral-based regions of interest (ROIs) [42]. To accomplish this, a registration 
procedure was used that aligns the cortical folding patterns and probabilistically 
assigns every point on the cortical surface to one of the 32 ROIs. For the purposes of 
this study, we focused on 6 ROIs bilaterally. For each ROI the mean cortical thickness 
was extracted for subsequent statistical analysis.
For our second approach, a vertexwise analysis, we mapped the thickness 
measures on the inflated surface of each participant’s reconstructed brain. This 
allows visualization across the surface without interference from cortical folding. 
Maps were smoothed using a circularly symmetric Gaussian kernel with a full 
width half maximum (FWHM) of 20 mm and averaged across participants using a 
non-rigid high-dimensional spherical method to align cortical folding patterns to 
a template supplied by FreeSurfer. This procedure provided accurate matching of 
morphologically homologous cortical locations among participants on the basis of 
each individual’s anatomy while minimizing metric distortion, resulting in a mean 
measure of cortical thickness at each vertex on the reconstructed surface.
Statistical comparisons between the surface maps were generated by computing a 
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general linear model of the group effects (corrected for age centered) on thickness 
at each vertex in the cortical mantle. Maps were created using a statistical threshold 
of p = 0.05. A cluster-wise procedure was performed to correct for multiple 
comparisons. This method utilizes a simulation to get a measure of the distribution 
of the maximum cluster size under the null hypothesis.  Z-maps are synthesized and 
smoothed using a residual FWHM, and then thresholded at p = 0.05. Next, areas 
of maximum clusters are recorded, under these specifications, and the procedure 
is repeated for 5000 iterations. Once the distributions of the maximum cluster size 
are obtained, correction for multiple comparisons is performed by finding clusters 
in the statistical maps using the same threshold as was given in the simulation 
procedure. For each cluster, the p value is the probability of seeing a maximum 
cluster of that size, or larger, during the simulation. Clusters remaining in similar 
areas of significance as in the original cortical thickness maps would indicate that 
the result is not likely due to chance. For each cluster, maximum, minimum, mean 
and standard deviation of the p-values were extracted.
Voxel-based	morphometry	(VBM)
Structural data was analyzed with FSL-VBM, a voxel-based morphometry style 
analysis carried out with FSL tools [43]. First, structural images were brain-extracted 
using BET [37]. Next, tissue-type segmentation was carried out using FAST4 [44]. 
The resulting GM partial volume images were then aligned to MNI152 standard 
space using the affine registration tool FLIRT [45, 46] followed by nonlinear 
registration using FNIRT [47, 48], which uses a b-spline representation of the 
registration warp field [49]. The resulting images were averaged to create a study-
specific template, to which the native gray matter images were then non-linearly re-
registered. The registered partial volume images were then modulated (to correct 
for local expansion or contraction) by dividing by the Jacobian of the warp field. The 
modulated segmentated images were then smoothed with an isotropic Gaussian 
kernel with a sigma of 2 mm. Finally, voxelwise general linear modeling (GLM) was 
applied using permutationbased nonparametric testing (5000 permutations). [50]
ROI’s for displaying significant volume loss were selected based on the Harvard-
Oxford cortical and subcortical atlas, which is also integrated in FSLview for inspection 
and identification. The following regions were selected: precuneus, hippocampus, 
parahippocampal gyrus, posterior cingulate gyrus, inferior frontal gyrus (sum of 
pars opercularis and pars triangularis) and frontal orbital cortex.
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Statistical analysis
Statistical analyses were performed with the Statistical Package for the Social 
Sciences (SPSS, Chicago, IL, USA) version 19.0. Demographical and cognitive group 
differences were compared with ANOVA.  The ROI-based measures (manual 
volumetric measurement, FreeSurfer automated measurement and mean CT) 
were compared between the 3 groups by means of a pairwise ANCOVA for each 
separate technique (manual volumetric measurement, FreeSurfer automated 
measurement and CT-ROI measurement), with volume as dependent variable, 
group as independent variable (fixed factor), and intracranial volume (ICV) and 
centered age as covariates. For the vertex-wise CT-analysis, statistical analysis was 
carried out by means of FreeSurfer (see above, paragraph 2.2.3). For VBM, voxel-
wise GLM was applied using permutation-based non-parametric testing, including 
a correction for multiple comparisons across space. Corrected p-values are stated 
in the result section (p
corr
).
RESULTS
Subject characteristics 
The three groups significantly differed with respect to age (MCI<AD, p=0.03; 
CON<AD, p=0.02), Mini-Mental state examination (MMSE) score (CON>MCI, p=0.03; 
MCI>AD, p<.001; CON>AD, p<.001) and score on the delayed recall task (CON>MCI, 
p<.001; MCI>AD, p<.05; CON>AD, p<.001), but not with respect to educational level. 
Subject characteristics are shown in table 1 and volumetric comparisons between 
the three groups are shown in supplementary table S2 (manual segmentation) and 
supplementary table S3 (automated segmentation).
Group differences 
Manual	volumetric	measurement		
Manual volumetric measurements of the right parahippocampal gyrus (PhG) were 
able to differentiate between controls and MCI patients (F=15.93, p
corr
<.001). 
In later stages of the disease (controls versus AD) differentiation was possible in 
the following structures: left hippocampus (F=5.14, p
corr
<.05), right hippocampus 
(F=6.86, p
corr
<.05), left PhG (F=29.87, p
corr
<.001), right PhG (F=21.21, p
corr
<.001), 
left orbitofrontal cortex (OFC) (F=20.24, p
corr
<.001), right orbitofrontal cortex (OFC) 
(F=11.28, p
corr
<.01), left posterior cingulate cortex (PCC) (F=4.90, p
corr
<.05), left 
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precuneus (PC) (F=7.50, p
corr
<.01) and right PC (F=15.88, p
corr
<.001). Discrimination 
between early and later stages of the disease (MCI versus AD) was possible by 
manual measurements of the left PhG (F=17.20, p
corr
<.001), left inferior prefrontal 
cortex (IPFC) (F=11.11, p
corr
<.01), left OFC (F=10.66, p
corr
<.01) and right PC (F=6.48, 
p
corr
<.01) (Table 2). 
Table 1. Subject characteristics
Con MCI AD
N 18 18 17
Age 64.56 (3.4) 65.11 (4.5) 70.59 (9.1)
Educational level 4 (1.4) 4 (1.8) 4 (1.9)
MMSE score 28.89 (0.9) 27.61 (2.3) 21.18 (3.9)
15 WLT learning 37.50 (7.6) 26.06 (9.8) 23.47 (11.7)
15 WLT memory 8.56 (1.9) 3.67 (2.8) 1.73 (2.4)
Fluency animals 23 (5.3) 21 (5.4) 13.93 (4.7)
Manual hippocampus 
volume L/R (mm3)
4656 (308)/ 
4758 (637)
4410 (482)/ 
4308 (796)
3883 (817)/ 
3807 (876)
ICV (ml) 1492 (100) 1539 (121) 1574 (125)
All volumetric measurements are corrected for intracranial volume. Values are mean (sd). 
MMSE: Mini-Mental state examination; WLT: wordlist; Con: controls; MCI: mild cognitive 
impairment; AD: Alzheimer’s disease.
Automated	volumetric	measurement
FreeSurfer automated volumetric measurements were able to differentiate 
between controls and MCI-patients in the left PCC (F=7.82, p
corr
<.01) and right PC 
(F=6.78, p
corr
<.05). As the disease progresses, differences between controls and AD 
were most notably in the left hippocampus (F=11.54, p
corr
<.01), right hippocampus 
(F=13.35, p
corr
<.001), left PCC (F=14.04, p
corr
<.001), right PCC (F=16.34, p
corr
<.001) and 
right PC (F=12.69, p
corr
<.001) regions. MCI and AD patients could be distinguished by 
automated measurements of the right PCC (F=9.85, p
corr
<.01).
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Cortical	thickness
Quantification of cortical thinning by atlas-based ROI-analysis
Differences in CT were only present in the comparison between controls and AD-
patients in the right PCC (F=9.27, p
corr
<.01) and right ERC (Table 2).
Vertex-wise group comparison with clusterbased correction
Vertex-wise comparison of CT between controls and AD revealed one cluster in 
the left hemisphere and three clusters in the right hemisphere that demonstrated 
significantly reduced cortical thickness in AD (Figure 1, Table 3). These clusters mainly 
comprised temporal and parietal cortical areas. Two clusters in the left hemisphere, 
entirely situated in the frontal lobe, showed increased cortical thickness between 
controls and AD. For the comparison between MCI and AD, thinning was found in AD 
patients compared to MCI in the left hemisphere in parietal and temporal regions. 
In the right hemisphere thinning was found in parietal, frontal and temporal regions 
(Figure 2, Table 3).
VBM
The comparison between controls and MCI or AD showed several regions of significant 
GM loss compared with controls (p < 0.05, TFCE-corrected). VBM measurements of 
the left and right hippocampus were able to differentiate between controls and MCI 
patients (p <.05 and p	<.001 respectively, TFCE corrected). In later stages (controls 
versus AD), differentiation was possible in the following structures: left (p<.001, 
TFCE corrected) and right (p<.001, TFCE corrected) hippocampus, left (p<.001, 
TFCE corrected) and right PhG  (p<.001, TFCE corrected), right IPFC (p <.001, TFCE 
corrected), left (p <.01, TFCE corrected) and right OFC (p <.01, TFCE corrected), left 
(p <.001, TFCE corrected) and right PCC (p <.001, TFCE corrected) and left (p <.01, 
TFCE corrected) and right PC (p <.001, TFCE corrected). Discrimination between 
early and later stages of the disease was found for the left (p <.001, TFCE corrected) 
and right (p <.001, TFCE corrected) hippocampus, left (p <.001, TFCE corrected) and 
right PhG (p <.001, TFCE corrected), left (p <.01, TFCE corrected) and right IPFC (p 
<.01, TFCE corrected), left (p <.01, TFCE corrected) and right OFC (p <.001, TFCE 
corrected), right PCC (p <.05, TFCE corrected), and left ((p <.01, TFCE corrected) and 
right PC (p <.05, TFCE corrected)) (Table 4).   
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Figure 1. Cortical-thickness (CT) analyses for the differentiation between controls 
and AD-patients as measured by FreeSurfer. A.	Left	hemisphere	lateral	view,	B.	Left	
hemisphere	medial	view,	C.	Right	hemisphere	lateral	view	and	D.	Right	hemisphere	
medial	 view. Vertex-wise comparison showed one cluster in the left hemisphere 
and three clusters in the right hemisphere displaying significantly reduced cortical 
thickness in AD (A, B, C and D: temporal and parietal cortical areas; blue) compared 
to controls. Two clusters in the left hemisphere, entirely situated in the frontal lobe 
showed increased cortical thickness between controls and AD (A and B: red-yellow).
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Figure 2. Cortical-thickness analyses for the differentiation between MCI and 
AD-patients as measured by FreeSurfer.  A.	 Left	 hemisphere	 lateral	 view,	 B.	 Left	
hemisphere	medial	view,	C.	Right	hemisphere	lateral	view	and	D.	Right	hemisphere	
medial	 view.	 Vertex-wise comparison showed thinning patterns in AD patients 
compared to MCI in the left hemisphere in parietal and temporal regions (A and B). 
In the right hemisphere thinning was found in parietal, frontal and temporal regions 
(C and D).
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DISCUSSION
The present study showed that four different techniques used to assess gray matter 
atrophy in the brain show different results in the same dataset. When comparing 
controls with MCI-patients, manual volumetric and VBM measurements show 
abnormalities in the MTL region whereas automated volumetric measurements 
show abnormalities in PPC but not in MTL regions. In AD, abnormalities in the PPC 
regions (manual volumetric measurements, CT and VBM) and less pronounced in 
PFC regions (manual volumetric measurements, CT and VBM), become apparent. 
Differences between early (MCI) and late (AD) phases of the disease were most 
noticeable in PFC regions (manual volumetric measurements and VBM). 
This is to our knowledge the first study directly comparing four different measures 
to assess gray matter atrophy in the brain. Previous studies assessing gray matter 
atrophy patterns in AD mainly focused on MTL regions [51-55]. This study evaluates 
the discriminative power of each of these measurements, in and outside the MTL. 
Differences between techniques
In the early phase of the disease when differentiation between controls and MCI 
is valuable, manual volumetric measurements and VBM were both able to detect 
differences in the MTL (PhG and Hc respectively) whereas automated FreeSurfer 
segmentation was sensitive to differences in the posterior parietal lobe. This is 
in line with current evidence stating that both manual volumetric measurements 
[10, 56, 57] and VBM are sensitive in an early stage, with a predominance of MTL 
regions [58-60]. A recent study found that brain volume differences measured by 
VBM were already present at an early presymptomatic stage of AD, when subjects 
had no memory complaint or measurable cognitive impairment that would allow 
a clinical diagnosis of MCI or dementia according to current criteria [50]. It is 
furthermore known from the literature that automated segmentation techniques 
such as FreeSurfer are less suitable for hippocampal segmentation due to a frequent 
overestimation of hippocampal tissue volume leading to false-negative results [61]. 
This method seems however accurate in differentiating between controls and MCI 
in the parietal lobe [62, 63], which is again in line with our findings. 
In later stages of the disease, manual and VBM measurements showed 
significant group differences in MTL, PPC and PFC regions. Automated segmentation 
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and, less pronounced, cortical thickness measurements were sensitive to differences 
in MTL and PPC, but not in PFC regions. 
For differential diagnosis and to monitor disease progression, it is also 
relevant to investigate which techniques were able to detect affected regions 
between subjects with MCI and AD. Manual volumetry and VBM were able to 
differentiate MCI and AD patients in the PhG (manual volumetry), hippocampus 
(VBM), IPFC, OPFC and PC. Automated volumetry was able to differentiate MCI and 
AD in the right PCC, and cluster based CT-analysis in the left precuneus.
Regional abnormalities  
Our study showed that regional distribution of gray matter abnormalities was 
technique-dependent. Manual volumetric segmentation and VBM first showed 
abnormalities in the MTL regions, followed by PPC and PFC regions in the later 
stages. Automated volumetric measurements first showed abnormalities in the 
PPC region, followed by MTL regions. Abnormalities in cortical thickness became 
apparent later in the disease process, mainly in MTL and PPC regions. The increased 
cortical thickness found in the comparison between controls and AD was found 
in middlefrontal and orbitofrontal cortex areas, regions previously reported to 
show increased volume in older subjects [64]. The nature of this increase however 
remains unclear. In later stages of the disease only manual volumetric and VBM 
measurements were able to detect differences between controls and AD in PFC 
regions.
Atrophy progression in Alzheimer’s disease 
Based on the current literature and our findings a sequence of brain abnormalities 
in AD can be formulated. Gray matter atrophy initially starts in the anterior 
parahippocampal gyrus (entorhinal cortex region), then spreads to other medial 
temporal lobe (hippocampus) and posterior parietal regions (posterior cingulate 
and precuneus regions) [50, 65-67]. In later stages of the disease, pathology extends 
to prefrontal cortex regions [68]. This pattern is consistent with the spread of AD 
pathology evidenced by histopathology.
Limitations
The present study had several limitations. Since only cross-sectional data were 
available, no evaluation of predictive value for early Alzheimer’s disease can be 
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made for each of these techniques. Only males were included in this study in 
order to reduce interindividual variation. Generalisation of our findings to females 
should therefore be done with caution. Previous studies did however not reveal 
substantial genderrelated differences with respect to atrophy in AD. In this study, 
efforts were made towards an equality of anatomical boundaries for all of the 
investigated techniques. Although differences between ROI’s were small, borders 
of manual, automated and VBM measurements were not entirely overlapping. This 
could have led to some bias in the dataset. Furthermore, all techniques assessed 
gray matter atrophy but approaches of each technique differed. For example, the 
comparison of VBM with manual and automated volumetric measurements is not 
straightforward since VBM analyzes the brain by a voxel-wise analysis compared 
to the ROI-approach in volumetric measurement. The same is true for the CT 
ROI-measurement where the mean thickness of gray matter in a ROI is analyzed 
compared to total cortical volume of a ROI in the volumetric approaches. However, 
the power of each technique in discriminating between groups was analyzed in a 
similar statistical manner (with a same amount of statistical corrections). Finally, 
in this study only FreeSurfer automated volumetry was evaluated. Other (atlas-
based) automated measurements, which are outside the scope of this study, are 
also valuable for evaluation of gray matter atrophy in AD [12, 69, 70].
Clinical implications
Manual volumetry can still be considered as the gold standard for the evaluation 
of gray matter atrophy in AD [10, 56, 57]. The discriminative power of manual 
volumetric measurements is however restricted to the MTL in the early phase. 
Since medial temporal lobe regions such as the parahippocampal gyrus are among 
the first areas affected by the disease [7], measurement of its volume is clinically 
important and manual volumetric measurements, however time-consuming, 
could complement standard clinical practice by reporting GM abnormalities at 
the single subject-level. Despite the methodological considerations discussed 
in the introduction, VBM is also sensitive in the early stage. VBM is however less 
suitable for clinical implementation due to it’s incapability for reporting reduced 
GM volume at the single subject-level. A recent study [71] showed that the 
predictive accuracy for AD-conversion in subjects with MCI is similar for automated 
(LEAP segmentation) [70] and manual hippocampal measurement. However, the 
automated measurement used in our study (FreeSurfer), seems less suitable for 
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evaluation of medial temporal lobe atrophy in the early phase, but can complement 
the diagnostic process by assessing the degree of (posterior) parietal atrophy [72]. 
Evaluation of both medial temporal and posterior parietal regions in the early phase 
can strengthen the diagnosis of underlying AD pathology.
CONCLUSION
We conclude that the discriminative ability of different techniques measuring gray 
matter atrophy in the brain is region-specific. Manual volumetric measurements 
together with VBM are preferred showing abnormalities in most of the investigated 
regions, with a predominance of the MTL in the early phase. Automated volumetric 
measurements show similar performances in the early phase of the disease, 
displaying significant differences in the PPC but show limited discriminative power 
in MTL regions. Automated measurements of cortical thickness are less sensitive 
in the MCI stage and it’s sensitivity is furthermore restricted to the MTL and PPC 
regions in later stages of the disease (AD). Our data furthermore suggests, in line 
with the literature, that patients suffering from MCI first show abnormalities in the 
MTL (PhG and hippocampus) and PPC (posterior cingulate and precuneus) followed 
by abnormalities in the PFC (orbitofrontal en inferior prefrontal cortex) in the later 
stages. 
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analysis of diffusion tensor imaging and 
a comparison with medial temporal lobe 
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ABSTRACT
The aim of the present study is to evaluate the diagnostic value of diffusion tensor 
imaging (DTI) for early Alzheimer’s disease (AD) in comparison to widely accepted 
medial temporal lobe (MTL) atrophy measurements. A systematic literature 
research was performed into DTI and MTL atrophy in AD and mild cognitive 
impairment (MCI). We included seventy-six studies on MTL atrophy including 8122 
subjects and fifty-five DTI studies including 2791 subjects. Outcome measure was 
the effect size (ES) expressed as Hedges g. In volumetric studies, atrophy of the MTL 
significantly differentiated between AD and controls (ES 1.32-1.98) and MCI and 
controls (ES 0.61-1.46). In DTI-Fractional anisotropy (FA) studies, the total cingulum 
differentiated best between AD and controls (ES=1.73) and the parahippocampal 
cingulum between MCI and controls (ES=0.97). In DTI-Mean diffusivity (MD) 
studies, the hippocampus differentiated best between AD and controls (ES=-1.17) 
and between MCI and controls (ES=-1.00). We can conclude that in general, the 
ES of volumetric MTL atrophy measurements was equal or larger than that of DTI 
measurements. However, for the comparison between controls and MCI-patients, 
ES of hippocampal MD was larger than ES of hippocampal volume. Furthermore, it 
seems that MD values have somewhat more discriminative power than FA values 
with higher ES in the frontal, parietal, occipital and temporal lobe.
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INTRODUCTION
Alzheimer’s disease (AD), the most common cause of dementia, affects about 
33.9 million people worldwide. Over the next forty years, the prevalence of AD is 
expected to triple due to the aging population [1]. This creates an urgent need for 
early diagnosis of the disease to enable treatment at an early stage.  Many AD-
related research has focused on mild cognitive impairment (MCI), a transitional state 
between normal aging and early AD [2, 3]. Estimates of annual conversion from MCI 
to AD show a great variability, from 5% to 40% per year [4], depending primarily 
upon the setting in which the studies were carried out (clinical versus population-
based studies).Medial temporal lobe (MTL) atrophy as assessed on structural 
magnetic resonance imaging (MRI) has proven to be an effective clinical aid in the 
early diagnosis of AD [5], and this method could predict AD in subjects with MCI [6-
8]. Still, the diagnostic accuracy of MTL atrophy for AD is only moderately high [9].
Recently, MRI techniques have become available which can measure the integrity of 
cerebral white matter (WM). It has been shown that WM integrity is decreased in 
subjects with MCI and AD suggesting a potential diagnostic value that may possibly 
help to improve the diagnostic accuracy of MTL atrophy measurements [10, 11]. 
Integrity of WM tracts can be assessed using diffusion tensor imaging (DTI), which 
measures the diffusion of water molecules in neural tissue. By means of DTI one 
can detect whole-brain diffusional abnormalities at a stage where macrostructural 
changes may not have become visible yet. Hence, DTI may be an early marker for 
neurodegeneration. DTI-studies mostly use fractional anisotropy (FA) and mean 
diffusivity (MD) measurements in a priori defined regions of interest (ROI) or 
whole-brain voxel wise analyses to evaluate the integrity of WM in subjects with 
AD and MCI. FA is a measure of anisotropic water diffusion and reflects the degree 
of directional diffusion in cellular structures within the fiber tracts. By using FA one 
can evaluate fiber density, axonal diameter and myelination in WM [12]. A decrease 
in FA indicates a loss of fiber tract integrity and thus WM damage [13]. MD is a 
measure of diffusion in the noncolinear direction of free diffusion (translational 
diffusion). MD reflects the average diffusion within a voxel [13, 14]. An increase in 
MD represents a loss of anisotropy due to an increase in free water diffusion [15]. 
Abnormally decreased FA and increased MD in subjects with MCI and AD compared 
to controls suggests tissue damage which is consistent with neuropathological data 
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demonstrating partial loss of myelin, axons, and oligodendrial cells in white matter 
[16].
To date there have been several descriptive reviews of DTI studies of AD and MCI 
[15, 17, 18] and one review recently quantified the diagnostic value of DTI in 
subjects with MCI and AD [19]. The aim of the present study was to evaluate the 
potential diagnostic value of DTI for early AD in comparison to widely accepted MTL 
atrophy measurements by using a meta-analysis approach. We tested the ability 
of MTL and DTI measurements to discriminate between controls, subjects with 
MCI, and subjects with AD-type dementia. This meta-analysis is the first to quantify 
the potential diagnostic value of DTI in comparison with widely used MTL atrophy 
measurements. Furthermore, it is the first time that effect size (ES) measures 
between subjects with MCI and AD are compared with each other. This is important 
from a clinical point of view, as it indicates the degree of overlap between MCI and 
AD. 
METHOD
Search	strategy
An online literature search of the database PUBMED was conducted by one rater 
(LC) up to August 2011. The keywords used for searching volumetric MTL and DTI 
studies are listed in Table 1. Abstracts of the retrieved articles were screened for 
relevance. Searching the references of relevant papers identified further articles for 
inclusion. 
Data	selection
Inclusion criteria were: (i) the study included subjects with AD and/or MCI; (ii) the 
data on average DTI and/or MTL values and standard deviation were provided; 
(iii) the article was limited to humans; and (iv) the article was written in English, 
Dutch, German, or French. If raw scores were not presented in the article, 
authors were contacted and resulting data were added to the meta-analysis. 
Since ES was calculated with correction for sample size (see below), studies with 
a relatively small sample size in one of the groups (n < 10) were also included. 
We excluded MTL-studies that did not correct for intracranial volume (ICV), post 
mortem studies and studies using patient subgroups of ‘vascular’ MCI or AD. For 
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the DTI articles, limitation of the search to the time period of the last 10 years 
ensured that the scanning techniques met current standards. We included DTI 
studies that used different methods of extracting DTI data: manual segmentation, 
(semi-) automated ROI or tractography. Studies using whole-brain voxelwise 
analyses (VBM) and tract-based spatial statistics (TBSS) were also included. 
Data	extraction	and	analysis
One rater (LC) recorded the mean and standard deviation of all the investigated 
structures for each subgroup (controls, MCI, AD) by means of a data extraction form 
using Microsoft Excel (Microsoft Corporation, Redmond, USA). Data on different 
MTL structures (hippocampus, entorhinal cortex and parahippocampal gyrus) were 
extracted separately. Values in ROI were taken from the average of left and right 
hemisphere. Articles that reported the visually rated MTA score [20] were also 
included. Diffusional data were classified in the same way, according to region 
and DTI modality. DTI- measurements of the following regions were included in 
the meta-analysis: frontal, parietal, temporal, or occipital lobe white matter (WM), 
hippocampus, parahippocampal gyrus, anterior, middle, posterior, parahippocampal 
and total cingulum, anterior and posterior corpus callosum (CC), uncinate fasciculus 
(UF), superior longitudinal fasciculus (SLF), and internal capsule. To correct for small 
sample size, ES was calculated using Hedge’s g, which is the difference between 
group means divided by the pooled standard deviation [21]. Effect sizes between 
0.2 and 0.5 were classified as small, between 0.5 and 0.8 as medium, and over 0.8 
as large [22]. The following group comparisons were made: subjects with AD versus 
controls, subjects with MCI versus controls and subjects with AD versus subjects 
with MCI. We only performed pooled analyses if at least 3 independent studies 
contributed data for a specific combination of region and technique [23].
Heterogeneity was assessed with Cochrane’s Q, which is calculated as the weighted 
sum of squared differences between individual study effects and the pooled effect 
across studies [24]. Since there was a significant level of heterogeneity between 
the studies, pooled Hedge’s g was calculated using a random effects model [25]. 
Basic assumption of the random effects model is that the effects being estimated 
in the different studies are not identical, but follow some distribution around a 
mean global effect. We performed meta-analysis to identify possible explanations 
for heterogeneity. We tested the effect of subject characteristics (age, Mini Mental 
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State Examination (MMSE) and Clinical Dementia Rating Scale (global score) (CDR)) 
and data acquisition parameters (MTL: field strength and slice thickness; DTI: field 
strength, b-value, voxel size, number of directions and number of excitations (NEX)) 
on Hedge’s g using random effects meta-regression. Analyses were only performed 
if at least 6 studies provided data for the analysis.
Publication bias or the tendency of researchers to handle the reporting of 
experimental results that are positive differently from those that are negative (or 
inconclusive), leads to bias in the overall published literature [26]. This bias may 
lead to an overestimation of observed effects. We tested for this with the Begg and 
Mazumdar adjusted rank correlation test [27] and with funnel plots. 
RESULTS 
MTL	atrophy
In total 2544 articles assessing MTL structures in AD and/or MCI were found. 
Seventy-six studies investigated atrophy in the MTL region and were subsequently 
included with a total of 8122 participants: 2431 subjects with AD, 2515 subjects 
with MCI and 3176 controls. Subject characteristics of the included MTL atrophy 
studies are provided in Table 2. Technical specifications of the MTL atrophy studies 
can be found in Supplementary Table 1.
MTL measurements
For the comparison between subjects with AD and controls, ES Hedge’s g was 
significant for all 4 measures studied (Table 3). Effect sizes were all large, ranging 
from 1.32 (parahippocampal gyrus) to 1.98 (entorhinal cortex). When comparing 
subjects with MCI and controls, Hedge’s g was again significant in all 4 measures 
investigated (Table 3). ES was large for entorhinal cortex volume (1.46), MTA-score 
(1.11) and hippocampal volume (0.89) and medium for parahippocampal gyrus 
volume (0.61). The comparison of subjects with MCI and AD was significant for all 
4 measures (Table 3). ES was large for entorhinal cortex (1.17), hippocampus (0.93) 
and parahippocampal gyrus (0.92) and medium for MTA-score (0.74).
Heterogeneity and meta-regression
Nine of 12 effect sizes showed a significant level of heterogeneity (Table 3). Fixed 
effects meta-regression showed no significant associations between ES and subject 
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characteristics or data acquisition parameters.
Publication bias
Four of 12 group comparisons (controls vs AD; entorhinal cortex and hippocampal 
volume, controls vs MCI; entorhinal cortex, MCI vs AD; hippocampal volume) 
displayed a significant level of publication bias as measured by Begg and Mazumdar’s 
rank correlations (Table 3). 
DTI
In total 415 articles on DTI in AD and/or MCI were found. Fifty-five studies were 
included in the meta-analysis with a total of 2791 participants: 819 AD, 715 MCI 
and 1257 controls. Subject characteristics of the included DTI studies are provided 
in Table 4. Technical specifications of the DTI studies can be found in Supplementary 
Table 2.
Fractional anisotropy
For the comparison between subjects with AD and controls, the ES was significant 
in 10 of the 15 investigated regions (Table 5). A large ES was found in the total 
cingulum (1.73), parahippocampal cingulum (1.17), splenium of the corpus callosum 
(CC) (1.10), uncinate fasciculus (1.03) and posterior cingulum (0.84). Medium effect 
sizes were found in the SLF (0.77), frontal lobe (0.70), genu CC (0.63), temporal lobe 
(0.57) and middle cingulum (0.42). 
Between subjects with MCI and controls, Hedge’s g was significant in 5 of the 12 
regions studied (Table 5). A large ES was found in the parahippocampal cingulum 
(0.97) and a medium effect size in the posterior cingulum (0.65). A small ES 
was detected in splenium CC (0.44), genu CC (0.41) and temporal lobe (0.38). 
The comparison between subjects with MCI and AD was significant in 5 of the 8 
regions studied: splenium CC (0.51), posterior cingulum (0.37), genu CC (0.35), 
frontal lobe (0.29) and temporal lobe (0.27). Effect sizes were all small (Table 5).
Mean diffusivity
For the comparison of AD and controls, the ES was significant in all the 10 
investigated regions (Table 6). A large ES was found in the hippocampus (-1.17), 
parietal lobe (-1.03), splenium CC (-0.94) and temporal lobe (-0.89). A medium ES 
was detected in the frontal lobe (-0.75), posterior cingulum (-0.74), UF (-0.72), genu 
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CC (-0.67), occipital lobe (-0.67) and internal capsule (-0.66). When comparing MCI 
with controls, Hedge’s g was significant in 7 of the 9 investigated regions (Table 5). 
A large ES was found in the hippocampus (-1.00) and a medium ES in the parietal 
lobe (-0.69). A small ES was found in splenium CC (-0.46), genu CC (-0.43), temporal 
lobe (-0.40), frontal lobe (-0.32) and posterior cingulum (-0.26). The comparison 
between subjects with MCI and AD was significant in 3 of the 5 regions studied: 
posterior cingulum (-0.40), genu CC (-0.32) and splenium CC (-0.04). All effect sizes 
were small (Table 5).
Heterogeneity and meta-regression
Twenty of 35 effect sizes for FA (Table 5) and 10 of 24 effect sizes for MD (Table 
6) showed a significant level of heterogeneity. To investigate possible sources of 
heterogeneity, fixed effect regression was performed using patient characteristics 
(age, MMSE, CDR) and acquisition details (field strength, b-value, voxel size, number 
of directions and number of excitation).  Meta-regression found some evidence 
that the ES was dependent on disease severity. In the comparison between controls 
and subjects with AD ES increased with severity of the disease: ES of parietal 
lobe FA (B=-0.1, p=0.04) and genu CC MD (B=-0.2, p=0.01) increased with lower 
MMSE-scores. Comparing controls and MCI-patients: ES of occipital lobe MD (B= 
-0.18, p<0.001) and hippocampal MD (B=-0.5, p=0.02) increased with lower MMSE-
scores (Figure 1). Meta-regression furthermore indicated that a number of technical 
parameters were associated with ES (Supplementary Table 3).
Publication bias
Seven of 59 group comparisons for DTI displayed a significant level of publication 
bias, measured by Begg and Mazumdar’s rank correlations. For FA, publication bias 
was present at comparisons between controls and AD in frontal WM, genu CC, 
splenium CC and uncinate fasciculus, and between controls and MCI in splenium 
CC. For MD, the parietal lobe (controls vs AD) and the hippocampus (controls vs 
MCI) showed a significant level of publication bias (Tables 5 and 6, Figure 2).
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DISCUSSION 
The aim of the present study was to compare the value of structural MTL 
measurements with DTI modalities in discriminating controls, subjects with MCI 
and AD. Volumetric MTL atrophy measurements showed large effect sizes in all MTL 
regions investigated. Besides volumetric assessment of MTL regions, also diffusivity 
measurements seem to be sensitive for group differences in distinct brain regions, 
especially in temporal, parietal, cingulate and callosal regions.
Group	differences	within	and	between	MRI	modalities
For all group comparisons, the absolute ES of volumetric MTL atrophy measurements 
was somewhat larger than for the DTI measurements. However, for the comparison 
between controls and MCI-patients, ES of hippocampal MD was larger than ES 
of hippocampal volume. This is in line with Müller [28] who stated that elevated 
diffusivity (MD) in hippocampal regions, particularly on the left side, was the 
strongest independent predictor of poor verbal memory performance in the total 
group of MCI patients and controls whereas hippocampus size could explain rather 
low proportions of variation in memory function. 
As expected, for both structural and DTI measurements, ES for the differences 
between AD and controls were larger than the ES for the differences between MCI/
controls, and MCI/AD. 
The largest difference in ES between MTL atrophy and DTI measurements was seen 
in the comparison between MCI and AD. In this comparison, the DTI measurements 
had smaller ES than MTL atrophy measurements, indicating that DTI measurements 
showed more overlap between subjects with MCI and AD than MTL atrophy 
measurements. This could mean that in subjects with cognitive impairment loss 
of WM integrity precedes macroscopic atrophy. It could also be due to the fact 
that the difference in average MMSE score between subjects with MCI and AD was 
slightly larger in the MTL atrophy studies (5.10) compared to the DTI studies (4.45), 
which may increase the ES for the MTL atrophy studies (see below).  
There may be several explanations for the differences in ES between MTL atrophy 
and DTI measurements. First, there are more studies available investigating MTL 
atrophy compared to DTI, resulting in somewhat smaller ES and larger standard 
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deviations for the DTI studies. Second, the ES is dependent on both the difference 
between the groups and the standard deviation and thus it is possible that in some 
regions DTI modalities have a somewhat lower ES due to a larger variability between 
subjects. Third, as mentioned above, subjects with MCI or AD included in MTL 
atrophy studies might have more severe cognitive impairment than subjects with 
MCI and AD included in DTI studies. However, we found no significant differences in 
severity of cognitive impairment in subjects with AD between MTL atrophy and DTI 
studies, as measured by the MMSE. For the MTL studies mean (sd) MMSE score for 
AD-patients was 21.41 (2.38) compared to 21.39 (3.04) for the AD-patients in the 
DTI studies (p=0.85). Although it is possible that for specific comparisons there may 
be differences in disease severity (see above), it seems unlikely that the differences 
in ES between MTL and DTI studies are in general attributable to differences in 
disease severity between the MTL atrophy and DTI studies. 
Topographic	differences 
DTI abnormalities were found in many different regions. FA and MD changes seem 
to follow a slightly different anatomical pattern. Highest ES (relative to controls) for 
DTI-FA were typically seen in cingulate and callosal areas (total cingulum, posterior 
cingulum, parahippocampal cingulum, splenium CC and uncinate fasciculus). For 
DTI-MD the largest differences were seen in the hippocampus, followed by the 
parietal lobe, splenium CC and temporal lobe. In general effect sizes of DTI-FA were 
comparable to those of DTI-MD. Smaller effect sizes in DTI-FA compared to DTI-MD 
were most notable in frontal, parietal, occipital and temporal lobe. This could be 
due to the fact that in regions with a more complex architecture, FA values are more 
variable due to a decrease in crossing fibers or other non-parallel organization [15].
It furthermore seems that the discriminative power of DTI-MD is slightly higher 
than for DTI-FA, with a broader set of regions showing significant white matter 
abnormalities. This finding is in line with the current literature stating that DTI-FA is 
a less sensitive marker for decreased white matter integrity than DTI-MD [29-31].
MTL atrophy was assessed in different ways and data suggest that entorhinal cortex 
(ERC) volume is the best volumetric discriminator as ERC showed the largest ES for all 
group comparisons. These results are in line with previous histological studies, which 
showed that the earliest neuropathological changes in AD appear in the ERC [32-34]. 
Furthermore, several MRI studies have suggested that volumetric measurements of 
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the ERC are more sensitive than hippocampal volume for predicting AD in subjects 
with MCI [35-37]. Structural MR studies also revealed abnormalities in AD or MCI 
outside the MTL region. Callosal atrophy [38-41], cingulum atrophy [33, 42, 43], 
parietal [44] and frontal atrophy [45] have all been reported to be abnormal in MCI 
or AD. 
Clinical	implications	
Our findings suggest that DTI may have the potential to be used in clinical practice 
in a similar way as MTL measurements. However, it is less likely that DTI will soon 
replace MTL atrophy assessment. First, there is limited information on how well 
DTI can discriminate subjects with AD from subjects with other types of dementia. 
At present there are insufficient studies available to provide pooled estimates for 
these differences. Preliminary findings suggest that FA values of the anterior WM are 
decreased in vascular dementia as well [46]. Another study [47] found that subjects 
with Lewy Body Dementia showed abnormalities in the corpus callosum, pericallosal 
areas and the frontal, parietal, occipital and, less prominently, in temporal white 
matter. Subjects with frontotemporal dementia (FTD) had greater reductions of FA 
in frontal brain regions relative to AD, whereas no other region in AD showed greater 
reductions of FA when compared to FTD [48]. Second, longitudinal DTI-studies on 
the prediction of AD in non-demented subjects are currently lacking. In the case 
of MTL measurements, studies indicate that MTL atrophy is a strong predictor for 
AD in subjects with MCI with an ES ranging from 0.54 to 2.25 [9]. Third, to date 
DTI measurements generally provided group differences rather than dichotomized 
values that can be used in clinical practice. Sensitive cut-off scores for different 
DTI-modalities in distinct brain regions need to be determined and validated. 
Limitations
The present study had several limitations. With regard to some brain structures our 
meta-analysis was based on relatively few studies, which reduced the accuracy of 
the parameter estimates. Moreover, as analyses of the different techniques were 
based on different studies, we cannot exclude the possibility that differences in 
ES resulted from differences in sample selection and other study characteristics. 
We frequently observed statistically significant heterogeneity between the studies. 
Meta-regression could only explain part of this heterogeneity. Moreover, for some 
parameters, the number of studies available for meta-regression analyses was small, 
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which limited statistical power.  In general slice thickness in DTI studies was higher 
than in MTL studies. This factor might have reduced sensitivity of DTI markers. The 
only outcome measure calculated in this study is the ES. Accuracy measurements 
such as sensitivity or specificity could not be taken into account since dichotomous 
data of the included studies was not available. One author [30] reported a sensitivity 
up to 89% for MD and 78% for FA measurements for the detection of hippocampal 
abnormalities in subjects with MCI. For a number of regions and comparisons, data 
had been published in less than 3 studies and could therefore not be included in 
the meta-analysis. For example, only a few studies investigated DTI in the entorhinal 
cortex or the perforant pathway. Furtermore, it was only possible to examine FA 
differences in all cingulum regions between controls and subjects with AD. Superior 
longitudinal fasciculus, uncinate fasciculus and internal capsule could also not 
be examined for all group comparisons. Our results may have been affected by 
publication bias and by the fact that not all studies presented means and standard 
deviations for the regions studied or did not reply to our request for data. However, 
it is unlikely that publication bias substantially influenced our results since Begg and 
Mazumdar’s rank correlation was only significant (p <.05) for 4 group comparison 
in the MTL studies and 7 group comparisons in the DTI studies. Furthermore, a 
number of these significant comparisons could be due to multiple testing effects 
since only one of these comparisons was significant at p < .01. We limited our 
meta-analysis to FA and MD. However, it has recently been suggested that the 
examination of directional diffusivities such as axial (DA) and radial diffusion (DR) 
may yield important information about the underlying neuropathology driving 
differences in FA as well [49-52]. One author suggested that DA and DR may be 
even more reliable markers of degeneration than FA [29]. Still, there are not enough 
studies to conduct a separate meta-analysis of these modalities. It has to be noted 
that in many studies FA values in the hippocampal region, which mainly consists of 
gray matter, are usually ignored. Mean FA values in the hippocampus are generally 
lower than 0.2, which is close to the noise level. Hippocampal FA therefore needs to 
be interpreted with caution. 
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CONCLUSION  
Despite the fact that one study suggested that DTI measurements seem to be more 
sensitive than volumetric measurements [30] or that measures of microstructure 
provide unique information not obtainable with volumetric mapping in regions 
known to be crucial in AD [53], our review does not support the notion that DTI 
is superior to structural MTL assessment in detecting early stage AD. Nonetheless, 
based on the current literature [19] and our findings, we can conclude that DTI is 
a sensitive method to detect white matter changes in subjects with MCI and AD. It 
seems that in widespread brain regions diffusivity is already impaired early in the 
disease process, with more severe white matter disruptions with increasing disease 
severity. There is a need of additional studies that test the predictive accuracy of 
DTI measurements for AD in subjects with MCI and that test differences in DTI 
measurements between AD and other dementias. In order to better understand the 
development of WM integrity loss in relation to grey matter loss and the diagnostic 
potential of DTI measurements, there is a particular need for longitudinal MRI 
studies that combine structural with DTI assessments. Such studies will advance our 
understanding of the effects of neurodegeneration on gray matter, white matter, 
and their interaction and will enhance our ability to detect subtle brain changes 
early in the disease process. Since diagnostic criteria for prodromal AD require the 
presence of episodic memory impairment in combination with at least one AD 
biomarker [5, 54], future studies should compare the use of DTI makers for the 
diagnosis of prodromal AD with that of other AD biomarkers such as CSF markers 
[55, 56], PET imaging markers [57] or familial genetic mutations [58].
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Table 1. Search terms used to search the databases PUBMED and ISI WEB OF KNOWLEDGE
Search terms
(“medial temporal lobe”) and (“magnetic resonance imaging”) and 
(“Alzheimer*” or “mild cognitive impairment”)
(“hippocampus”) and (“magnetic resonance imaging”) and 
(“Alzheimer*” or “mild cognitive impairment”)
(“entorhinal cortex”) and (“magnetic resonance imaging”) and 
(“Alzheimer*” or “mild cognitive impairment”)
(“parahippocampal gyrus”) and (“magnetic resonance imaging”) 
and (“Alzheimer*” or “mild cognitive impairment”)
(“diffusion tensor imaging”) and (“Alzheimer*” or “mild cognitive 
impairment”)
Table 2. Subject characteristics medial temporal lobe studies
Study N Age MMSE CDR Regions Diagnostic 
criteria
Pitkänen et al. (1996) [59] HC 1
Controls 76 59.7 
(19.9)
AD 55 69.9 
(8.3)
No 
data
No data
Convit et al. (1997) [60] HC 5
Controls 27 69.3 
(8.3)
29.3 
(5.5)
MCI 22 74.1 
(7.3)
28.3 
(5.4)
AD 27 72.3 
(7.4)
18.3 
(4.3)
No data
Kaye et al. (1997) [61] HC, PHG 1
Controls 18 86.8 
(1.9)
28.4
AD 12 90.4 
(5.2)
26.9 No data
Mori et al. (1997) [62] HC, PHG 1
Controls 12 66.2 
(4.9)
≥ 28
AD 46 70.3 
(7.1)
19.6 
(3.5)
No data
Jack et al. (1998) [63] HC 1
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Controls 24 81.04 
(3.78)
28.79 
(1.28)
AD 24 80.42 
(4.02)
20.74 
(4.60)
0.85 
(0.43)
Juottonen et al. (1998) [64] ERC 2
Controls 32 72 
(4.1)
28.3 
(1.4)
AD 30 70.3 
(8.5)
20.7 
(3.7) 
1.53 
(0.51)
Krasuski et al. (1998) [65] HC, PHG 1
Controls 21 69.3 
(6.8)
29.7 
(0.2) 
AD 13 71.2 
(8.3)
23.7 
(2.7)
No data
Laakso et al. (1998) [66] HC 1
Controls 42 72.0 
(4.0)
28.0 
(1.0)
MCI 42 70.0 
(5.0)
28.0 
(2.0)
AD 55 70.0 
(8.0)
22.0 
(4.0)
No data
Visser et al. (1999) [8] HC, PHG, 
MTA
1
-        Con 18 76.8 
(4.0)
27.1 
(2.8) 
-        AD 7 79.6 
(4.9)
16.6 
(6.0) 
No data
Barber et al. (2000) [67] HC, PHG 1
-        Con 26 76.2 
(5.0)
28.1 
(2.0)
-        AD 22 77.3 
(5.0)
16.5 
(4.0)
No data
de Toledo-Morrell et al. 
(2000) [68] 
HC, PHG 1
Controls 30 72.4 
(64-84)
≥ 28
AD 18 68.6 
(49-84)
24.1 
(20-28)
No datta
Laakso et al. (2000) [69] HC, ERC 2
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Con 30 69.0 
(9.0)
29.0 
(1.0)
AD 30 73.0 
(9.0)
20.0 
(4.0)
1.27 
(0.83)
Xu et al. (2000) [70] HC. ERC 1
Controls 30 78.9 
(6.2)
28.5 
(1.6)
MCI 30 78.4 
(6.4)
25.7 
(2.8)
AD 30 78.5 
(6.3)
20.6 
(5.0)
No data
De Santi et al. (2001) [71] HC 1; 5
Controls 11 76.5 
(5.4)
29.1 
(1.5)
MCI 15 74.6 
(6.7)
28.5 
(1.9)
AD 12 76.1 
(7.0)
20.3 
(7.2)
No data
Du et al. (2001) [72] HC, ERC 1
Controls 40 75.1 
(4.3)
29.0 
(0.9)
MCI 36 75.1 
(8.2)
25.8 
(3.6)
AD 29 75.8 
(5.1)
17.7 
(5.7)
No data
Goncharova et al. (2001) 
[73]
ERC 1
Controls 34 70.3 
(6.6)
29.2 
(0.7)
AD 16 71.4 
(9.1)
27.3 
(1.1)
No data
Wolf et al. (2001) [74] HC 1
Controls 17 78.5 
(3.1)
28.3 
(1.3)
MCI 12 78.5 
(2.2)
25.7 
(1.1)
AD 10 78.2 
(3.0)
22.9 
(2.0)
No data
Bottino et al. (2002) [75] HC, PHG 1
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Controls 20 69.1 
(4.84)
29.1 
(0.7)
AD 39 73.1 
(7.21)
20.2 
(3.6)
No data
Hsu et al. (2002) [76] HC 1
Controls 20 74.0 
(6.2)
29.0 
(1.3)
MCI 20 74.2 
(6.7)
27.7 
(2.7)
AD 20 74.5 
(6.2)
22.7 
(3.5)
No data
Killiany et al. (2002) [77] HC, ERC 2
Controls 28 71.8 29.2
MCI 94 72 29.1
AD 16 69.8 24.2 No data
Mega et al. (2002) [78] HC 3
Controls 10 73.0 
(7.4)
29.2 
(1.0)
MCI 10 71.0 
(5.2)
28.9 
(1.3)
No data
Pantel et al. (2002) [79] HC, PHG 1
Controls 22 65.3 
(0.8)
MCI 21 65.2 
(0.9)
AD 12 63.7 
(7.4)
18.75 
(4.0)
No data
Du et al. (2003) [80] ERC 1
Controls 23 76.5 
(7.9)
29 
(1.0)
AD 21 74.5 
(6.7)
22 
(7.0)
No data
Du et al. (2004) [81] HC, ERC 1
Controls 25 76.8 
(7.8)
29.0 
(1.0)
AD 20 75.3 
(7.2)
21.0 
(7.2)
No data
Pennanen et al. (2004) [37] HC, ERC 1; 5
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Controls 59 72.7 
(4.3)
27.3 
(1.8)
MCI 65 72.8 
(4.5)
24.0 
(2.5)
AD 48 71.1 
(8.1)
21.4 
(3.5)
No data
Testa et al. (2004) [82] HC 2
Controls 25 70.0 
(8.0)
29.0 
(1.0)
AD 27 74.0 
(9.0)
21.0 
(4.0)
No data
Müller et al. (2005) [28] HC 3
Controls 18 66.9 
(9.0)
28.7 
(1.0)
aMCI 18 67.3 
(8.7)
25.2 
(2.2)
No data
Bastos-Leite et al. (2006) 
[83]
MTA-
score
2
Controls 15 68.9 
(8.0)
27.9 
(1.9)
AD 21 69.3 
(10.9)
18.8 
(4.5)
No data
Kalus et al. (2006) [84] HC, ERC, 
PHG 
1
Controls 10 70.8 
(5.6)
29.0 
(27-30)
MCI 10 76.0 
(11.5)
22.4 
(19-28)
AD 10 73.9 
(9.8)
19.2 
(6-27)
No data
Teipel et al. (2006) [85] HC, ERC, 
PHG
2
Controls 22 61.5 
(8.9)
29.4 
(0.7)
AD 34 69.0 
(8.0)
23.1 
(4.1)
No data
Uotani et al. (2006) [86] HC 5
Controls 20 65.7 
(8.7)
29.6 
(0.8)
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MCI 7 73.2 
(8.6)
26.9 
(2.1)
AD 33 70.9 
(8.3)
14.1 
(8.1)
No data
van de Pol et al. (2006) [87] HC, MTA-
score
1
Controls 73 75.0 
(8.0)
No 
data
AD 103 71.0 
(9.0)
No 
data
1.0 (0.5-
3)
Barnes et al. (2007) [88] HC 7
Controls 11 56.0 
(14.3)
29 (1)
AD 19 56.3 
(10.6)
20 (7) No data
Meyer et al. (2007) [89] HC, ERC 1, 4
Controls 52 65.6 
(11.0)
29.50 
(0.73)
MCI 30 77.2 
(8.52)
26.27 
(1.80)
AD 19 78.74 
(5.05)
16.84 
(9.66)
No data
Ridha et al. (2007) [90] HC, MTA-
score
2
Controls 47 65.5 
(11.4)
29.5 
(0.7) 
AD 26 65.7 
(11.5)
19.4 
(4.0)
No data
Slavin et al. (2007) [91] HC 1; 5
Controls 17 70.2 
(3.6)
28.2 
(1.3)
aMCI 18 74.4 
(7.7)
26.8 
(1.3)
No data
Colliot et al. (2008) [92] HC 1; 3
Controls 25 64.0 
(8.0)
No 
data
aMCI 24 74.0 
(8.0)
27.2 
(1.4)
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AD 25 73.0 
(6.0)
24.4 
(2.7)
No data
Delano-Wood et al. (2008) 
[93]
HC 3
Controls 20 78.14 
(7.06)
MCI 20 78.00 
(7.32)
No 
data
No data
Duara et al. (2008) [94] MTA-
score
1; 3
Controls 117 71.7 
(5.7)
29 
(1.2)
aMCI 91 76.4 
(6.0)
26.6 
(2.3)
AD 53 79.9 
(6.0)
22.9 
(3.8)
No data
Kenny et al. (2008) [95] ERC 1
Controls 37 75.4 
(6.8)
28.1 
(1.6)
AD 26 78.1 
(5.0)
18.7 
(4.4)
No data
Appel et al. (2009) [96] MTA-
score
1; 3
Controls 40 71.0 
(5.6)
29.3 
(0.9)
(a)MCI 118 74.7 
(6.3)
26.9 
(2.3)
AD 34 76.6 
(6.5)
22.7 
(2.8)
No data
Bai et al. (2009) [97] HC 3
Controls 23 70 
(5.0)
28.3 
(1.5)
aMCI 39 71 
(5.0)
27 
(1.6)
No data
Cho et al. (2009) [98] MTA-
score
1
Controls 27 No 
data
No 
data
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AD 33 74.4 
(7.8)
16.55 
(4.40)
1.7 (0.81)
Feczko et al. (2009) [99] ERC 1
Controls 47 76.2 
(6.8)
29.0 
(1.3)
0
AD 29 73.8 
(11.7)
22.9 
(3.8)
0.88 
(0.22)
Ferrarini et al. (2009) [100] HC 1
Controls 50 70.8 
(5.8)
28.1 
(1.4)
MCI 30 71.9 
(6.2)
26.7 
(1.3)
AD 50 71.3 
(7.7)
18.5 
(3.4)
No data
Henneman et al. (2009) 
[101]
MTA-
score
2; 3
Controls 19 66 
(9.0)
29 
(1.0)
MCI 25 71 
(6.0)
25 
(3.0)
AD 31 67 
(8.0)
23 
(4.0)
No data
Henneman et al. (2009) 
[102]
HC, MTA-
score
2; 3
Controls 34 67 
(9.0)
28 
(2.0)
MCI 44 71 
(6.0)
26 
(3.0)
AD 64 67 
(9.0)
22 
(5.0)
No data 
Hyun et al. (2009) [103] MTA-
score
1
Controls 27 No 
data
No 
data
AD 33 74.4 
(7.8) 
16.55 
(4.40)
1.7 (0.81)
Jauhiainen et al. (2009) 
[104]
HC, ERC 2; 3
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Controls 21 71.2 
(4.9)
27.7 
(2.0)
aMCI 14 72.4 
(7.3)
25.6 
(3.1)
AD 15 73.1 
(6.7)
21.7 
(3.7)
0.8 (0.3)
Lee et al. (2009) [105] HC 2; 4
Controls 95 72.7 
(7.1)
29.7 
(10.5)
MCI 73 73.6 
(7.5)
27.2 
(12.9)
AD 47 77.2 
(7.2)
21.2 
(12.9)
No data
Loewenstein et al. (2009) 
[106]
MTA 6
Controls 108 72.23 
(5.4)
aMCI 78 76.27 
(6.4)
AD 48 77.08 
(6.2)
No 
data
No data
Morra et al. (2009) [107] HC 1; 3
Controls 100 76.6 
(4.8)
29.1 
(0.9)
0.0   (0.9)
MCI 200 75.4 
(7.0)
26.9 
(1.9)
1.5 (0.8)
AD 100 75.9 
(7.2)
23.4 
(1.9)
4.5 (1.6)
Rogalski et al. (2009) [108] HC, ERC, 
PHG
3
Controls 14 73.6 
(6.7)
29.4 
(0.8)
aMCI 14 76.8 
(7.0)
26.9 
(2.0)
No data
Bird et al. (2010) [109] MTA 1
Controls 25 65.3 
(7.6)
aMCI 6 65.3 
(11.0)
27.0 
(1.5)
164 | Chapter 5: Meta-analysis DTI and MTL measurements
AD 7 66.6 
(7.5)
26.1 
(2.8)
No data
Bouwman et al. (2010) 
[110]
MTA 1
Controls 138 60.0 
(10.0)
28.3 
(1.8)
MCI 65 70.0 
(8.0)
26.3 
(2.7)
AD 145 68.8 
(8.0)
21.5 
(4.6)
No data
Cherubini et al. (2010) [111] HC 2; 3
Controls 30 67.9 
(7.4)
28.97 
(1.24)
aMCI 30 66.8 
(6.0)
27.57 
(2.10)
AD 30 68.7 
(7.8)
21.33 
(4.03)
No data
Choo et al. (2010) [33] HC, ERC 2; 5
Controls 18 70.7 
(5.2)
No 
data
MCI 19 71.6 
(7.1)
AD 19 71.1 
(5.1)
0.95 
(0.44)
Desikan et al. (2010) [112] HC 1; 3
Controls 208 76.0 
(4.9)
29.1 
(1.0)
0
MCI 353 74.5 
(7.4)
27.0 
(1.8)
1.6 (0.9)
AD 163 74.9 
(7.5)
23.3 
(1.9)
4.2 (1.6)
Jhoo et al. (2010) [113] HC 2; 4; 5
Controls 17 70.8 
(5.4)
28.4 
(1.9)
aMCI 17 70.8 
(7.0)
24.4 
(3.7)
AD 17 70.7 
(5.8)
16.9 
(3.8)
0.79 
(0.25)
Johnson et al. (2010) [114] HC 1
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Controls 32 70.3 
(6.3)
29.4 
(0.84)
AD 27 73.0 
(6.5)
27.5 
(2.25)
0.5
Lehmann et al. (2010) [115] HC, ERC, 
PHG
2
Controls 10 59.7 
(6.3)
29.8 
(0.4)
AD 10 60.0 
(7.6)
20.4 
(5.8)
No data
Liu et al. (2010) [116] HC 2; 3
Controls 94 74.0 
(5.0)
29.0 
(1.0)
MCI 79 74.0 
(6.0)
27.0 
(2.0)
AD 118 75.0 
(6.0)
21.0 
(5.0)
1.3 (0.5)
Luckhaus et al. (2010) [117] HC 2
Controls 12 65.7 
(4.1)
28.0 
(1.53)
MCI 30 64.1 
(9.5)
27.5 
(1.88)
No data
AD 15 68.7 
(7.6)
23.47 
(1.88)
Mueller et al. (2010) [118] HC, ERC 1; 3
Controls 53 69.5 
(7.3)
29.3 
(1.1)
aMCI 20 73.5 
(7.1)
28.0 
(2.1)
AD 18 69.1 
(9.6)
21.6 
(5.1)
No data
Pengas et al. (2010) [119] HC 2
Controls 28 64.9 
(61-73)
29.3 
(0.8)
aMCI 24 67.6 
(63-72)
26.8 
(1.4)
No data
Ryu et al. (2010) [120] HC 2
Controls 14 70.6 
(5.2)
24.1 
(2.3)
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AD 23 74.4 
(6.3)
17.6 
(4.8)
No data
Sanchez-Benavides et al. 
(2010) [121]
HC, ERC 1; 5
Controls 34 71.7 
(5.9)
28.9 
(1.2)
MCI 24 74.3 
(6.2)
26.0 
(2.3)
No data
AD 20 75.3 
(6.6)
21.4 
(3.4)
Schott et al. (2010) [122] HC 1; 3
Controls 199 76.0 
(5.1)
29.1 
(1.0)
0.03 
(0.11)
MCI 334 74.9 
(7.2)
27.0 
(1.8)
1.58 
(0.89)
AD 144 75.2 
(7.3)
23.5 
(1.9)
4.19 
(1.55)
Westman et al. (2010) [123] HC 1; 5
Controls 100 73.0 
(6.0)
29.0 
(1.0)
0
MCI 100 75.0 
(5.0)
27.0 
(3.0)
0.5
AD 100 76.0 
(6.0)
21.0 
(5.0)
1.2 (0.5)
Yakushev et al. (2010) [124] HC 1
Controls 18 69.0 
(6.7)
28.9 
(1.0)
AD 20 69.8 
(7.4)
25.7 
(1.7)
0.63 
(0.22)
Zarei et al. (2010) [125] HC 2
Controls 22 70.7 
(6.0)
28.7 
(1.4)
AD 16 69.5 
(6.7)
22.9 
(3.2)
No data
Echavarri et al. (2011) [126] HC, PHG 1; 3
Controls 18 64.5 
(3.3)
28.8 
(27-30)
MCI 18 65.1 
(4.5)
27.6 
(22-30)
Chapter 5: Meta-analysis DTI and MTL measurements | 167 
AD 18 72.2 
(9.7)
21 (10-
28)
No data
Jacobs et al. (2011) [44] HC, PHG 5
Controls 35 69.1 
(7.7)
28.2 
(1.5)
MCI 30 69.2 
(8.1)
26.3 
(2.0)
AD 9 73.8 
(4.3)
24.8 
(3.1)
No data
Prestia et al. (2011) [127] HC 1
Controls 19 72.5 
(7.8)
29.1 
(1.0)
AD 20 72.7 
(9.1)
22.0 
(4.3)
No data
Zhang et al. (2011) [128] HC 3
Controls 243 77.8 
(4.5)
MCI 146 78.8 
(4.6)
No 
data
No data
Data are mean (sd) or mean (range).Volumetric measurements of HC: hippocampus, 
ERC: entorhinal cortex, PHG: parahippocampal gyrus.MMSE: Mini-mental state 
examination; CDR: Clinical Dementia rating scale (AD group); MTA: Medial temporal 
lobe atrophy; Con: healthy controls; MCI: mild cognitive impairment, subtypes not 
specified or all subtypes included; aMCI: amnestic-type MCI ; AD: Alzheimer’s disease. 
Main diagnostic criteria: (1) NINCDS-ADRDA: probable and/or possible AD = McKhann et 
al., 1984 [129]; (2) NINCDS-ADRDA: probable AD – McKhann et al., 1984 [129]; (3) MCI 
according to Petersen et al., (1999) [3] or  (2001) [130]; (4) MCI according to Winblad et 
al., 2004; (5) Diagnostic and Statistical Manual of Mental Disorders (DSM) Fourth edition; 
(6) National Alzheimer Coordinating Center guidelines (NACC) – Washington.; (7) Based on 
genetic or pathological analysis.  
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Table 5. Effect size DTI-fractional anisotropy studies  
Effect size Heterogeneity Publication Bias
Hedges g (CI) p-value Cochrane’s Q p-value K-tau p-value
Controls vs AD N studies  
(N Controls /N AD)
Frontal Lobe 15 (309/265) 0.70 (0.35;1.04) 0.001 48.13 <0.001 0.56 0.004
Parietal Lobe 13 (284/240) 0.26 (0.13;0.66) 0.19 51.04 <0.001 0.38 0.08
Occipital Lobe 14 (298/244) 0.11 (-0.09;0.32) 0.29 10.11 0.52 -0.39 0.09
Temporal Lobe 18 (357/314) 0.57 (0.29;0.84) <0.001 45.0 <0.001 0.24 0.17
Hippocampus 4 (63/70) 1.36 (-0.16;2.88) 0.08 40.88 <0.001 0.67 0.31
Total cingulum 5 (84/90) 1.73 (0.22;3.23) 0.02 63.33 <0.001 0.80 0.09
ACg 3 (59/58) 1.37 (-0.30;3.04) 0.11 30.18 <0.001 0.33 1.00
MCg 3 (43/44) 0.42 (-0.006;0.85) 0.05 0.12 0.94 -0.33 1.00
PCg 10 (186/196) 0.84 (0.63;1.05) <0.001 7.11 0.63 -0.16 0.60
PHg 7 (134/128) 1.17 (0.40;1.95) 0.003 22.88 <0.001 0.80 0.09
Genu CC 19 (417/361) 0.63 (0.42;0.83) <0.001 31.29 0.03 0.39 0.02
Splenium CC 22 (467/417) 1.10 (0.65;1.55) <0.001 178.92 <0.001 0.34 0.03
SLF 7 (125/136) 0.77 (0.15;1.39) 0.01 31.54 <0.001 0.62 0.07
UF 5 (84/94) 1.03 (0.48;1.58) <0.001 11.68 0.02 1.00 0.03
Internal capsule 9 (136/139) 0.09 (-0.19;0.37) 0.54 1.81 0.94 0.14 0.76
Controls vs MCI N studies  
(N Controls /N MCI)
Frontal Lobe 10 (444/345) 0.26 (-0.11;0.62) 0.17 37.26 <0.001 0.02 1.00
Parietal Lobe 8 (196/177) 0.02 (-0.26;0.29) 0.90 10.31 0.17 0.50 0.11
Occipital Lobe 9 (434/335) 0.18 (-0.13;0.49) 0.25 5.47 0.37 -0.47 0.26
Temporal Lobe 14 (517/412) 0.38 (0.11;0.65) 0.006 37.34 <0.001 0.30 0.15
Hippocampus 6 (310/247) 0.55 (-0.16;1.26) 0.12 42.12 <0.001 0.33 0.45
PHG 3 (270/189) 0.06 (-0.12;0.25) 0.52 0.39 0.84 1.00 0.30
PCg 10 (402/327) 0.65 (0.32;0.98) <0.001 29.47 <0.001 0.38 0.15
PHg 4 (68/68) 0.97 (0.61;1.32) <0.001 0.09 0.99 0.00 1.00
Genu CC 16 (573/466) 0.41 (0.18;0.64) <0.001 37.74 <0.001 0.27 0.16
Splenium CC 17 (602/504) 0.44 (0.25;0.64) <0.001 31.97 0.01 0.40 0.03
SLF 4 (285/214) 0.66 (-0.02;1.34) 0.06 17.45 <0.001 1.00 0.09
UF 3 (47/51) 0.26 (-0.28;0.81) 0.35 3.71 0.16 1.00 0.30
MCI vs AD N studies  
(N MCI/N AD)
Frontal Lobe 6 (145/120) 0.29 (0.05;0.54) 0.02 2.67 0.75 0.07 1.00
Parietal Lobe 6 (167/146) -0.09 (-0.32;0.13) 0.40 1.35 0.93 0.13 0.85
Occipital Lobe 6 (145/120) -0.07 (-0.40;0.26) 0.69 1.65 0.80 -0.1 1.00
Temporal Lobe 10 (212/195) 0.27 (0.03;0.51) 0.03 11.90 0.22 -0.11 0.72
PCg 6 (120/123) 0.37 (0.12;0.63) 0.004 4.88 0.43 0.07 1.00
PHg 4 (68/68) 0.46 (-0.14;1.06) 0.13 8.44 0.04 -0.67 0.31
Genu CC 10 (224/211) 0.35 (0.16;0.54) <0.001 4.69 0.86 -0.2 1.00
Splenium CC 12 (274/256) 0.51 (0.11;0.91) 0.01 51.01 <0.001 0.06 0.84
CI: Confidence interval; MCI: mild cognitive impairment; AD: Alzheimer’s disease. 
Data shown in bold are statistically significant. ACg: anterior cingulum; 
MCg: middle cingulum; PCg: posterior cingulum; PHg: parahippocampal 
cingulum; UF: uncinate fasciculus; SLF: superior longitudinal fasciculus, 
PHG: parahippocampal gyrus.
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Table 6. Effect size DTI-mean diffusivity studies 
Effect size Heterogeneity Publication Bias
Hedges g (CI) p-value Cochrane’s Q p-value K-tau p-value  
Controls vs AD N studies  
(N Controls /N AD)
Frontal Lobe 10 (165/176) -0.75 (-1.24;-0.27) 0.002 38 <0.001 -0.47 0.07
Parietal Lobe 9 (155/166) -1.03 (-1.58;-0.49) <0.001 38.73 <0.001 -0.61 0.03
Occipital Lobe 8 (123/139) -0.67 (-1.00;-0.33) <0.001 11.81 0.11 0.14 0.71
Temporal Lobe 12 (187/207) -0.89 (-1.30;-0.48) <0.001 37.76 <0.001 -0.27 0.24
Hippocampus 7 (125/131) -1.17 (-1.81;-0.53) <0.001 31.35 <0.001 -0.62 0.07
PCg 9 (156/164) -0.74 (-0.97;-0.51) <0.001 5.57 0.70 -0.11 0.75
Genu CC 12 (226/216) -0.67 (-0.98;-0.35) <0.001 26.79 0.005 -0.30 0.19
Splenium CC 12 (226/216) -0.94 (-1.53;-0.35) 0.002 81.10 <0.001 -0.36 0.12
UF 4 (65/76) -0.72 (-1.27;-0.17) 0.01 7.32 0.06 0.00 1.00
Internal capsule 7 (118/118) -0.66 (-1.19;-0.13) 0.01 21.66 <0.001 -0.43 0.23
Controls vs MCI N studies  
(N Controls /N MCI)
Frontal Lobe 7 (325/249) -0.32 (-0.62;0.001) 0.05 10.88 0.09 -0.24 0.55
Parietal Lobe 5 (77/786) -0.69 (-1.09;-0.28) 0.01 6.12 0.19 0.00 1.00
Occipital Lobe 6 (315/244) -0.19 (-0.55;-0.17) 0.30 11.49 0.04 0.20 0.71
Temporal Lobe 10 (379/289) -0.40 (-0.56;-0.24) <0.001 7.41 0.60 -0.24 0.37
Hippocampus 7 (344/276) -1.00 (-1.62;-0.40) 0.001 46.74 <0.001 -0.81 0.02
PHG 3 (270/189) -2.52 (-6.62;1.58) 0.23 246.13 <0.001 0.33 1.00
PCg 7 (342/257) -0.26 (-0.43;-0.10) 0.002 5.16 0.52 -0.62 0.07
Genu CC 10 (379/289) -0.43 (-0.69;-0.17) 0.001 14.96 0.09 -0.02 1.00
Splenium CC 10 (379/289) -0.46 (-0.76;-0.15) 0.004 20.79 0.01 -0.21 0.53
MCI vs AD N studies  
(N MCI/N AD)
Temporal Lobe 6 (89/113) -0.17 (-0.45;0.12) 0.25 3.74 0.59 0.13 0.85
Hippocampus 3 (68/70) -0.33 (-0.77;-0.11) 0.14 3.39 0.18 1.00 0.30
PCg 5 (88/99) -0.40 (-0.70;-0.11) 0.007 2.12 0.70 0.00 1.00
Genu CC 6 (89/113) -0.32 (-0.61;-0.03) 0.03 2.61 0.76 0.07 1.00
Splenium CC 6 (89/113) -0.04 (-0.07;0.003) 0.03 8.54 0.13 0.00 1.00
CI: Confidence interval; MCI: mild cognitive impairment; AD: Alzheimer’s disease. 
Data shown in bold are statistically significant. PCg: posterior cingulum, UF: uncinate 
fasciculus; PHG: parahippocampal gyrus.
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Figure 1. Meta-regression with MMSE as predictor and absolute effect size as outcome measure. (A) FA values of 
the parietal lobe between controls and subjects with Alzheimer’s disease (AD); B = -0.1 ± 0.04, p = 0.04. (B) MD of 
the genu corpus callosum (CC) between controls and subjects with AD; B = -0.2 ± 0.05, p = 0.01. 
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Figure 2. Funnel plots of standard errors plotted against effect sizes in order to identify publication bias. 
(A) Comparison between controls and subjects with Alzheimer’s disease (AD) for frontal lobe fractional anisotropy 
(FA). Begg and Mazumdar tau = 0.56, p	= 0.004. (B) Comparison between controls and AD for FA of the genu corpus 
callosum (CC). Begg and Mazumdar tau = 0.39, p	= 0.02. (C) Comparison between controls and AD for FA of the 
splenium CC. Begg and Mazumdar tau = 0.34, p	= 0.03. (D) Comparison between controls and AD for FA of the 
uncinate fasciculus. Begg and Mazumdar tau = 1.00, p	= 0.03. (E) Comparison between controls and subjects with 
MCI for FA of the splenium CC. Begg and Mazumdar tau = 0.40, p	= 0.03. (F) Comparison between controls and 
AD for mean diffusivity (MD) of parietal WM. Begg and Mazumdar tau = -0.61, p	= 0.03. (G) Comparison between 
controls and subjects with MCI for MD of the hippocampus. Begg and Mazumdar tau = -0.81, p	= 0.02.
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SUPPLEMENTAL MATERIAL
Supplementary table 1. Technical specifications medial temporal lobe 
studies. Technical details of MTL studies included in the meta-analysis.
Study Total N 
Field 
strength 
(Tesla)
Slice thick-
ness (in mm)
Volumetric measurement of MTL 
structures
Pitkänen et al. (1996) [1] 131 1.5 1.5 Manual tracing
Convit et al. (1997) [2] 76 1.5 4 Manual tracing
Kaye et al. (1997) [3] 30 1.5 2.5 Manual tracing
Mori et al. (1997) [4] 58 1.5 1.5 Semi-automated tracing
Jack et al. (1998) [5] 48 1.5 1.6 Manual tracing
Juottonen et al. (1998) [6] 62 1.5 1.75 Manual tracing
Krasuski et al. (1998) [7] 34 1.5 0.5 Manual tracing
Laakso et al. (1998) [8] 139 1.5 1.5 Manual tracing
Visser et al. (1999) [9] 25 0.6 5 Manual tracing
Barber et al. (2000) [10] 48 1 1 Manual tracing
de Toledo-Morrell (2000) [11] 48 1.5 5 Manual tracing
Laakso et al. (2000) [12] 60 1.5 2 Manual tracing
Xu et al. (2000) [13] 90 1.5 1.6 Manual tracing
Du et al. (2001) [14] 105 1.5 1.4 Manual tracing
De Santi et al. (2001) [15] 38 1.5 1.3 Manual tracing
Goncharova et al. (2001) [16] 50 1.4 5 Manual tracing
Wolf et al. (2001) [17] 39 1.5 1.5 Manual tracing
Bottino et al. (2002) [18] 59 1.5 0.6 Manual tracing
Hsu et al. (2002) [19] 60 1.5 1 Manual tracing
Killiany et al. (2002) [20] 138 1.5 1.5 Manual tracing
Mega et al. (2002) [21] 20 1.5 1.5 Manual tracing
Pantel et al. (2002) [22] 55 1.5 - Manual tracing
Du et al. (2003) [23] 44 1.5 1.4 Manual tracing
Du et al. (2004) [24] 45 1.5 1.4 Manual tracing
Pennanen et al. (2004) [25] 172 1.5 2 Manual tracing
Testa et al. (2004) [26] 52 1.5 1.3 VBM + manual tracing
Müller et al. (2005) [27] 36 1.5 1 Manual tracing
Bastos-Leite et al. (2006) [28] 36 1.5 1.5 N.A.
Kalus et al. (2006) [29] 30 1.5 1 Manual tracing
Teipel et al. (2006) [30] 56 1.5 1.2 Manual tracing
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Study Total N 
Field 
strength 
(Tesla)
Slice thick-
ness (in mm)
Volumetric measurement of MTL 
structures
Uotani et al. (2006) [31] 60 - 5 Manual tracing
van de Pol et al. (2006) [32] 176 1.5 1.5 Manual tracing
Barnes et al. (2007) [33] 30 1.5 1.5 Manual tracing
Meyer et al. (2007) [34] 101 1.5 - Manual tracing
Ridha et al. (2007) [35] 73 1.5 1.5 Manual tracing
Slavin et al. (2007) [36] 35 4 1.5 Manual tracing
Colliot et al. (2008) [37] 74 1.5 1.5 Automated segmentation
Delano-Wood (2008) [38] 40 1.5 3.8 Manual tracing
Duara et al. (2008) [39] 261 1.5 1.5 N.A.
Kenny et al. (2008) [40] 63 1.5 1.6 Manual tracing
Appel et al. (2009) [41] 192 1.5 1.5 N.A.
Bai et al. (2009) [42] 62 1.5 2 VBM + semi-automated tracing
Cho et al. (2009) [43] 60 1.5 - N.A.
Feczko et al. (2009) [44] 76 1.5 1.25 Automated segmentation
Ferrarini et al. (2009) [45] 130 1 1.3 Manual tracing
Henneman et al. (2009) [46] 75 1.5 1.5 N.A.
Henneman et al. (2009) [47] 142 1.5 1.5 Automated segmentation
Hyun et al. (2009) [48] 60 1.5 - N.A.
Jauhiainen et al. (2009) [49] 50 1.5 1 Manual tracing
Lee et al. (2009) [50] 215 1.5 - Semi-automated tracing
Loewenstein et al. (2009) [51] 234 1.5 1.5 N.A.
Morra et al. (2009) [52] 400 1.5 1.2 Automated segmentation
Rogalski et al. (2009) [53] 28 1.5 1.6 Manual tracing
Bird et al. (2010) [54] 38 1.5 1.5 N.A.
Bouwman et al. (2010) [55] 348 1 1.5 N.A.
Cherubini et al. (2010) [56] 90 3 1 Automated segmentation
Choo et al. (2010) [57] 56 3 1.4 Manual tracing
Desikan et al. (2010) [58] 724 1.5 - Automated segmentation
Jhoo et al. (2010) [59] 51 3 1.4 Manual tracing
Johnson et al. (2010) [60] 59 3 1 Automated segmentation
Lehmann et al. (2010) [61] 20 1.5 1.5 Manual tracing
Liu et al. (2010) [62] 291 1.5 1.2 Automated segmentation
Luckhaus et al. (2010) [63] 57 1.5 1.8 Manual tracing
Mueller et al. (2010) [63] 91 4 2 Manual tracing
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Study Total N 
Field 
strength 
(Tesla)
Slice thick-
ness (in mm)
Volumetric measurement of MTL 
structures
Pengas et al. (2010) [64] 52 1.5 1.8 Manual tracing
Ryu et al. (2010) [65] 37 1.5 1 Automated segmentation
Sanchez-Benavides et al. (2010) 
[66]
78 1.5 1.5 Semi-automated tracing
Schott et al. (2010) [67] 677 1.5 - Semi-automated tracing
Westman et al. (2010) [68] 300 1.5 1.2 Manual tracing
Yakushev et al. (2010) [69] 38 1.5 1 Manual tracing
Zarei et al. (2010) [70] 38 1.5 1 Automated segmentation
Echavarri et al. (2011) [71] 54 3 1 Manual tracing
Jacobs et al. (2011) [72] 74 1.5 1.5 Semi-automated tracing
Prestia et al. (2011) [73] 39 1 1.3 Manual tracing
Zhang et al. (2011) [74] 389 3 1 Automated segmentation
MTL: Medial Temporal Lobe; VBM: Voxel Based Morphometry. N.A.: not applicable (only 
qualitative MTA-rating was provided in the study).
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Supplementary table 2. Technical specifications diffusion tensor imaging studies
Technical details of DTI studies included in the meta-analysis.
Study Total N 
Field 
strength 
(Tesla)
Number of 
directions 
Voxel size b-value
NEX DTI modality
(mm) (s/mm2)
Rose et al. (2000) [75] 20 1.5 6 1.2 x 2.3 x 6.0 875 1
Manual placement of standard 
ROI’s
Bozzali et al. (2002) [76] 26 1.5 8 2.0 x 2.0 x 5.0 1044 1 Automated segmentation
Stahl et al. (2003) [77] 19 1.5 6 1.8 x 1.8 x 3.6 1000 10 VBM
Fellgiebel et al. (2004) [78] 43 1.5 6 Slice thickness 5.0 900 6
Manual placement of standard 
ROI’s
Head et al. (2004)  [79] 50 1.5 7 2.5 x 2.5 x 4.0 1005 4 Manual tracing
Sugihara et al. (2004) [80] 30 1.5 6 Slice thickness 5.0 1000 1
Manual placement of standard 
ROI’s
Choi et al. (2005) [81] 20 1.5 6 1.9 x 1.9 x 5.0 1000 4
Manual placement of standard 
ROI’s
Fellgiebel et al. (2005) [82] 63 1.5 6 1.8 x 1.8 x 5.0 900 4 Tractography
Duan et al. (2006) [83] 28 1.5 25 1.9 x 1.9 x 5.0 1000 1
Manual placement of standard 
ROI’s
Naggara et al. (2006) [84] 24 1.5 25 1.8 x 1.8 x 3.0 1000 2
Manual placement of standard 
ROI’s
Rose et al. (2006) [85] 34 1.5 6 Slice thickness 2.5 1100 1 VBM
Taoka et al. (2006) [86] 30 1.5 6 1.8 x 1.8 x 6.3 1000 6 Tractography
Chen et al. (2007) [87] 20 1.5 25 1.9 x 1.9 x 3.0 1000 1 Automated segmentation
Firbank et al. (2007) [88] 30 1.5 6 2.6 x 1.9 x 6.0 4000 1
Manual placement of standard 
ROI’s
Huang and Auchus (2007) [89] 18 1.5 12 1.9 x 1.9 x 3.0 1000 1
Manual placement of standard 
ROI’s
Müller et al. (2007) [90] 36 1.5 6 1.8 x 1.8 x 5.0 900 1
Manual placement of standard 
ROI’s
Stahl et al. (2007) [91] 50 1.5 6 1.8 x 1.8 x 3.6 1000 10
Manual placement of standard 
ROI’s
Zhang et al. (2007) [92] 52 1.5 6 2.3 x 2.3 x 5.0 1000 1
Manual placement of standard 
ROI’s
Cho et al. (2008) [93] 22 1.5 25 2.0 x 2.0 x 4.0 1000 1
Manual placement of standard 
ROI’s
Delano-Wood (2008) [38] 40 1.5 42 3.8 x 3.8 x 2.8 1990 7
Tractography + manual place-
ment of ROI’s
Ding et al. (2008) [94] 37 1.5 25 1.9 x 1.9 x 5.0 1000 1
Manual placement of standard 
ROI’s
Fujie et al. (2008) [95] 32 3 12 1.8 x 1.8 x 3.0 700 1 Tractography
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Study Total N 
Field 
strength 
(Tesla)
Number of 
directions 
Voxel size b-value
NEX DTI modality
(mm) (s/mm2)
Parente et al. (2008) [96] 61 1.5 6 1.8 x 1.8 x 6.5 1000 3
Manual placement of standard 
ROI’s
Shim et al. (2008) [97] 38 1.5 25 2.0 x 2.0 x 5.0 1000 1
Manual placement of standard 
ROI’s
Ukmar et al. (2008) [98] 47 1.5 6 2.5 x 1.9 x 6.0 1000 1
Manual placement of standard 
ROI’s
Yasmin et al. (2008) [99] 38 1 12 1.8 x 1.8 x 3.0 700 6 Tractography
Bai et al. (2009) [100] 44 1.5 25 1.9 x 1.9 x 4.0 1000 2
Manual placement of standard 
ROI’s
Chen et al. (2009) [101] 40 1.5 25 1.9 x 1.9 x 5.0 1000 2
Manual placement of standard 
ROI’s
Chen et al. (2009) [102] 60 1.5 25 1.9 x 1.9 x 5.0 1000 2
Manual placement of standard 
ROI’s
Kiuchi et al. (2009) [103] 49 1.5 6 1.8 x 1.8 x 3.0 1000 6 Tractography
Liu et al. (2009) [104] 63 1.5 30 1.7 x 1.7 x 5.0 1000 1
TBSS + manual placement of 
ROI’s  
Mielke et al. (2009) [105] 75 3 32 2.2 x 2.2 x 2.2 700 2 Tractography + manual tracing
Nakata et al. (2009)  [106] 41 1 12 1.8 x 1.8 x 3.0 700 6 Tractography
Rogalski (2009) [53] 28 1.5 24 2.0 x 2.0 x 3.0 800 6
Manual placement of standard 
ROI’s
Stricker et al. (2009) [107] 30 3 15 1.9 x 1.9 x 3.0 1500 4
TBSS + manual placement of 
ROI’s
Wang et al. (2009) [108] 20 3 16 1.9 x 1.9 x 2.0 1000 1
Manual placement of standard 
ROI’s
Zarei et al. (2009) [109] 38 1.5 60 2.0 x 2.0 x 2.0 700 1 TBSS, tractography
Zhang et al. (2009) [110] 37 4 6 2.0 x 2.0 x 3.0 800 4 Tractography
Catheline et al. (2010) [111] 30 1.5 6 2.4 x 2.4 x 2.5 800 1 Tractography
Cherubini et al. (2010) [56] 90 3 12 1.5 x 1.5 x 2.0 1000 1 Automated segmentation
Choo et al. (2010)  [57] 56 3 25 0.94 x 0.94 x 0.94 1000 1
Tractography, manual placement 
of VOI’s
Hong et al. (2010) [112] 30 1.5 25 Slice thickness 4.0 1000 1
Manual placement of standard 
ROI’s
Jhoo et al. (2010) [59] 51 3 25 0.94 x 0.94 x 0.94 1000 1
Tractography, manual placement 
of VOI’s
NEX: Number of excitations; ROI: Region of interest; VOI: Volume of Interest; TBSS: Tract-based Spatial Statistics.
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Supplementary table 3. Significant univariate regressions for DTI effect sizes and 
technical parameters
Meta-regression indicated that a number of technical parameters were associated with 
effect size (ES). An increasing number of directions was associated with a higher ES. A 
possible explanation for this finding is that with an increasing number of directions contrast 
of FA/MD maps improves. The contrast-to-signal variance ratio between the main WM 
and the surrounding regions significantly increases as number of directions increases 
allowing a better delineation of the gray–white matter junction and thus a more precise 
FA determination [120, 121]. The ES of splenium FA seemed to increase with decreasing 
b-value and increasing field strength (MCI vs AD). This could be explained by the fact that 
a higher field strength provides better spatial and contrast resolution compared to a lower 
field strength. In one study FA values were significantly higher at 3.0 Tesla compared with 
1.5 Tesla [122]. In general, a higher b-value leads to lower signal-to-noise levels and higher 
FA values [89, 124]. Our finding is therefore somewhat counterintuitive. However, there 
seems to be a lot of variability between studies regarding the effect of b-value on FA, since 
other studies found that FA values were not dependent on changes in b-value [123, 124]. 
The ES of parietal MD (controls vs MCI) and genu CC MD (MCI vs AD) seems to increase with 
increasing voxel size. The ES of hippocampal MD on the contrary, seems to increase with 
a decrease in voxel size. A possible explanation is that in broader structures (e.g. corpus 
callosum) a higher voxel size can clearly reveal possible differences whereas in smaller 
structures (e.g. hippocampus) a smaller voxel size is needed for better resolution. Current 
evidence indicates that in general, mean diffusivity values are not affected by voxel size 
[125].
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Supplementary table 3 
Effect size Significant univariate regressions
Hedges g (CI) p-value DTI parameter p-value
FA
Controls vs AD N studies (N Controls /N AD)
Occipital Lobe 14 (298/244) 0.11 (-0.09;0.32) 0.29 Directions 0.05
Total cingulum 5 (84/90) 1.73 (0.22;3.23) 0.02 Field srength 0.008
ACC
3 (59/58) 1.37 (-0.30;3.04) 0.11
Directions
B-value (-)
0.04
0.04
Splenium CC 22 (467/417) 1.10 (0.65;1.55) <0.001 Directions 0.008
Controls vs MCI N studies (N Controls /N MCI)
PCC 10 (402/327) 0.65 (0.32;0.98) <0.001 Directions 0.006
MCI vs AD N studies (N MCI/N AD)
Splenium CC 12 (274/256) 0.51 (0.11;0.91) 0.01 Field srength
B-value (-)
0.03
0.01
MD
Controls vs AD N studies (N Controls /N AD)
Frontal Lobe 10 (165/176) -0.75 (-1.24;-0.27) 0.002 Directions 0.053
Parietal Lobe 9 (155/166) -1.03 (-1.58;-0.49) <0.001 Directions 0.009
Splenium CC 12 (226/216) -0.94 (-1.53;-0.35) 0.002 Directions 0.04
Internal capsule 7 (118/118) -0.66 (-1.19;-0.13) 0.01 Directions 0.02
Controls vs MCI N studies (N Controls /N MCI)
Parietal Lobe 5 (77/786) -0.69 (-1.09;-0.28) 0.01 Voxel size (+) 0.04
MCI vs AD N studies (N MCI/N AD)
Hippocampus 3 (68/70) -0.33 (-0.77;-0.11) 0.14 Field strength
Voxel size (-)
0.06
0.06
Genu CC 6 (89/113) -0.32 (-0.61;-0.03) 0.03 Voxel size (+) 0.01
CI: Confidence interval; MCI: mild cognitive impairment; AD: Alzheimer’s disease. Data 
shown in bold are statistically significant. PCC: posterior cingulum; PHC: parahippocampal 
cingulum; UF: uncinate fasciculus; SLF: superior longitudinal fasciculus. 
Regression: + or – = polarity of regression coefficient/slope.
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Reduced callosal white matter integrity 
surpasses cerebrospinal fluid and atrophy 
markers as predictor of decline in subjects 
with MCI : a combined volumetry and DTI 
study
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ABSTRACT
Background: Microstructural damage of white matter (WM) tracts is a prominent 
feature of Alzheimer’s disease (AD). To date, it is still unknown whether subtle 
abnormalities in WM tissue microstructure precede volumetric alterations in gray 
matter (GM) and how alterations in both tissue-types are related to each other. 
Methods: In 3 memory clinics, we recruited 57 patients with mild cognitive 
impairment (MCI) and 35 patients with mild AD, and combined these with data of 
18 healthy controls (Con). The discriminative ability of atrophy and diffusion tensor 
imaging (DTI) was explored in 6 regions-of-interest: hippocampus, parahippocampal 
gyrus, posterior cingulum, isthmus of the cingulum and genu and splenium of the 
corpus callosum. Effect sizes (ES) were calculated in order to detect the measurement 
with the highest diagnostic potential. The value of both DTI and volumetry for 
predicting decline in MCI patients at 2 years follow-up was additionally investigated.
Results: Compared to controls, MCI-patients had lower GM volumes in the 
parahippocampus (ES=1.34), posterior cingulum (ES=1.29) and isthmus (ES=1.03) 
and AD-patients showed lower baseline volumes in the hippocampus (ES=1.48), 
parahippocampus (ES=1.33) and isthmus cingulate (ES=0.72). All investigated 
ROIs showed group differences in WM integrity with highest ES found for 
parahippocampal (ES>3.0) and hippocampal diffusivity (ES>2.5), followed by 
posterior cingulum (ES±2.5), isthmus (ES±2.0) and genu (ES±1.8). No differences 
were found between MCI/AD. Smaller hippocampal volumes in the patient group 
(MCI+AD) were associated with higher hippocampal diffusivity. Baseline axial and 
mean diffusivity values in the genu were able to discriminate MCI-stable and MCI-
decline. 
Conclusions: DTI metrics are more sensitive for group differences than atrophy 
measurements. Our results suggest that diffusion changes precede and occur 
independent of GM atrophy. DTI metrics in the genu are able to predict cognitive 
decline in MCI.
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INTRODUCTION
Medial temporal lobe (MTL) atrophy as assessed on structural MRI has proven to be 
an effective clinical aid in the early diagnosis of AD [1]. MTL atrophy is however not 
entirely specific for AD since it can also be found in other forms of dementia [2]. It 
is furthermore known that AD pathology is not restricted to the MTL, also posterior 
parietal and prefrontal regions are involved [3, 4]. Apart from GM atrophy, it has 
been shown that white matter (WM) integrity is decreased in subjects with MCI and 
AD [5], suggesting a potential diagnostic value on a microstructural level that may 
help to improve the diagnostic accuracy of volumetric AD biomarkers. The integrity 
of WM can be assessed using diffusion tensor imaging (DTI) which measures the 
diffusion of water molecules in neural tissue [6]. In general, WM integrity of the 
following regions seems to be affected: hippocampal gyrus, temporal white matter, 
genu and splenium of the corpus callosum and posterior cingulum [6-9].
The underlying mechanism responsible for these WM changes is not yet known. 
It is presumed that there is a local variation in cell density, oligodendrocytes, 
myelination and amyloid plaques causing altered diffusion of water molecules 
in certain brain regions. In the majority of DTI studies of AD, the investigation 
of WM abnormalities was only performed assessing changes in fractional 
anisotropy (FA) and mean diffusivity (MD). However, contributions to FA and MD 
alterations could be due to changes of diffusion either parallel or perpendicular 
to the principal direction of the tensor. These measurements are referred to 
as axial (AXD), and radial diffusivity (RAD) respectively. An increase in RAD is 
thought to signify increased space between fibers (suggesting demyelination 
or dysmyelination) [10] whereas increases in AXD suggest axonal damage [11]. 
Alterations in diffusion metrics which reflect the integrity of WM tracts not only 
may give  important cues to elucidate the pathophysiological cascade, but could 
also have diagnostic potential and thus possibly serve as an early marker for AD. 
 
The aim of this study is to investigate the pattern of gray and white matter alterations 
in MCI and AD-patients in a multicenter setting. To date, no study has compared 
the diagnostic value of both volumetry and DTI-markers in a multicenter setting 
in both MCI and AD-patients [12]. Multicenter study designs are important since 
they show greater generalizability of findings than single-center studies. First, we 
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explored the ability of automated GM atrophy measurements and DTI metrics to 
discriminate between healthy controls (Con), subjects with MCI, and subjects with 
AD in 6 regions of interest (ROI). These ROIs were selected based on their pivotal 
role in AD and consisted of the hippocampus, parahippocampal gyrus, posterior 
cingulum, isthmus of the cingulum and genu and splenium of the corpus callosum. 
Effect sizes (ES) were calculated in order to quantify and compare the potential 
diagnostic value of both DTI and atrophy measurements. In the second place we 
investigated associations between the degree of GM loss and WM integrity in the 
selected ROIs. Third, we investigated the value of these markers for predicting 
cognitive decline at 2 years follow-up in MCI patients.
METHODS
Subjects
Healthy controls were recruited by means of an advertisement in local newspapers. 
An extensive neuropsychological test battery was administered and subjects were 
included when their performance did not deviate from normal on the Verbal 
Learning Test [13, 14]. Patients with MCI and AD were selected from LeARN, a 
multicenter study investigating the clinical value of novel biomarkers for AD. Four 
academic memory clinics (Leiden University Medical Centre, Maastricht University 
Medical Centre, Radboud University Nijmegen Medical Centre and VU University 
Medical Centre) specialized in the diagnosis and treatment of memory disorders 
participated in the study. For the present study, participants were selected from 3 of 
the 4 participating centers where diagnosis based on expert panel judgments was 
available. Inclusion and exclusion criteria are described in a previous paper [15]. 
The MCI-group consisted of both amnestic and non-amnestic subjects, in order to 
obtain a representative sample of subjects visiting a memory clinic. An overview of 
clinical and biomarker characteristics of the AD-group can be found in Appendix 1. 
Clinical and cognitive assesment
Baseline	clinical	assessment
All participants underwent a standard diagnostic workup, including clinical history 
taking, medical and neurological examination, clinical chemistry, functional 
evaluation using the Clinical Dementia Rating scale (CDR) [16], rating scales for 
depression and neuropsychiatric symptoms, a neuropsychological test battery and 
neuroimaging. Cerebrospinal fluid (CSF) was collected for a subsample of the total 
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population. The MMSE [17] was administered as a general cognitive screening 
instrument. Subjects were invited annually for follow-up assessment during 2 
years, including questionnaires, MMSE and cognitive tests. Diagnosis was made by 
an expert panel which consisted of a neurologist, a psychiatrist and a geriatrician 
with at least 5 years of clinical experience. An adjusted Delphi method was applied 
starting with the assessment of each case by each expert individually, followed by 
solving all diagnostic discrepancies during a group discussion meeting. Outcome 
measure was  decline (both on a cognitive and/or functional level), which was 
again determined by the three clinical experts. They were asked to individually 
judge observed decline by answering the question “In your opinion, what was the 
course of cognitive or daily functioning during the 2-year follow-up?”.  The study 
was approved by the Medical Ethics Committee of each participating center and 
written informed consent was obtained from all participants and from the primary 
caregiver of the AD patients in accordance with the committee’s guidelines and 
with the Declaration of Helsinki [18]. 
Neuropsychological	examination
A neuropsychological test battery was performed to evaluate performance in several 
cognitive domains. An overview of both patient and informal caregiver assessments 
at baseline and follow-up is presented in a previous publication [15].
MRI acquisition and imaging analysis
Scan	protocol
At each site, patients were scanned according to the routine MRI-protocol. Scanners 
and protocols at different sites varied but all scanning was performed at 3.0 Tesla 
(See AppendixS1 for a detailed description of the scan protocols). Before the start of 
the study, a dummy procedure was carried out in order to optimize the homogeneity 
of scan quality in each center. All scans included a three-dimensional T1 weighted 
gradient echo (3DT1) sequence and diffusion weighted images (DTI) (See Tables S1 
and S2 for a detailed description of the scan protocols).
Preprocessing	of	diffusion	data	
The DTI data were processed with the freely available MR diffusion toolbox 
ExploreDTI version 4.8.3 (www.exploredti.com) [19]. Briefly, in a sequence of pre-
processing steps the diffusion-weighted images were corrected for subject motion 
194 | Chapter 6: A combined volumetry and DTI study
and eddy current induced distortions, incorporating the B-matrix rotation to 
preserve the diffusion gradient orientation information correctly [20]. Correction 
for echo-planar imaging (EPI) distortion was performed using T1 data as reference 
[21]. The diffusion tensor was estimated with “RESTORE”, a robust non-linear least-
squares method [22]. From this diffusion tensor, the DTI metrics FA, MD, RAD and 
AXD were derived.
FreeSurfer	automated	volumetry 
Cortical reconstruction and volumetric segmentation was performed with 
FreeSurfer version 5.1.0 (http://surfer.nmr.mgh.harvard.edu). The precise technical 
details of these procedures are described elsewhere [23, 24]. In short, each dataset 
is corrected for intensity non-uniformities, skull-stripped, and then segmented to 
identify the boundaries between GM and WM and to create a surface representation 
of the cortical WM. Finally, the cerebral cortex is parcellated into units based on 
its gyral and sulcal structure [25]. According to probabilistic information estimated 
from a reference atlas, a neuroanatomical label is assigned to each vertex of the 
surface model and the corresponding measures (i.e., volume) are calculated for 
each section. All procedures with FreeSurfer are conducted in native space. The 
following GM regions have been chosen for further analysis because they all share 
an early vulnerability to AD pathology: hippocampus, parahippocampal gyrus, 
posterior and isthmus cingulate (See supplemental figure S1). 
Template	based	ROI-analyses	of	DTI	metrics
Regional WM integrity was assessed using the DTI metrics FA, MD, RAD and AXD. 
ROIs were mainly adopted from the cortical parcellation analysis, now focussing on 
WM regions just below the cortical mantle. Because of the importance of diffusivity 
changes in callosal regions in early AD, we additionally investigated diffusion 
abnormalities in the genu and splenium of the corpus callosum. Bilateral ROIs were 
created based on a template (called ‘Bert’) provided by FreeSurfer. Because the 
results of ExploreDTI were in native T1 space, the FA, MD, AXD, and RAD volumes 
were mapped to this participant on the basis of the registration of each T1 to this 
participant using FSL’s flirt and fnirt from the FSL toolbox (version 5.0.4, see http://
fsl.fmrib.ox.ac.uk/fsl/fslwiki [26]). Within the selected WM ROIs the average of each 
DTI metrics was computed.  
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CSF analyses 
CSF was obtained by lumbar puncture between the L3/L4 or L4/L5 intervertebral 
space, and collected and aliquoted into polypropylene tubes. CSF samples were 
stored at -80ºC at each center and samples of Maastricht and Nijmegen were 
transported on dry ice to Amsterdam for analysis after up to 2.5 years. The 
commercially available INNOTEST enzyme-linked immunosorbent assay was used 
(ELISAs; Innogenetics, Ghent, Belgium) to quantify CSF Ab1-42, performed by 
experienced laboratory technicians. 
Statistical analysis
Analysis was performed with the Statistical Package for Social Sciences (SPSS 
version 20). Between-group differences on clinical, demographic and cognitive 
characteristics were analyzed using the independent sample t-test for continuous 
and χ2 for categorical variables (significant values set at p<0.05). Univariate analysis 
of covariance (ANCOVA) was used to test the discriminative ability of CSF markers, 
gray matter volume and average DTI metrics. Group differences were investigated 
in the splenium and genu of the corpus callosum, left and right hippocampus, 
parahipocampal gyrus, posterior and isthmus cingulum. Gender, demeaned age 
and demeaned center code were included as covariates to account for the potential 
effects of age, gender and multicenter settings on group differences. Effect sizes 
were calculated using Hedge’s g, which is the difference between the group means 
divided by the pooled standard deviation. Effect sizes between 0.2 and 0.5 were 
classified as small, between 0.5 and 0.8 as medium, and over 0.8 as large [27]. 
In order to investigate the relation between GM and WM tissue abnormalities, 
correlation analysis (one-tailed) were conducted within the patient group (MCI and 
AD). To detect whether WM abnormalities were independent of GM abnormalities, 
GM volumes were entered as a covariate in one of the statistical models. When 
volumetric data were analysed, intracranial volume (ICV) was added as a control 
variable. In order to detect which markers (CSF, atrophy or DTI) at baseline were able 
to predict decline at follow-up, we investigated which markers differed between the 
groups of MCI-decline and MCI-stable.
Correction for intracranial volume (ICV)
To account for age-related cortical shrinkage we measured the intracranial volumes 
196 | Chapter 6: A combined volumetry and DTI study
(ICV) with the FSL Brain Extraction Tool [28].
Correction for multiple comparisons
To control for Type I errors, we performed the false discovery rate (FDR) controlling 
procedure in all cases, a correction for multiple comparisons [29]. This method 
differs from the classical Bonferroni approach in that it is less stringent and as such 
also reduces the increased probability of making Type II errors. 
RESULTS
Subject characteristics
MCI and AD-patients differed from healthy controls in terms of age (Con vs MCI: 
p<.01, Con vs AD: p<.001), gender (p<.001), MMSE (p<.001), delayed recall (p<.001) 
and MTA-score (Con vs MCI: p<.05, Con vs AD: p<.001) (Table 1). AD-patients 
showed lower MMSE (p<.001) and lower delayed recall scores (p<.05) compared to 
MCI-patients. CSF values of t-tau (p<.05) were higher in AD-patients compared to 
MCI. Values of CSF Ab1-42 and the degree of MTL atrophy as assessed by a visual 
rating scale (MTA-score) did not differ between both patient groups (Table 1).
Patterns of gray matter atrophy 
Relative to controls, MCI-patients had significantly lower GM volumes in the left and 
right parahippocampus (p<.001), right posterior cingulum (p<.05), and left (p<.01) 
and right isthmus of the cingulum (p<.001) (Table 2). After correction for multiple 
comparisons, only left (p<.01) and right parahippocampal gyrus volume (p<.01) 
significantly differed between Con and AD. No significant GM atrophy differences 
were found between MCI and AD-patients in the investigated regions (Table 2).
Loss of WM integrity 
MCI-patients showed lower FA values in the bilateral isthmus and posterior 
cingulate, parahippocampal gyrus (all p<.001), hippocampus (left: p=.013, right: 
p=.002) and genu (p<.001) and splenium (p<.05) of the corpus callosum compared 
to healthy controls. Radial and mean diffusivity of the isthmus, parahippocampal 
gyrus, hippocampus and genu were higher in MCI-patients compared to controls 
(all p<.001). Diffusivity differences between controls and MCI were also found in 
the splenium (p=.003 for MD and p=.004 for RAD). Values of axial diffusivity were 
increased in MCI-patients relative to controls in the posterior and isthmus cingulum, 
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parahippocampal gyrus, genu (all p<.001), splenium (p=.028) and hippocampus 
(left: p=.01, right: p<.001) (Table 3). Patients with AD showed lower FA values in 
the bilateral isthmus (left: p<.001, right: p<.01), posterior cingulum (p<.001), 
parahippocampal gyrus (p<.001), left hippocampus (p=.036), and genu (p<.001) of 
the corpus callosum compared to healthy controls. Axial, radial and mean diffusivity 
of the genu, isthmus, posterior cingulum, parahippocampal gyrus, and hippocampus 
were higher in AD-patients compared to controls (all p<.001). Mean diffusivity of 
the splenium  (p=.035) was higher in AD-patients compared to controls. (Table 3). 
Similar to the GM atrophy results, no DTI metrics significantly differed between MCI 
and AD-patients.
Table 1. Subject characteristics. 
Controls MCI AD
N 18 57 35
Age (years) 64.6 (3.4)‡¶ 68.5 (8.5) 71.80 (9.3)
Male (%) 100†¶ 71 66
Years education 5.9 (2.3) 6.0 (2.8) 5.2 (2.7)
MMSE score 28.9 (1.0)†¶ 25.8 (3.0)¶ 22.6 (3.2)
Wordlist delayed recall 8.6 (1.9) †¶ 3.7 (3.0)^ 2.3 (3.3)
MTA-score 1.1 (0.9)◊¶ 2.1 (2.8) 2.7 (2.0)
CSF Ab1-42 - 684.3 (250.7) 598.6 (230.8)
CSF t-tau (pg/mL) - 471.9 (285.6)^ 644.8 (348.6)
CSF p-tau (pg/mL) - 54.6 (26.4) 68.2 (35.3)
NOTE: Values are mean (SD). Abbreviations: MMSE = Mini-Mental state examination; MTA 
= medial temporal lobe atrophy; Ab1-42 = beta amyloid 1-42; t-tau = total tau, p-tau = 
phosphorylated tau; MCI = mild cognitive impairment; AD = Alzheimer’s disease. 
†p<0.001 compared with the MCI group. ‡p<0.01 compared with the MCI group. ◊p<0.05 
compared with the MCI group.  ¶p<0.001 compared with the AD group. §p<0.01 compared 
with the AD group. ^p<0.05 compared with the AD group. 
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Table 2. Regional gray matter volumes (in mm3) of controls and patients with MCI 
or AD.
Controls MCI AD
Hippocampus
Left 3833 (288) 3460 (857) 3147 (590)
Right 3837 (286) 3589 (773) 3195 (655)
Parahippocampus
Left 1314 (170) †§ 951 (342) 957 (340)
Right 1357 (295) †§ 965 (305) 978 (383)
Posterior cingulate
Left 4465 (344) 3795 (652) 3835 (541)
Right 4106 (427)◊ 3644 (581) 3512 (592)
Isthmus cingulate
Left 3872 (521)‡ 3320 (552) 3485 (550)
Right 3558 (436)† 2982 (494) 3201 (562)
NOTE: All analyses stated in the table are corrected for ICV, age, gender and center. Values 
are mean (SD). Abbreviations: MCI = mild cognitive impairment; AD = Alzheimer’s disease. 
Results are corrected for multiple comparisons [29]. †p<0.001 compared with the MCI 
group, ‡p<0.01 compared with the MCI group. ◊p<0.05 compared with the MCI group, 
§p<0.01 compared with the AD group. 
Quantification and comparison of effect sizes of volumetry and DTI-metrics 
In order to quantify and compare the potential diagnostic value of DTI and atrophy 
measurements, effect sizes were calculated. Highest ES (>3.0) was found for 
diffusivity measurements in the parahippocampal gyrus (Con vs AD, Con vs MCI) 
and hippocampus (Con vs MCI, Con vs AD), followed by diffusivity measurements 
in the posterior and isthmus cingulate and genu (all Con vs MCI, Con vs AD). 
Volumetric measurements showed somewhat lower effect sizes ranging from 0.7 
(hippocampus, Con vs MCI) to 1.48 (hippocampus, Con vs AD) (supp Table S3).
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Associations between gray and white matter abnormalities
In the patient group (MCI/AD, n=92) was found that smaller hippocampal volumes 
were associated with higher values of hippocampal diffusivity (MD, RAD, AXD), 
especially in the left hemisphere (Fig. 1, supplemental Table S4). 
Group differences in WM diffusivity did not change when analyses were additionally 
corrected for GM volumes indicating that WM diffusivity differences were 
independent of GM atrophy patterns.
MCI decline vs MCI stable
None of the GM volumes of the investigated structures or CSF values differed 
between MCI-patients showing decline at follow-up compared to MCI-patients 
that remained stable (Table 4). With respect to diffusivity, values of MD (p=.013) 
and AXD (p=.001) of the genu were higher in MCI-subjects who clinically declined 
compared to MCI-subjects without decline (Table 4, Fig. 2).
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Table 4. Differences between MCI-stable and MCI-decline.
NOTE: Volumetric measurements are corrected for intracranial volume. Values are mean 
(SD). Abbreviations: MMSE = Mini-Mental state examination; MTA = medial temporal lobe 
atrophy; FA = fractional anisotropy; MD = mean diffusivity; RAD = radial diffusivity; AXD 
= axial diffusivity; Ab1-42 = beta amyloid 1-42; t-tau = total tau, p-tau = phosphorylated 
tau; MCI = mild cognitive impairment; AD = Alzheimer’s disease.  Results are corrected for 
multiple comparisons [29]. * p	< .05, ** p	< .01 for differences between groups. Analyses 
were corrected for age and center (no gender differences were present).
MCI-stable MCI-decline
N 26 31
Age 65.2 (9.0)** 71.3 (7.0)
Male (%) 65 74
Years education 5.8 (3.0) 6.1 (2.7)
Baseline MMSE score 25.7 (2.5) 25.7 (3.3)
Baseline wordlist delayed 
recall
4.4 (3.0) 3.2 (2.9)
Hippocampus (mm3)
Left 3765 (555) 3203 (771)
Right 3844 (674) 3373 (796)
Parahippocampus (mm3)
Left 1002 (315) 907 (361)
Right 1010 (298) 926 (310)
Posterior cingulum (mm3)
Left 3909 (501) 3700 (751)
Right 3841 (472) 3477 (619)
Isthmus of the cingulum 
Left 3282 (463) 3351 (595)
Right 3043 (486) 2930 (501)
Genu corpus callosum
FA .54 (.09) .51 (.08)
MD 1.07 (.14)* 1.20 (.15)
RAD .72 (.17) .84 (.17)
AXD 1.78 (.11)** 1.92 (.15)
MTA-score 1.2 (1.6) 2.7 (3.3)
CSF Ab1-42 733.4 (283.5) 637.5 (211.4)
CSF t-tau 403.8 (345.4) 536.9 (201.9)
CSF p-tau 47.1 (30.9) 61.8 (19.3)
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Fig. 1. Associations between volumetric and mean diffusivity values in hippocampal 
regions. (A, B) Group differences between controls, MCI and AD for left (A) and 
right (B) hippocampal mean diffusivity (*all p<.001), (C) Associations between 
diffusivity in the left hippocampus (r=-.52; p=<.01) and (D) Associations between 
left hippocampal volume and mean diffusivity in the right hippocampus (r=-.19; 
p<.05). The bilateral hippocampus was the only structure, among those considered 
in the present study, where associations were found between GM atrophy and WM 
integrity. NOTE: MCI = mild cognitive impairment; AD = Alzheimer’s disease; MD = 
mean diffusivity.
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Fig. 2. Diffusivity differences in anterior and posterior parts of the corpus callosum 
in MCI-stable vs MCI-decline (2 years follow-up). The anterior part of the corpus 
callosum (CC) (genu) is depicted in green and the posterior part of the CC is depicted 
in blue (splenium.) *Differences between MCI-stable and MCI-decline were found 
in the genu: mean and axial diffusivity metrics (MD: p = .013, AXD p	= .04). No 
differences in anisotropy (FA) or radial diffusivity (RAD) were found between MCI-
stable and MCI-decline. NOTE: MCI = mild cognitive impairment; FA = fractional 
anisotropy; MD = mean diffusivity; RAD = radial diffusivity; AXD = axial diffusivity.
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DISCUSSION
The present study applied a combined volumetric MRI and DTI method on selected 
regions of interest to obtain complementary information on both GM atrophy 
and microstructural WM alterations in brain tissue of MCI and AD-patients in a 
multicenter setting. The concomitant measurement of both GM volume and WM 
diffusion measures allowed us to detect the brain tissue effects of underlying AD-
pathology. Together with the expert panel diagnosis, the novelty in this study was 
the investigation of the potential of DTI to discriminate between progressive and 
stable MCI-patients in relation to volumetry, CSF and neuropsychological data. 
It was found that diffusivity measurements are more sensitive for group differences 
(higher ES) than atrophy measurements. DTI metrics are furthermore not 
significantly influenced by the effects of ageing, gender and center in apriori selected 
ROIs. Group differences in WM diffusivity did not change when analyses were 
additionally corrected for GM volumes indicating that WM diffusivity differences 
were independent of GM atrophy patterns. Baseline axial and mean diffusivity 
values in the genu were able to discriminate MCI-stable and MCI-decline.
Previous findings showed a widespread pattern of GM atrophy in AD and a more 
restricted GM atrophy pattern in MCI patients [30]. In our study, a similar pattern 
of GM differences was found in the bilateral parahippocampal gyrus (Con/MCI 
and Con/AD), isthmus of the cingulum (Con/MCI) and right posterior cingulum 
(Con/MCI). Other structures were more susceptible to ageing (hippocampus) 
effects or did not survive the correction for multiple comparisons (hippocampus, 
left posterior cingulum, isthmus of the cingulum (Con/AD)). Group differences in 
diffusivity were evident in all the investigated structures. Highest ES was found 
for the parahippocampal gyrus, followed by the hippocampus, posterior and 
isthmus cingulate, and genu (Con/AD). For the discrimination between Con/MCI, 
ES was highest for the parahippocampal gyrus, followed by the hippocampus and 
posterior cingulate. In line with previous studies we found that changes in absolute 
diffusivity (MD, RAD and AXD) were more sensitive for group differences than 
changes in anisotropy (FA) [31]. This could be explained by the fact that if both 
AXD and RAD are increased in AD, MD is increased and therefore FA can remain 
relatively unperturbed [32]. Important to note is that DTI group differences were 
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less influenced by the effects of ageing, gender and scanner differences than GM 
atrophy differences. 
Predictors of decline  
Only baseline diffusivity (MD and AXD) in the genu of the corpus callosum differed 
between MCI-decline and MCI-stable. These differences were furthermore 
independent of age, gender or site differences. No demographic, CSF or volumetric 
measurements were able to predict cognitive decline after 2 years in the group 
of MCI patients. Several studies found an early involvement of the genu in early 
and preclinical stages of AD [33, 34]. A possible explanation for our findings is that 
the genu contains the highest density of small-diameter fibers, which are known 
to be most susceptible to neurodegeneration [35]. As a result, WM damage in the 
genu becomes more evident with disease progression, and diffusion metrics in this 
region thus allow discrimination between decliners and non-decliners. Secondly, 
with disease progression, inter-hemispheric connections of prefrontal regions 
become abnormal, a process in which the genu is known to play a central role [36]. 
We indeed found differences between MCI-stable and MCI-decline on the verbal 
fluency test, a test known to rely on prefrontal regions during active retrieval of 
semantic information (p=.02). Other authors however state that the splenium of the 
CC is the site of maximum damage in early AD [32]. Despite the fact that diffusivity 
in the splenium differed between both patient groups and controls, the splenium 
did not show any predictive value for decline in the group of MCI-subjects. 
Loss of WM integrity is independent of GM atrophy
The associations between the degree of GM atrophy and elevated values of absolute 
diffusivity (MD, RAD, AXD) in the bilateral hippocampus are in line with previous 
studies [37] and suggest the presence of Wallerian degeneration of connecting fibers, 
secondary to GM atrophy in this region [38]. However, our results did not change 
when analyses were additionally corrected for GM volume, suggesting that WM 
diffusivity differences were independent of GM atrophy patterns and that Wallerian 
degeneration is not the primary mechanism of WM change in AD. The lack of a 
significant correlation between diffusivity and volumetric measurements in regions 
outside the hippocampus strengthens the idea that DTI and MR-based volumetry 
measures represent different aspects of underlying pathology [39]. These findings 
are in line with previous work [33, 40] and neuropathological evidence indicating 
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that WM changes in AD are not solely due to Wallerian degeneration [41].
Similarities between MCI and AD-patients
MCI and AD patients differed with respect to MMSE and delayed recall 
scores (MCI>AD) in the absence of GM or WM differences. Values of 
diffusivity (MD, RAD, AXD) in some ROIs were even lower in AD compared 
to MCI patients. These inconsistencies are likely to be due to differences in 
the clinical stage of the recruited patients. Since MCI patients represent a 
heterogeneous group of subjects, their profile of GM and WM abnormalities 
may be similar to that of AD patients, without major consequences in daily life. 
Another possibility is that the majority of loss of WM integrity occurs at the time 
of disease manifestation, while further progression to dementia is accompanied 
by lower rates of WM change. Previous studies found the same pattern of overlap 
between MCI and AD [42-44]. The similarity of in	 vivo volumetric and diffusivity 
measures in the AD and MCI groups, together with a different clinical status, 
could be explained by the fact that the AD group has less cognitive reserve which 
could have led to an earlier transition to AD compared to an extended MCI 
status in the group with less impaired global and episodic memory impairment. 
Except for the higher preservation of cognitive functioning, subjects with MCI 
did not differ from AD patients with respect to educational level or head size, 
both direct indicators of cognitive reserve [45]. Other, more standardized 
measures of cognitive reserve were however unavailable in the present study. 
The group of MCI-patients in our study consisted of both amnestic and non-amnestic 
subtypes. The heterogeneous nature of this sample allowed us to investigate decline 
in a representative sample of subjects visiting a memory clinic. The same pattern 
of diffusion abnormalities was furthermore found in MCI-decline vs MCI-stable 
when only amnestic MCI (aMCI) subjects were included in the statistical analyses 
(n=32) (data not shown). Diffusivity abnormalities in the genu were again the only 
predictors of decline in the group of aMCI.
Strengths and Limitations
It can be considered a strength that for this diagnostic study a memory clinic 
population was used as we aim to generalize our findings to these subjects who 
are eligible candidates for clinical trials. As a consequence, however, our findings 
may not be applicable to other settings, including the general population. The 
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use of different MR imaging units and acquisition protocols could have potentially 
introduced bias. Apart from uniformity during the preprocessing, we additionally 
corrected for the effect of site differences in all analyses. The present study adopted 
an automated ROI-analysis based on apriori hypotheses. An advantage is that 
typical problems associated with voxel-based methods (e.g. alignment) or manual 
ROI definition (e.g. subjective, time-consuming) are avoided. A disadvantage of 
the automated atlas-based ROI approach is that changes are only revealed in pre-
selected areas, lacking whole brain volumetric and diffusion information. 
Clinical implications
Despite the clinical relevance of current DTI-findings in understanding the underlying 
pathology of AD, many of these findings are not yet readily transferrable to clinical 
practice. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) and ADNI-2, did 
not adopt DTI as a core protocol due to the uncertain long-term test-retest precision 
[46], questionable relevance to clinical trials, and absence of an established 
calibration method [47]. These pitfalls should be thoroughly investigated and 
resolved before DTI can be successfully implemented in everyday clinical practice. In 
order to implement DTI data as a biomarker for AD, future studies need to establish 
and validate cut-offs, and standardize automated techniques for use in clinical 
practice. After overcoming these methodological issues, a quantitative metric of 
absolute diffusivity (MD, RAD or AXD) could be extracted from posterior parietal 
(e.g. PCC) or temporal regions (e.g. parahippocampal gyrus or hippocampus) in 
order to evaluate the presence of neurodegenerative processes (diagnosis). For 
tracking disease progression, one could measure absolute diffusivity in the anterior 
part of the corpus callosum (genu) to evaluate which MCI-patients are prone to 
decline within 2 years (prognosis). The clear boundaries of the corpus callosum 
make this major WM tract easy to delineate, in comparison to WM portions in 
medial temporal structures. 
CONCLUSION
The present study demonstrated significant GM and WM differences between AD, 
MCI and healthy controls in a multicenter setting. Diffusivity measurements are more 
sensitive for group differences (higher ES) than volumetric measurements and are 
less influenced by the effects of ageing, gender and center in apriori selected ROIs. 
Our results suggest that diffusion changes precede and also occur independently of 
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GM atrophy. DTI metrics in medial temporal, posterior parietal and callosal regions 
may serve as an early marker for degeneration, even before atrophy is detectable. 
Diffusivity differences in the genu of the corpus callosum are able to predict decline 
in a group of MCI-subjects. Translation of the current findings to clinical practice 
remains to be demonstrated.
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SUPPLEMENTAL MATERIAL
Supplementary Table S1. T1 scan protocol parametersa
a All acquisitions were made in the sagittal plane
Supplementary Table S2. DTI scan protocol parametersa
a All acquisitions were made in the axial (transversal) plane
b Number of B0 acquisitions
c Acquisition was made with a voxel size of 2 x 2 x 2.4 mm3 and then interpolated.
Supplementary Table S3. Effect sizes (Hedge’s g) of volumetry and DTI 
metrics.
Center Mode TR (ms) TE (ms) Flip angle 
(0)
Matrix Slices Voxel size 
(mm3)
MUMC 3D FFE 8.2 3.7 8 240 x 240 180 1 x 1 x 1
VUMC 3D FFE 7.8 3 12 256 x 256 176
0.9375 x 
0.9375 x 1
NUMC 3D FFE 2300 4.7 12 256 x 256 192 1 x 1 x 1
Center TR (ms) TE (ms) Matrix Slices Voxel size 
(mm3)
B0b
Direc-
tions
b value (s/
mm2)
MUMC 8250 80 128 x 128 70 2 x 2 x 2 1 61 1000
VUMC 13000 94 256 x 256 45 1 x 1 x 2.4c 5 30 1000
NUMC 13000 102 128 x 128 81 2 x 2 x 2 1 30 1000
Measure Group Hedge’s g CI 95- CI 95+
RAD PHG Con/AD -3.45 -4.32 -2.57
MD PHG Con/AD -3.45 -4.32 -2.57
AXD PHG Con/AD -3.16 -4 -2.32
RAD PHG Con/MCI -3.02 -3.74 -2.3
MD HC Con/AD -2.98 -3.79 -2.17
MD PHG Con/MCI -2.91 -3.62 -2.2
AXD HC Con/AD -2.82 -3.61 -2.03
RAD HC Con/AD -2.79 -3.57 -2
RAD HC Con/MCI -2.67 -3.35 -1.98
AXD PCC Con/AD -2.63 -3.39 -1.86
Measure Group Hedge’s g CI 95- CI 95+
MD PCC Con/MCI -2.56 -3.23 -1.88
MD PCC Con/AD -2.56 -3.31 -1.8
FA PHG Con/MCI 2.55 1.87 3.22
AXD PHG Con/MCI -2.45 -3.11 -1.78
RAD PCC Con/MCI -2.44 -3.11 -1.78
FA PCC Con/MCI 2.43 1.77 3.09
AXD PCC Con/MCI -2.38 -3.03 -1.72
MD isthmus Con/AD -2.26 -2.98 -1.54
FA PHG Con/AD 2.26 1.54 2.98
RAD PCC Con/AD -2.22 -2.94 -1.51
AXD isthmus Con/AD -2.09 -2.79 -1.39
RAD isthmus Con/AD -1.95 -2.63 -1.27
MD genu Con/AD -1.87 -2.55 -1.2
RAD genu Con/AD -1.82 -2.49 -1.15
AXD genu Con/AD -1.82 -2.49 -1.15
FA PCC Con/AD 1.8 1.13 2.47
AXD isthmus Con/MCI -1.76 -2.37 -1.16
AXD genu Con/MCI -1.73 -2.33 -1.13
MD genu Con/MCI -1.72 -2.32 -1.12
MD isthmus Con/MCI -1.48 -2.06 -0.9
HC volume Con/AD 1.48 0.84 2.11
FA isthmus Con/MCI 1.46 0.88 2.04
PCC volume Con/AD 1.39 0.76 2.02
PHG volume Con/MCI 1.34 0.77 1.92
PHG volume Con/AD 1.33 0.7 1.95
PCC volume Con/MCI 1.29 0.72 1.85
MD HC Con/MCI -1.23 -1.8 -0.67
FA isthmus Con/AD 1.13 0.52 1.74
FA genu Con/MCI 1.11 0.55 1.67
FA genu Con/AD 1.05 0.45 1.66
Isthmus volume Con/MCI 1.03 0.47 1.58
FA HC Con/AD 1 0.4 1.6
AXD splenium Con/MCI -0.87 -1.42 -0.33
AXD HC Con/MCI -0.83 -1.38 -0.29
RAD isthmus Con/MCI -0.81 -1.35 -0.26
MD splenium Con/MCI -0.79 -1.34 -0.24
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NOTE: Only left side of the brain was taken into account.
CI = confidence interval; RAD = radial diffusivity; AXD = axial diffusivity; MD = mean diffusivity; 
FA = fractional anisotropy; PHG = parahippocampal gyrus; PCC = posterior cingulum; Con = 
Controls; MCI = mild cognitive impairment; AD = Alzheimer’s disease. 
Supplementary Table S4. Associations between GM atrophy and WM integrity
Structure MD L MD R RAD L RAD R AXD L AXD R
Hippocampus L -.52** -.19* -.23* -0.15 -.52** -.23*
Hippocampus R -.45** -0.1 -0.12 -0.07 -.48** -0.14
NOTE: Differences in anisotropy (FA) were not associated with hippocampal volume.
MD = mean diffusivity; RAD = radial diffusivity; AXD = axial diffusivity; L = left, R = right.
* p	< .05, ** p	< .01 
Measure Group Hedge’s g CI 95- CI 95+
AXD splenium Con/AD -0.73 -1.31 -0.14
Isthmus volume Con/AD 0.72 0.14 1.31
RAD genu Con/MCI -0.72 -1.26 -0.18
HC volume Con/MCI 0.68 0.14 1.22
MD splenium Con/AD -0.57 -1.14 0.01
FA HC Con/MCI 0.39 -0.14 0.93
RAD splenium Con/MCI -0.38 -0.92 0.15
FA splenium Con/AD -0.36 -0.93 0.21
FA splenium Con/MCI -0.16 -0.69 0.37
RAD splenium Con/AD -0.12 -0.69 0.44
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Supplemental Fig. S1. Regions-of-interest selected for the present study. The following 
structures were selected for further analysis based on their pivotal role in Alzheimer’s 
disease: hippocampus (blue), parahippocampal gyrus (red), posterior cingulum (green), 
and isthmus of the cingulum (yellow). (A) Sagittal view showing the hippocampus and 
parahippocampal gyrus, (B) Coronal view showing the posterior cingulum, hippocampus 
and parahippocampal gyrus and (C) Sagittal view showing the isthmus and posterior part 
of the cingulum.
Appendix	1.	Clinical	characteristics	of	the	Alzheimer	group
Alzheimer diagnosis was made by an expert panel which had access to clinical, functional 
and neuropsychological data, together with quantitative MRI information (e.g. vascular 
pathology (infarcts, microbleeds), degree of medial temporal lobe atrophy (MTA) as 
measured by the visual rating scale [48]). Since no other biomarker (e.g. CSF) apart from 
MTA was included in the expert panel diagnosis, some AD-cases a posteriori showed a non-
AD-like CSF profile (n=14). We further investigated this group and excluded 2 subjects from 
the initial group of 37 AD-subjects since both patients showed a neuropsychological profile 
with mainly executive problems together with an MTA-score below cut-off [1], probably 
due to vascular dementia. From the remaining AD-subjects with a non-AD-like CSF profile 
(n=12), 6 patients were categorized as ‘SNAP’ [49] showing abeta 1-42 values just above the 
cut-off (>550 in stead of the suspected ≤550) together with elevated values of t-tau (>375) 
and p-tau (>52) [50]. Of the 6 remaining subjects, 2 showed severe MTA as assessed by the 
visual rating scale (left+right side, >6), 3 cases showed severe episodic memory problems 
matching an Alzheimer profile and 1 patient showed severe memory problems together 
with highly impaired activity of daily living (ADL). 
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Can FreeSurfer compete with manual 
volumetric measurements in Alzheimer’s 
disease?
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ABSTRACT
Alzheimer’s disease (AD) results in tremendous structural and functional changes 
in the brain. The performance of automated brain segmentation techniques may 
be less precise when applied in AD-patients, possibly leading to false allocations 
of gray matter, white matter or cerebrospinal fluid. FreeSurfer has been shown to 
operate as an accurate and reliable instrument to measure cortical thickness and 
volume of neuroanatomical structures. Considering the principal role of FreeSurfer 
in the imaging field of AD, the present study aims to investigate the robustness of 
FreeSurfer to capture morphological changes in the brain against varying processing 
variables in comparison to manual measurements (the gold standard). T1-weighted 
MRI scan data were used pertaining to a sample of 53 individuals (18 healthy 
participants, 18 patients with mild cognitive impairment, and 17 patients with mild 
AD). Data were analyzed with different FreeSurfer versions (v4.3.1, v4.5.0, v5.0.0, 
v5.1.0), on a custom-built cluster (LINUX) and a Macintosh (UNIX) workstation. 
Group differences across versions and workstations were most consistent for 
both the hippocampus and posterior cingulate, regions known to be affected in 
the earliest stages of the disease. Furthermore, it was found that later versions of 
FreeSurfer were more sensitive for group differences, and corresponded best with 
the gold standard. In conclusion, later versions of FreeSurfer were more accurate 
than earlier versions, especially in medial temporal and posterior parietal regions. 
This development is very promising for future applications of FreeSurfer in research 
studies, and encourages the future role of FreeSurfer as a candidate marker in 
clinical practice.
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INTRODUCTION
Considering the increase of the aging population in our society and age being the 
greatest risk factor for the development of dementia, there is a growing interest 
in understanding and treating dementia. Currently, Alzheimer’s disease (AD) is 
estimated to affect 35 million patients worldwide (or 0.5% of the global population) 
and this number is estimated to increase to 115 million by 2050 [1]. On a brain level, 
Alzheimer’s disease (AD) pathology results in excessive structural and functional 
damage, secondary to processes such as accumulation of amyloid-beta and tau 
proteins, neuroinflammation and neuronal death [2]. Structural and functional 
imaging measurements are currently evaluated for clinical use in predicting or 
diagnosing AD [3, 4]. An indispensable part of this effort is the development of a 
robust method to measure morphological and pathological changes in the brain [5]. 
Manual volumetric measurements are still regarded gold standard for evaluation of 
local brain atrophy [5, 6], however, clinical settings require diagnostic instruments 
that are quick, reliable and easy to implement. FreeSurfer (Athinoula A. Martinos 
Center for Biomedical Imaging, Boston) comprises a popular and freely available set 
of tools for deriving neuroanatomical volume and cortical thickness measurements 
by means of automated brain segmentation (http://surfer.nmr.mgh.harvard.edu). 
At present, more than 80 studies are published using FreeSurfer to investigate 
structural changes in the brain of (early) AD patients (Source: PubMed, http://www.
ncbi.nlm.nih.gov/pubmed/). 
Due to the variation in software and hardware environments, both in research and 
clinical practice, an equally important question related to measuring brain atrophy 
concerns the power and robustness of automated techniques to capture (small) 
morphological and pathological changes in the brain against these varying processing 
conditions. Since the pathological events seen in AD affect the morphology of the 
brain, it is conceivable that with such fundamental changes in brain structure, minor 
changes in processing conditions could affect the segmentation process and thus 
observed group differences. In a previous study we systematically evaluated how 
the morphometric results derived from FreeSurfer may be affected by the following 
processing variables: FreeSurfer version (v4.3.1, v4.5.0, and v5.0.0), workstation 
type (Macintosh and Hewlett-Packard), and Macintosch Operating System version 
(OSX 10.5 and OSX 10.6) [7]. Results revealed significant differences between 
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FreeSurfer version v5.0.0 and the two earlier versions ranging between 8.8 ± 6.6% 
(range 1.3 – 64.0%) (volume) and 2.8 ± 1.3% (1.1 – 7.7%) (cortical thickness). About 
twice as small differences were found between either the two workstation types 
or between OSX 10.5 and OSX 10.6. These differences almost peer with effect sizes 
reported in neurodegenerative studies. Our previous study investigated changes 
in healthy young subjects and patients suffering from psychotic disorder [7]. 
Brain changes in these groups are less pronounced than those found in aging and 
neurodegenerative diseases. In view of the fact that FreeSurfer is extensively used 
in studies of ageing, a next step is a validation of FreeSurfer in a neurodegenerative 
population. The novelty in this study is that a comparison with manual volumetry is 
included as reference method, which is required in order to validate the accuracy of 
the segmentation results and thus subsequently detect which abnormalities are due 
to neurodegeneration and which can be classified as error. Such validation studies 
require a comparison with manual segmentations or even post- mortem assessments 
(see [8] for a discussion on the limitations of both reference methods). The accuracy 
of the cortical thickness measures is more difficult to validate and requires mainly 
post-mortem (histological) measurements [9]. Only few studies directly compared 
FreeSurfer with manual volumetric measurements, mainly focusing on the medial 
temporal lobe in AD [10, 11], major depressive disorder [12], and temporal lobe 
epilepsy [13, 14]. These studies generally suggest that manual volumetry is slightly 
superior or equally sensitive to FreeSurfer automated volumetric measurements.
The aim of the present study is to investigate whether the sensitivity of FreeSurfer 
to detect group differences is consistent over different software versions and 
operating systems despite tremendous morphological changes typically seen in 
AD-patients. Stability of group differences across various processing conditions 
is investigated, and in order to understand which processing condition fits 
best with the ‘reference’ group differences, FreeSurfer’s group differences are 
compared with manual volumetry, the gold standard in research practice [6, 15]. 
To the best of our knowledge, this is the first study assessing group differences 
across various processing conditions and validating these findings against gold 
standard measurements. Based on the literature, six well-established AD signature 
regions were chosen. Hippocampal atrophy is known to play a major role in the 
development of AD [16], but is however not specific for AD [17]. Since other medial 
temporal lobe (e.g. parahippocampal gyrus)[18], prefrontal (e.g. inferior prefrontal 
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and orbitofrontal cortex) [19] and posterior parietal regions (e.g. posterior cingulate 
and precuneus) [20] have shown to be altered during the disease process, these 
regions are additionally evaluated.
METHODS
Participants
Three groups of male participants were included: 18 healthy participants without 
any subjective memory impairment (CON), 18 patients with amnestic MCI (aMCI), 
and 17 patients with mild AD [18, 21]. Mean age (years ± sd) of the included 
individuals was 64.6 ± 3.4, 65.1 ± 4.5, and 70.6 ± 9.1, respectively. The study was 
approved by the ethics committee of the Maastricht University Medical Center and 
all participants gave written informed consent in accordance with the committee’s 
guidelines and with the Declaration of Helsinki [22].
MRI	acquisition
MRI scans were administered with a 3T whole-body MR system release 2.0 (Philips 
Achieva, Philips Medical Systems, Best, The Netherlands) equipped with an eight-
element head coil (SENSE, factor 2). Anatomical T1 images were acquired with a 
gradient echo sequence with TR = 8.0 ms, TE = 3.7 ms, FA = 8°, FOV = 240 x 240 
mm2, matrix = 240 x 240, number of slices = 180, voxel size = 1.0 x 1.0 x 1.0 mm3.
FreeSurfer
Automated volumetry
Cortical reconstruction and volumetric segmentation was performed with FreeSurfer, 
which is freely available (http://surfer.nmr.mgh.harvard.edu). The technical details 
of these procedures have been described previously (for a recent overview 
see:  [9]) . Briefly, in this approach, brain areas are segmented using a nonlinear 
template matching [23]. After linearly registering the test image to the template, 
the algorithm estimates the nonlinear transformation between a given MRI and a 
probabilistic atlas of the selected brain structure constructed from a cohort of 40 
subjects aged 19-87 years using a maximum likelihood criterion [24]. Probabilistic 
labels are warped back to the individual MRI using the inverse of this transform. 
The final segmentation is accomplished by maximizing the a posteriori probability in 
the Bayes formula at each voxel. Voxel-wise probabilistic labels and their predicted 
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image intensities serve as the prior term, while the intensity similarity between the 
target image and the template serves as the likelihood term. In this study, both voxel 
and tabulated volumes (corrected for partial volume effects) were used. Important 
to note is that voxel volumes are most suited to obtain a proper comparison with 
manual volumetry, because of the absence of partial volume correction. 
Cortical thickness (CT)
The FreeSurfer CT pipeline has been described and validated in previous 
publications [25-28]. To summarize, processing involves intensity normalisation, 
registration to Talairach space, skull stripping, segmentation of WM, tesselation of 
the WM boundary, smoothing of the tesselated surface and automatic topology 
correction. The tesselated surface is used as the starting point for a deformable 
surface algorithm to find the WM and then the pial boundary. For each point on 
the tesselated WM surface, the CT is calculated as the average of the distance from 
the WM surface to the closest point on the pial surface and from that point back to 
the closest point on the WM surface [26]. The cortex of the brain was automatically 
subdivided into gyral-based regions of interest (ROIs) [24]. To accomplish this, a 
registration procedure was used that aligns the cortical folding patterns and 
probabilistically assigns every point on the cortical surface to one of the 34 ROIs. For 
the purposes of this study, we focused on 6 ROIs bilaterally. For each ROI the mean 
cortical thickness was extracted for subsequent statistical analysis. This technique is 
referred to as CT-parcellation.
For our second approach, a vertex-wise analysis, the thickness measures 
were mapped on a spherically inflated surface of each participant’s reconstructed 
brain. This allows visualization across the surface without interference from cortical 
folding. By means of a combination of linear and non-linear transformations, the 
spherical cortical folding patterns were aligned to a spherical template provided 
by FreeSurfer. This technique, called “surface- based intersubject registration” [29], 
provides an accurate matching of morphologically homologous cortical locations 
across participants on the basis of each individual’s anatomy while minimizing 
metric distortions. The resulting CT map was smoothed by a circularly symmetric 
Gaussian filter with a full width half maximum (FWHM) set to 20 mm in order 1) 
to compensate for residual misalignments; 2) to increase the signal-to-noise ratio; 
and 3) to make the data more normally distributed. This technique is referred to as 
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CT-vertex henceforth.
Quality control was performed after each step of the automated FreeSurfer 
pipeline (volumetry and cortical thickness) to account for possible errors (e.g. 
misregistrations, outliers).
Manually	defined	ROIs
For the manual tracing we used GIANT (General Image Analysis Tools; [30]), a 
software program which allows tracing of regions of interest (ROI) in a triplanar 
and rotatable 3D surface-rendered view, and calculation of GM volumes of interest. 
Boundaries of the selected frontal and temporal structures were set according 
to criteria described in a previous publication [31]. Boundaries of the posterior 
cingulate and precuneus cortex were adapted from [32] and [33], respectively. 
Both raters (LC, CE) were blind to the demographic and cognitive characteristics of 
the participants. Intra-rater reliability was determined by the Intraclass Correlation 
Coefficient (ICC) [34]. ICC’s for each region can be found in a previous publication 
[35] (Supplementary Table S1).
Regions	of	interest	(ROI)	selected	from	the	Desikan	atlas
For the purpose of this study, we used the Desikan atlas and focused on one subcortical 
ROI and five cortical ROIs bilaterally: the hippocampus, the parahippocampal gyrus 
(PhG), the inferior prefrontal cortex (IPFC), the orbital frontal cortex (OPFC), the 
posterior cingulate cortex (PCC), and the precuneus (PC) (see Appendix for more 
details on which FreeSurfer ROIs [24]) were selected and merged). FreeSurfer ROIs 
were chosen in accordance with the anatomical borders of the manually defined 
ROIs: e.g. FreeSurfer’s definition of the isthmus was most consistent with our 
definition of the posterior cingulate cortex as adopted for the manual segmentation 
and was subsequently used. The posterior cingulate cortex ROI included in the 
FreeSurfer automated measurement is more rostral compared to our definition. 
Intracranial	volume
The ICV was calculated from the inner skull contours produced by the FSL Brain 
Extraction Tool [36] and visually checked.
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Processing	conditions
Workstations
Several workstations and corresponding operating systems (OS) were used: an 
iMac with OSX 10.5, a MacPro with OSX 10.6 (called “iMac2” and “MacPro2” in 
Gronenschild et al. 2012, respectively), and a custom-built cluster equipped with 
Intel i7 quad-cores (3.20 GHz) running under Scientific Linux 6.2 (called “RadCluster” 
henceforth). Both Macintosh (Mac) workstations were used in 32 bits mode and the 
RadCluster in 64 bits mode.
Software versions
Four versions of FreeSurfer were used: v4.3.1, released on 19 May 2009, version 
v4.5.0, released on 11 August 2009, version v5.0.0, released on 16 August 2010, 
and version v5.1.0, released on 24 May 2011. For the Mac workstations these are 32 
bits versions, whereas for the RadCluster these are 64 bits versions. An additional 
remark with respect to v5.1.0 should be made: we used an intermediate version of 
the processing pipeline in order to resolve issues around the order of the correction 
for intensity non-uniformity stage and Talairach stage in the pipeline (see also 
https://surfer.nmr.mgh.harvard.edu/fswiki/TalFailV5.1).
Statistical	Analysis
Group analysis of the segmentation results was performed in two ways. In the first 
approach, analysis was performed with IBM SPSS version 19 (Chicago, IL, USA) 
on Macintosh version 19.0. FreeSurfer-based volumes, manual volumes and CT-
parcellations were compared between the three groups by means of univariate 
pair-wise ANCOVA with either volume or CT-parcellation as dependent variable, 
group as independent variable and centered age as covariate. For both volumetric 
measurements, intracranial volume (ICV) was taken as an additional covariate. 
To correct for multiple comparisons, we applied the false discovery rate (FDR) 
controlling procedure [37].
Our second approach was a vertex-wise analysis of CT using FreeSurfer tools. 
Statistical comparisons between the CT maps were generated by computing a 
general linear model (GLM) of the CT group differences (corrected for centered age) 
at each vertex in the cortical mantle, with a statistical threshold set to p	= 0.05. A 
cluster-wise procedure was performed to correct for multiple comparisons [38]. This 
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method utilizes a simulation to get a measure of the distribution of the maximum 
cluster size under the null hypothesis.  Z-maps are synthesized and smoothed 
using a residual FWHM, and then thresholded at p = 0.05. Next, areas of maximum 
clusters are recorded, under these specifications, and the procedure is repeated for 
5000 iterations. Once the distributions of the maximum cluster size are obtained, 
correction for multiple comparisons is performed by finding clusters in the statistical 
maps using the same threshold as was given in the simulation procedure. For each 
cluster, the p value is the probability of seeing a maximum cluster of that size, or 
larger, during the simulation. Clusters remaining in similar areas of significance as in 
the original cortical thickness maps would indicate that the result is not likely due 
to chance. For each cluster, maximum, minimum, mean and standard deviation of 
the p-values were extracted.
To quantify the differences of the results of the above vertex-wise analyses across 
FreeSurfer versions or workstations, the measure of spatial overlap (Dice coefficient, 
[39]) of the respective clusters was computed. Its range is between 0 (no overlap) 
and 1 (complete overlap, i.e., exactly similar). It is generally accepted that a value 
larger than 0.7 indicates a good agreement [40].
RESULTS
Subject characteristics can be found in Table 1. A complete overview of the 
comparison CON vs. AD for each selected ROI is illustrated in Fig. 1 (the group 
comparisons CON vs. MCI and MCI vs. AD are shown in the supplemental material, 
Figs. S1-S2 respectively). Each cell is color-coded according to its p-value after 
correction for multiple comparisons. In case of CT-vertex we have taken the minimal 
p-value in each ROI.
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Table 1. Subject characteristics
Con MCI AD
N 18a 18c 17
Age 64.56 (3.4) 65.11 (4.5) 70.59 (9.1)
Educational level 4 (1.4) 4 (1.8) 4 (1.9)
MMSE score 28.89 (0.9)b,d 27.61 (2.3)f 21.18 (3.9)
15 WLT learning 37.50 (7.6) 26.06 (9.8) 23.47 (11.7)
15 WLT memory 8.56 (1.9)d,e 3.67 (2.8)c 1.73 (2.4)
Fluency animals 23 (5.3) 21 (5.4) 13.93 (4.7)
Manual  
hippocampus
4656 (308)/4758 4410 (482)/4308 3883 (817)/3807
volume L/R (mm3) -637 -796 -876
ICV (ml) 1492 (100) 1539 (121) 1574 (125)
All volumetric measurements are corrected for intracranial volume. Values are mean 
(sd). MMSE: Mini-Mental state examination;WLT: wordlist; Con: controls; MCI: mild 
cognitive impairment; AD: Alzheimer’s disease. 
a p < 0.05 for difference between CON and AD
b p < 0.05 for difference between CON and MCI
c p < 0.05 for difference between MCI and AD
d p < 0.001 for difference between CON and AD
e p < 0.001 for difference between CON and MCI
f p < 0.001 for difference between MCI and AD
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Fig. 1 Overview of statistical significances across FreeSurfer versions and workstations for 
the comparison of controls versus AD. Each cell is color-coded according to its p-value in 
four categories, see coding scale at right. The first set of four columns refers to the MacOSX 
10.5 workstation, the second set to the MacOSX 10.6 workstation, and the third set to the 
custom-built cluster workstation (called RadCluster). In each set, the columns present the 
results for version v4.3.1*, v4.5.0, v5.0.0, and v5.1.0, respectively. Finally, the last column 
refers to the p-values based on the manual outlining. Only the results after correction for 
multiple comparisons are shown. Four separate FreeSurfer measurements were used: 1) 
number of voxels within a segmented ROI (called voxel volume); 2) tabulated ROI volume 
(equal to voxel volume but corrected for partial volume effects); 3) mean cortical thickness 
(CT) within an ROI (called CT-parcellation-based); 4) vertex-wise CT cluster (called CT- 
vertex). Abbreviations are as follows: HIPPO = hippocampus; ERC = entorhinal cortex; PhG= 
parahippocampal gyrus; IPFC = inferior prefrontal cortex; OPFC = orbital prefrontal cortex; 
PCC = posterior cingulate cortex; PC = precuneus; L = left; R = right.
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Fig. 2 Significance of cortical thickness differences between controls and ADs obtained 
from the vertex-wise analysis before and after correction for multiple comparisons (left 
hemisphere). The color scale at the right depicts the range of p-values shown (expressed 
in 10-x). The colors yellow-red indicate cortical thickening, the color blue indicate cortical 
thinning. The results for four FreeSurfer versions are displayed, from top to bottom: v4.3.1*, 
v4.5.0, v5.0.0, and v5.1.0, all obtained on a MacOSX 10.6 workstation.
Robustness	of	FreeSurfer	across	workstations	and	software	versions
Generally, it can be noted that FreeSurfer derives more significant results for 
later versions in case of volumetric measurements (either voxel or tabulated). In 
addition, the CT- vertex method produces consistent results through versions as 
well as workstations, especially for MTL regions. With respect to cross-workstation 
differences, it can be observed that MacOSX 10.6 is most similar to RadCluster, in 
particular for v5.1.0. For both voxel and tabulated volumetric measurements, group 
differences between workstations and software versions were most consistent 
in hippocampal and posterior cingulate regions. Group differences in the PhG, 
OPFC R and PC L were only found in FreeSurfer v5.0.0 and/or v5.1.0, across all 
workstations. The CT-vertex results for MacOSX 10.6 and all FreeSurfer versions are 
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illustrated in Fig. 2 for the left hemisphere (comparison CON vs. AD, both corrected 
and uncorrected results are displayed). Cortical thinning (negative effects, blue 
colored) was mainly observed in temporal and parietal cortical areas. Cortical 
thickening (positive effects, red-yellow colored) was apparent in the frontal lobe 
only for versions v4.5.0 and v5.1.0. For the other versions, these positive clusters 
did not survive the correction for multiple comparisons. For the comparison CON 
vs. MCI, no significant clusters were found.
The Dice coefficients for the agreement of the CT surface clusters (positive and 
negative effects taken together) are summarized in Tables 2 and 3. In most 
cases the agreement was good to excellent, and better between workstations 
than between FreeSurfer versions. In order to detail these findings, worst and 
best agreements for the cross-workstation comparisons are shown in Fig. 3. 
Vertices depicted in green indicate the presence of the clusters in the results 
of both workstations. Red and yellow indicate the presence of only one of 
the respective workstations. The corresponding Dice coefficients were 0.68 
and 0.97, respectively. A complete disagreement was found for the posterior 
cingulate cortex (see left medial view). Similarly, the worst and best results for 
the cross-version comparisons are shown in Fig. 4, with corresponding Dice 
coefficients of 0.58 and 0.94, respectively. A disagreement was found in the 
frontal lobe, and posterior cingulate cortex (see left medial view). 
Table 2. Cortical thickness surface cluster similarities (Dice coefficients) across 
workstations
MCI vs. AD MacOSX10.6 RadCluster
MacOSX10.5 0.80 – 0.94 0.75 – 0.92
MacOSX10.6 - 0.78 – 0.90
CON vs. AD
MacOSX10.5 0.82 – 0.96 0.75 – 0.96
MacOSX10.6 - 0.68 – 0.97
CON: controls; MCI: Mild cognitive impairment; AD: Alzheimer’s disease.
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Table 3. Cortical thickness surface cluster similarities (Dice coefficients) across 
FreeSurfer versions
MCI vs. AD v4.5.0 v5.0.0 v5.1.0
v4.3.1* 0.78 – 0.93 0.69 – 0.80 0.78 – 0.85
v4.5.0 - 0.66 – 0.82 0.73 – 0.85
v5.0.0 - - 0.78 – 0.89
CON vs. AD
v4.3.1* 0.75 – 0.89 0.61 – 0.78 0.70 – 0.86
v4.5.0 - 0.58 – 0.75 0.63 – 0.82
v5.0.0 - - 0.68 – 0.94
CON: controls; MCI: Mild cognitive impairment; AD: Alzheimer’s disease.
Fig. 3 CT Cluster similarities for the worst (top row) and best (bottom row) agreement 
found between workstations. The worst agreement was found for FreeSurfer v5.0.0 
between MacOSX 10.6 (yellow) and RadCluster (red) and left hemisphere: SI = 0.68. The 
best agreement was found for FreeSurfer v5.0.0 between MacOSX 10.6 9 (yellow) and 
RadCluster (red) and right hemisphere: SI = 0.97. Vertices colored green indicate the 
presence of the clusters in the results of both workstations.
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Comparison	of	FreeSurfer	group	differences	with	gold	standard	measurements
When comparing AD-patients with controls, a good agreement was found 
between later versions of FreeSurfer and manual measurements, especially in 
MTL and posterior parietal regions. It is however remarkable that compared to 
the highly significant effect found for manual volumes, no group differences were 
found in the left OPFC for the automated measurements except in one instance, 
i.e., CT-vertex approach on MacOSX 10.5, version v4.5.0. For the right PCC, the 
opposite pattern was found where manual volumetric measurements did not show 
group differences in the right PCC compared to the automated measurements 
(all versions and workstations except for the CT-vertex approach). Compared to 
manual volumetric measurements, FreeSurfer seems less sensitive for detecting 
differences in prefrontal regions (both volume and CT). For the FreeSurfer 
volumetric and CT-parcellation measurements, group differences between CON vs. 
MCI were most apparent in posterior parietal regions (PCC and PC) whereas for the 
manual volumetric measurements, differences in the MTL were found (right PhG). 
The CT-vertex technique was unable to detect group differences between CON vs. 
MCI. When MCI and AD-patients were compared, group differences were mainly 
found in posterior parietal regions for the FreeSurfer volumetric measurements, 
compared to differences in MTL and prefrontal regions found with the manual 
volumetric measurement. For the comparison MCI vs. AD, the CT-vertex technique 
corresponded best with manual volumetric measurements and was even more 
sensitive for group differences than manual volumetry in posterior parietal regions. 
The CT-parcellation technique was unable to detect group differences between 
MCI vs. AD.
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Fig. 4 CT Cluster similarities for the worst (top row) and best (bottom row) agreement found 
between FreeSurfer versions. The worst agreement was observed for RadCluster between 
versions v4.5.0 (yellow) and v5.0.0 (red) and left hemisphere: SI = 0.58. The best agreement 
was observed for MacOSX between versions v5.0.0 (yellow) and v5.1.0 (red) and right 
hemisphere: SI = 0.94. Vertices colored green indicate the presence of the clusters in the 
results of both workstations. The colors yellow and red denote the clusters found in only 
one of the workstations.
DISCUSSION
Alzheimer’s disease pathology has a massive impact on both the structure and 
function of the ageing brain. Performance of automated brain segmentation 
techniques may be less precise when applied in these patients due to fundamental 
changes in certain brain structures. FreeSurfer has been shown to operate as an 
accurate instrument to measure brain atrophy in neurodegenerative diseases [35, 
41-44], emphasizing the need for both validation and comparison of the FreeSurfer 
pipeline with manual volumetry in a cohort of subjects with and without Alzheimer’s 
disease pathology. To the best of our knowledge, this is the first study evaluating 
the robustness of FreeSurfer to capture morphological and pathological changes 
against varying processing conditions, both in healthy old subjects and subjects 
suffering from (early) AD. For direct comparison, atrophy was also measured by 
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means of manual volumetry, nowadays regarded as gold standard.
Overall, consistent results across versions and workstations were obtained for the 
hippocampus and PCC in case of volumetry. These structures seem less affected by 
changes in processing parameters, a finding of particular relevance for the imaging 
field of AD since these structures are known to be primarily involved in the disease 
process [4, 45]. With respect to CT vertex-wise analyses, consistency was observed 
across versions and workstations for the PhG, left PCC, and left PC. In addition, the CT-
vertex technique was much more sensitive than the CT-parcellation technique. This 
finding is in line with previous work which found that CT-vertex was more sensitive 
than CT-parcellation in discriminating AD and controls [46]. The partial disagreement 
between CT-parcellation and manual volumetry may be related to the fact that 
effective validation of the CT technique requires postmortem investigations, and 
that manual volumetric measurements are thus not the most appropriate source of 
comparison. Furthermore, although differences between ROI’s were small, borders 
of manual and FreeSurfer measurements were not entirely overlapping.
The FreeSurfer v5.1.0 results for MacOSX 10.6 are almost identical to those for 
RadCluster; only the CT-vertex results for the right PCC and PC deviate. In addition, 
a higher level of agreement was found between MacOSX 10.6 and Radcluster than 
between MacOSX 10.5 and 10.6. This supports the hypothesis in our previous 
paper, namely that most probably the number of bits under which the operating 
system is running (either 32 bits or 64 bits) is an important factor [7]. Although both 
MacOSX 10.5 and 10.6 were used in 32 bits mode, our results may suggest that 
the underlying UNIX shell for MacOSX 10.6 nonetheless uses mathematical libraries 
with 64 bits precision.
Only few studies reported on the capability of FreeSurfer to discriminate groups 
in comparison to manual volumetric measurements [10-12, 14, 47]. In general, 
these studies suggest that manual volumetry is slightly superior or equally sensitive 
to FreeSurfer automated volumetric measurements. While the previous studies 
focussed on one ROI (e.g. hippocampus), the present study extends these findings by 
examining all cortical signature regions in AD, and thereby increasing the diagnostic 
relevance and generalizability.
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For the comparison CON vs. AD, the present study found that manual volumetry 
and later versions of FreeSurfer (v5.0.0 and v5.1.0) were both sensitive in detecting 
hippocampal and parahippocampal volume reduction. Group differences in the 
posterior parietal lobe were less consistent between FreeSurfer and manual 
volumetry and it was found that later versions of FreeSurfer (v5.0.0 and v5.1.0) 
corresponded best with gold standard measurements. Furthermore, FreeSurfer 
was less sensitive for group differences in prefrontal regions compared to manual 
volumetric measurements (comparison CON vs. AD and MCI vs. AD).  In the early 
phase of the disease (CON vs. MCI), FreeSurfer is more sensitive for group differences 
in posterior parietal regions compared to the MTL which is most pronounced in 
manual volumetry.
Limitations
One limitation may be related to the composition of the study population that 
comprised 18 healthy controls, 18 patients with amnestic MCI, and 17 patients with 
mild AD. Only males were included in this study in order to reduce interindividual 
variation. Generalization of our findings to females should therefore be done 
with caution. Previous studies did however not reveal substantial gender related 
differences with respect to atrophy in AD [13]. The sample size of the present study 
is relatively small, which may possibly limit the ability to detect differences between 
groups that might become apparent when sample sizes are larger. Nonetheless, data 
was normally distributed and based on the inclusion of a time-intensive technique 
such as manual volumetry and on our hypothesis, sample size was fair enough to 
effectively address our research questions. Neurodegenerative processes in AD do 
not occur randomly, but likewise do not follow the boundaries set out by atlases. 
This is in line with the notion that locations of neurodegeneration may not coincide 
with predefined ROIs and thus such ROIs may harbor intrinsically less discriminative 
power, i.e., local effects are averaged out. On the other hand, the discriminative 
power of the manually defined ROIs was high in all cases, except for the IPFC and 
right PCC. Obviously, differences in the locations of the ROI boundaries between 
FreeSurfer and manual outlining may play a role, leading to overestimation of 
the volumes by the automated technique [8, 10, 47, 48]. To correct for multiple 
comparisons, we performed the FDR controlling procedure instead of the classical 
Bonferonni approach because the former is less stringent and as such reduces the 
increased probability of making Type II errors [49, 50]. 
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As a consequence, correction for multiple comparisons was done over 14 
comparisons for the FS automated volumetry and 12 for manual volumetry, which 
is slightly in favor of the manual technique. The two latest versions of FreeSurfer 
(5.2.0 and 5.3.0) were not included in the present analyses. However, a literature 
search (PUBMED) showed us that near half of the published FreeSurfer papers in 
the field of AD thus far used one of the versions evaluated in this paper (n=34). 31 
papers did not specify the version used, 3 used newer versions and 17 studies used 
earlier releases (e.g. version 3.0). This finding clearly emphasizes the importance of 
the results reported in the present study.
Implications	for	research	and	clinical	practice
From the present study follows that despite the large morphological changes on a 
brain level, FreeSurfer can reliably be used to investigate structural brain alterations 
in AD. Another important finding is that, compared to manual volumetry, later 
versions of FreeSurfer are more accurate than earlier versions. This development 
is very promising for future applications of FreeSurfer in scientific studies on 
neurodegenerative diseases, and encourages the future role of FreeSurfer in clinical 
settings. While FreeSurfer is created for use in
research settings, the potential of FreeSurfer for use in clinical practice is promising. 
Based on our findings, we would suggest focusing on automated volumetry of 
posterior parietal regions in the early phase, followed by segmentation of MTL 
regions and measurements of CT in the later stages. The potential of CT-vertex 
measurements as a marker of disease progression should be further investigated in 
large-scale longitudinal studies. Prior work of our group has shown that mixing up 
versions, workstations or operating systems might lead to significant differences in 
cortical thickness or volumetry in schizophrenic patients [7]. However, the current 
findings are much more optimistic, showing that the latest version of FS produces 
much more stable results, even in patients with heavily atrophied brains. While this 
is an important scientific finding, we agree with the FreeSurfer developers that it is 
still advised to try to keep the research environment stable
CONCLUSION
The present study showed that FreeSurfer is a robust method to measure 
morphological and pathological changes in both healthy and atrophied brains. 
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Overall, consistent results across versions and workstations were obtained 
particularly for the hippocampus and PCC in case of volumetry. Later versions of 
FreeSurfer (v5.0.0 and v5.1.0) corresponded best with gold standard measurements 
(manual volumetry), especially in MTL regions. In addition, the CT-vertex technique 
was much more sensitive than the CT-parcellation technique. The continuous efforts 
of the developers of FreeSurfer to improve its performance are very promising for 
AD research and the neuroimaging field in general, and thus potentially also for 
clinical practice.
APPENDIX
The analysed cortical and subcortical ROIs were composed of the following 
FreeSurfer segmentation IDs with their corresponding structure names:
HIPP:   17 (left hippocampus) / 53 (right hippocampus)
PHG:    1016 (left parahippocampal) / 2016 (right parahippocampal)
IPFC:   1018 (left pars opercularis) / 2018 (right pars opercularis)
 1020 (left pars triangularis) / 2020 (right pars triangularis)
OPFC:  1012 (left lateral orbitofrontal) / 2012 (right lateral orbitofrontal)
 1014 (left medial orbitofrontal) / 2014 (right medial orbitofrontal)
PCC:    1010 (left isthmus cingulate) / 2010 (right isthmus cingulate)
PC:       1025 (left precuneus) / 2025 (right precuneus)
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For Supplemental Table 1. ‘Anatomical boundaries of investigated 
structures’ please see Chapter 4, page 126-130.
Supplementary Figure. 1 Overview of statistical significances across FreeSurfer versions and 
workstations for the comparison of controls versus MCI. Each cell is color-coded according 
to its p-value in four categories, see coding scale at right. The first set of four columns refers 
to the MacOSX 10.5 workstation, the second set to the MacOSX 10.6 workstation, and the 
third set to the custom-built cluster workstation (called RadCluster). In each set, the columns 
present the results for version v4.3.1*, v4.5.0, v5.0.0, and v5.1.0, respectively. Finally, the 
last column refers to the p-values based on the manual outlining. Only the results after 
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correction for multiple comparisons are shown. Four separate FreeSurfer measurements 
were used: 1) number of voxels within a segmented ROI (called voxel volume); 2) tabulated 
ROI volume (equal to voxel volume but corrected for partial volume effects); 3) mean cortical 
thickness (CT) within an ROI (called CT-parcellation-based); 4) vertex-wise CT cluster (called 
CT-vertex). Abbreviations are as follows: HIPPO = hippocampus; ERC = entorhinal cortex; 
PhG = parahippocampal gyrus; IPFC = inferior prefrontal cortex; OPFC = orbital prefrontal 
cortex; PCC = posterior cingulate cortex; PC = precuneus; L = left; R = right. 
Supplementary Figure. 2 Overview of statistical significances across FreeSurfer versions and 
workstations for the comparison of MCI versus AD. Each cell is color- coded according to its 
p-value in four categories, see coding scale at right. The first set of four columns refers to 
the MacOSX 10.5 workstation, the second set to the MacOSX 10.6 workstation, and the third 
set to the custom-built cluster workstation (called RadCluster). In each set, the columns 
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present the results for version v4.3.1*, v4.5.0, v5.0.0, and v5.1.0, respectively. Finally, the 
last column refers to the p-values based on the manual outlining. Only the results after 
correction for multiple comparisons are shown. Four separate FreeSurfer measurements 
were used: 1) number of voxels within a segmented ROI (called voxel volume); 2) tabulated 
ROI volume (equal to voxel volume but corrected for partial volume effects); 3) mean cortical 
thickness (CT) within an ROI (called CT-parcellation-based); 4) vertex-wise CT cluster (called 
CT-vertex). Abbreviations are as follows: HIPPO = hippocampus; ERC = entorhinal cortex; 
PhG = parahippocampal gyrus; IPFC = inferior prefrontal cortex; OPFC = orbital prefrontal 
cortex; PCC = posterior cingulate cortex; PC = precuneus; L = left; R = right.
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The stability of resting state networks in 
aging: relevance for early memory 
dysfunction 
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ABSTRACT
Reduced functional connectivity (FC) and atrophy in hubs of the default mode 
network (DMN) is a consistent and early finding in Alzheimer’s disease (AD). In 
order to use FC changes in the DMN as candidate biomarker for AD, its stability in 
normal aging needs to be assessed. Test-retest-reliability of RSNs was investigated 
both in healthy young (HY) and healthy old (HO) subjects. Twenty HY and twenty 
HO subjects underwent three scanning sessions on a 3.0 Tesla MRI. Differences in 
FC were investigated in eight RSNs. Within-group analyses showed no change over 
time (intraclass correlation coefficients: 0.53-0.85). Between-group comparisons 
showed more FC in the DMN and auditory system in HY compared to HO subjects. 
Inverse correlations were found between instability of specific DMN areas and 
neuropsychology:more variability in precuneal connectivity was linked with lower 
performance. As expected, FC in the DMN and auditory system decreases with 
aging. Activity in major RSNs remains stable over time, and instability in key hubs 
of the DMN could become a predictor for future memory problems, supporting its 
potential as a future biomarker.
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INTRODUCTION
Brain activation in the past has mainly been studied using the BOLD signal in task-
related fMRI paradigms, aimed at localizing a variety of memory functions including 
age associated effects [1-3]. The last decade, task-related decreases are found in 
certain regions which remain active in an organized fashion during the resting state 
of the brain [1, 2]. One of these so-called ‘resting state networks’ (RSNs) is the 
default mode network (DMN), particularly relevant for aging and dementia since 
this network is vulnerable to atrophy, deposition of the amyloid protein, and show 
a reduced glucose metabolism [3]. Furthermore, the DMN comprises several areas 
that are also affected early on in Alzheimer’s disease (AD), such as the posterior 
cingulate cortex, medial and lateral prefrontal cortex, medial inferior parietal lobe, 
precuneus, and the medial temporal lobe (Hafkemeijer, et al., 2012; Jacobs, et al., 
2013). Because of this reason, the DMN is considered to hold great potential as 
clinical biomarker. Besides the DMN, the brain consists of a number of other low 
frequency RSNs, such as the visual and auditory networks [4]. The potential effects 
of normal aging on these functional hubs have not thoroughly been investigated [5].
The first step toward a biomarker is assuring that age-effects do not influence the 
reliability of RSNs. In view of a number of studies demonstrating the utility of RSNs 
[6, 7], it remains to be investigated if rs-fMRI is a stable and reliable technique for 
identifying and characterizing abnormalities in a variety of diseases. As it is widely 
known that pathophysiological processes of neurodegenerative diseases (e.g. AD) 
begin many years prior to clinical symptoms, efforts currently aim at detecting 
AD-pathology in clinically (still) asymptomatic individuals. The ultimate goal of 
establishing these so-called ‘biomarkers’ is the identification of and intervention in 
individuals at the preclinical stage to delay and possibly even prevent onset of the 
clinical syndrome.
The present study aimed at investigating the test-retest reliability (i.e. stability) of 
RSNs within and between healthy old and healthy young subjects over 3 different 
time points. Test-retest reliability was investigated both on a voxel-wise basis (FSL) 
and by means of the intraclass correlation coefficient (ICC) (SPSS). As the DMN is the 
most investigated RSN and thus far has the closest link to AD, our second aim was 
to investigate whether individual changes in stability in certain hubs of the DMN are 
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associated with cognitive performance. If instability over time is linked with subtle 
cognitive alterations in healthy old subjects, this finding would be of particular 
relevance for early diagnosis and intervention in at-risk individuals.
METHODS AND MATERIALS
Subjects
Forty healthy subjects were included and gender-matched: 20 elderly subjects 
(HO) (age between 54-66 years) and 20 young subjects (HY) (age between 23-29 
years). Subjects were recruited for the RIMCAD study (Retroactive Interference 
during Memory Consolidation in Aging and Dementia) by means of advertisement. 
Exclusion criteria were significant medical (e.g. cancer, thyrotoxicosis), neurological 
(e.g. epilepsy), or other psychiatric disorders (e.g. schizophrenia, depression, 
Parkinson’s disease); current use of medication which is known to influence 
cerebral function (e.g. anti-depressants); pregnancy or any other contraindication 
against MRI-scanning (e.g. metal implants, claustrophobia). One subject in the 
elderly group was excluded because MRI images were not available for all three 
time points. The Ethical Review Board of the University Hospital of Cologne had 
approved the study, and the study was accomplished in compliance with the latest 
revision of the Declaration of Helsinki. Written informed consent was provided by 
all subjects. 
Neuropsychological	assessment	and	study	design
All subjects received neuropsychological examination to confirm their healthy 
status, including Mini-mental state examination (MMSE) [8], immediate and 
delayed recall of the German version of the Verbal Learning and Memory test [9], 
Trail Making Test (TMT) part A and B [10] and Rey-Osterrieth Complex Figure test 
[11]. Three separate experimental sessions were organized, with on average two 
weeks in between each session. At the time of the first visit subjects were tested 
neuropsychologically whereafter the first MRI examination was performed. At the 
second and third visit (2 weeks and 4 weeks from baseline, respectively) only MRI 
scanning was performed.
MRI	data	acquisition	
All imaging was performed using a 3.0 Tesla Siemens Trio MRI scanner (Siemens, 
Erlangen, Germany) equipped with a standard head coil for radio frequency 
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transmission and signal reception. For each participant, 3 resting-state scans were 
acquired (one per visit) (191 continuous T2*-weighted echo planar imaging (EPI) 
volumes; repetition time = 2200 ms ; echo time = 30 ms; flip angle = 90°; 36 axial 
slices; matrix 64 x 64; voxel size 3.1 x 3.1 x 3.0 mm; scan time = 7 minutes). During 
the scans, participants were instructed to keep their eyes closed, think of nothing in 
particular, and not to fall asleep. In addition, a high-resolution T1 anatomical image 
was obtained for each subject using a three-dimensional magnetization-prepared, 
rapid acquisition gradient echo sequence.  To control for cerebral abnormalities 
(e.g. tumor, subclinical stroke) and macroangiopathy, T2-weighted FLAIR and Time-
of-Flight measurements were acquired in the older subjects only.
Data	preprocessing	and	analyses
Data analysis was carried out using FMRIB’s Software Library (FSL version 4.1.9; www.
fmrib.ox.ac.uk/fsl). Preprocessing was carried out with MELODIC and consisted of 
motion correction, removal of nonbrain tissue (using the Brain Extraction Tool), 
spatial smoothing using a 5 mm full-width-at-half-maximum Gaussian kernel, and 
high-pass temporal filtering equivalent to 100 seconds (0.01 Hz). After preprocessing, 
fMRI volumes were registered to the subject’s high-resolution T1-weighted scan 
using affine registration (FLIRT) and subsequently to standard space (MNI152) 
images using nonlinear registration (FNIRT) with a warp resolution of 10 mm. 
Assessment	of	functional	connectivity		
Functional connectivity of RSNs was defined in terms of the similarity of the BOLD 
fluctuations in each brain voxel in relation to characteristic fluctuations in eight 
predefined components (RSNs of interest). For the selection of these components 
an existing template was used containing a weighted mask of networks that are 
most reliably (and reproducibly) identified from a model-free analysis of the spatio-
temporal structure of resting-state BOLD fluctuations [12]. These predefined 
components include over 80% of the total brain volume and comprise: medial and 
lateral visual systems (component 1 and 2, respectively), auditory and somato-
sensory system (component 3), sensori-motor system (component 4), default 
mode network (component 5), executive control (component 6), and right and left 
visuo-spatial and working memory networks (component 7 and 8, respectively). 
Components accounting for cerebrospinal fluid (CSF) and total brain white matter 
(WM) were furthermore included to capture activations for both sources of noise.  
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To investigate FC, a voxel-wise comparison of the resting state signal was carried 
out using a regression technique referred to as the “dual-regression” method [13, 
14]. This technique is based on first extracting the temporal pattern of resting state 
signal fluctuations within a RSN (represented by each component in the predefined 
template) or CSF or WM, for each individual  rs-fMRI dataset separately (spatial 
regression). Matrices describing the temporal dynamics for each component and 
subject separately were created and subsequently used in a linear model fit against 
the subject’s fMRI data set (temporal regression) in order to estimate subject-
specific correlation maps. After this dual regression, spatial maps of all subjects 
were concatenated into single 4-dimensional files for each RSN. The regions that 
showed differences in FC between groups were visualized by means of FSLview 
and subsequently used to extract mean Z-values from each individual spatial map 
(FWE-corrected p < 0.05). These values represent connectivity to the given RSN with 
higher absolute z-values reflecting stronger connectivity to a RSN. 
Statistical	analysis
To investigate our first aim, non-parametric permutation tests (5000 permutations) 
were used in order to detect statistically significant differences between the 
groups within the boundaries of the spatial maps defined by the predefined 
template (See Figure 6 in Beckmann et al., 2005 [12]). A family-wise error (FWE) 
correction for multiple comparisons was performed, implementing threshold-
free cluster enhancement (TFCE) using a significance threshold of p < 0.05 [15]. 
First, main effects of group (old versus young), time (first, second and last time 
point) and the interaction group by time were examined. (Normalized) gray matter 
volume was added as an additional covariate in all permutation tests in order to 
correct for the effect of gray matter differences between subjects [16] (together 
with demeaned ‘age’ and/or ‘education’; depending on the research question). 
Our second aim was to detect subtle differences in FC of the DMN within HO and HY 
subjects over time, and to correlate these individual changes in FC over time with 
neuropsychological test performance. For these additional statistical analyses on 
a subject-level, masks of selected regions-of-interest (ROI) were created by means 
of FSLview. Regions in the medial temporal lobe (hippocampus), posterior parietal 
lobe (precuneus and posterior cingulate gyrus) and frontal lobe (anterior cingulate 
gyrus) were selected based on their relevance for AD [17, 18]. ROIs were placed 
on the T1_MNI152_2mm template by using the Harvard-Oxford (sub)cortical 
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structural atlases, provided within FSL and resulting masks were subsequently used 
for extracting mean Z-scores for further analysis. 
(Non-imaging)	statistical	analysis
To quantify test-retest reliability (or measurement reproducibility), intraclass 
correlation coefficients (ICC) were calculated for each individual resting state 
network [19, 20]. First, the template containing each of the eight resting state 
networks was split into separate masks, one for each network, by means of fslsplit. 
Mean Z-scores of functional connectivity in the resulting masks (i.e. separate resting 
state networks) were extracted for each time point and were subsequently exported 
to SPSS (version 19.0; SPSS, Chicago, IL, USA). The ICC was calculated over the three 
different time points (SPSS – ICC, two-way mixed effects model for consistency). 
Different guidelines exist for the interpretation of ICC, but one reasonable scale is 
that an ICC value of less than 0.40 indicates poor reproducibility, ICC values in the 
range 0.40 to 0.75 indicate fair to good reproducibility, and an ICC value of greater 
than 0.75 shows excellent reproducibility [21].
ROI-based statistical analyses were performed using SPSS whereas correlation 
analyses were performed within both groups to assess relationships between 
regional FC within the DMN and neuropsychological test performance. Mean 
Z-scores of FC between a certain ROI and the rest of the DMN were extracted and 
transferred to SPSS. The absolute difference in FC between the first and the last 
time point was calculated (since we expected to find most variability between both 
utmost points of time) for each separate region with a higher value indicating larger 
differences between both time points, and thus more instability of FC over time for 
a given subject in a particular structure. To control for Type I errors, a false discovery 
rate (FDR) controlling procedure was performed in order to correct for multiple 
comparisons [22].
RESULTS
Demographics	and	cognitive	performance
Subject characteristics are shown in Table 1. As expected from our study design, 
mean age of the old group differed significantly from that of the young group (p 
<.001). In the old group, education was lower compared to the younger group (p 
<.01). Differences in cognitive performance between old and young subjects were 
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found for the delayed recognition trial of the VLMT memory test (p =.008) and the 
delayed recall of the Rey-Osterrieth Complex Figure test (p =.04). 
Identification	of	FC	differences	between	HO	and	HY	subjects	across	all	time	
points
After correcting for GM and education, increased FC in older compared to younger 
subjects was found in all networks except the default mode network and the left 
dorsal visual stream (Table 2, Figure 1). Regions of increased FC in older subjects were 
mainly situated in frontal and occipital regions (Table 2, Figure 1). After correcting 
for GM and education, increased FC in younger compared to older people was found 
in all components except the lateral visual cortex (Table 2, Figure 2). These regions 
of increased FC in younger subjects were mainly situated in frontal and parietal 
regions (Table 2, Figure 2). For the whole group, no significant differences over 
time were found in each of the eight investigated networks. Likewise, no significant 
differences were found for the time x group interaction. 
Table 1. Subject characteristics.
Values are mean (sd). MMSE: Mini-Mental state examination; VLMT: verbal  
learning and memory test; TMT: trail making test; CF Rey: Rey complex figure test.
Differences between both age groups significant at *** p	<0.001, ** p	<0.01 and * p	<0.05. 
Old (n=19) Young (n=20)
Age (in years) 59.2 (6.1)*** 24.6 (2.8)
Education (in years) 12.4 (3.3)** 15.6 (2.7)
Female (in %) 47 50
MMSE score 29.4 (0.7) 29.5 (0.9)
VLMT learning 50.9 (9.3) 56.4 (8.8)
VLMT memory
*delayed recall 
(number of words)
10.7 (2.8) 11.6 (2.9)
*delayed recognition 
(number of words)
11.7 (3.1)** 13.8 (1.3)
TMT-A (sec.) 26.0 (13.0) 20.6 (9.6)
TMT-B (sec.) 53.4 (29.0) 39.2 (17.9)
CF Rey score IR 35.9 (0.3) 35.5 (0.9)
CF Rey score DR 22.5 (6.3)* 27.0 (4.5)
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Quantification	of	test-retest	reliability	by	means	of	ICC
Test–retest reliability, expressed by means of the intraclass correlation coefficient 
(ICC), was investigated for both groups separately, and for each individual RSN. In 
HY subjects, ICCs varied from 0.53 (sensory-motor system) to 0.81 (medial visual 
system and auditory system). All networks, except the lateral visual system (0.66) 
and sensory motor system (0.53), showed excellent reproducibility in HY subjects 
(Table 3). For HO subjects, ICCs varied between 0.54 (executive control) and 0.85 
(right dorsal visual stream). The medial visual cortex (0.82), auditory system (0.78) 
and dorsal visual stream (left/right) (0.77/0.85) showed excellent reproducibility 
whereas the lateral visual cortex (0.73) and the default mode network (0.73) showed 
good reproducibility. The sensory-motor system (0.57) and executive control 
networks (0.54) showed fair reproducibility over time (Table 3). A visualization of 
test-retest reliability in the DMN is shown in Figure 3. Since the individual variability 
of FC within the DMN was most evident in HO subjects (subject number 1-19), the 
effect on neuropsychological test performance was further investigated.  
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Table 3. Intraclass correlation coefficient (ICC) analysis for healthy old vs. healthy 
young subjects.
 
Values are depicted for each separate resting state network. 
 
Figure 1. Regions showing increased functional connectivity in older subjects (p <.05 family-
wise error [FWE]-corrected). (A) lateral visual cortical areas in yellow, sensory-motor system 
in red (B) right dorsal visual stream in green (C) medial visual system in brown, auditory 
system in blue, (D) executive control in dark blue. All images have been co-registered into 
the space of the MNI 152 template. The left hemisphere of the brain corresponds to the 
right side of the image.
Old (n=19) Young (n=20)
Medial visual system 0.82 0.81
Lateral visual system 0.73 0.66
Auditory system 0.78 0.81
Sensory-motor system 0.57 0.53
Default mode network 0.73 0.75
Executive control 0.54 0.8
Dorsal visual stream right 0.85 0.76
Dorsal visual stream left 0.77 0.77
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Figure 2. Regions showing increased functional connectivity in younger subjects (p <.05 
family-wise error [FWE]-corrected). (A) auditory system depicted in red/yellow, sensory-
motor system in blue (B) default mode network depicted in green, executive control in 
blue (C) right dorsal visual stream depicted in purple, left dorsal visual stream in yellow. All 
images have been coregistered into the space of the MNI 152 template. The left hemisphere 
of the brain corresponds to the right side of the image. The image shows saggital, coronal 
and axial views.
262 | Chapter 8: Stability of resting state networks in aging
Figure 3. Quantification of test-retest reliability within the default mode network (DMN) by 
means of the intraclass correlation coefficient (ICC). Functional connectivity values within 
the DMN are depicted for each subject and time point separately. Subjects 1-19 belong 
to the group of healthy old subjects, subjects 20-39 belong to the group of healthy young 
subjects. The ICC reflecting test-retest reliability over all time points was 0.75 for healthy 
young subjects compared to 0.73 for healthy old subjects. 
Associations	between	stability	of	RSNs	and	NP	test	performance
On a group level, no differences in stability were found over time. Next, in line with 
the findings above, we investigated on a subject-level whether stability differences 
in key hubs of the default mode network were linked with performance on 
neuropsychological tests. 
Lower FC in older compared to younger subjects was mainly found in the DMN. 
ROIs in the DMN were selected based on their relevance for AD. Correlation 
analyses in older subjects were performed in order to investigate if changes in FC 
between a ROI and the DMN over time were linked with neuropsychological test 
performance at baseline. Variability over time in HO subjects was assessed for each 
separate ROI and was expressed as absolute difference between time point 1 and 
3 (Figure 4). It was found that higher variability over time in the precuneus was 
associated with a decrease in MMSE score (r=-0.56, p < 0.01), lower immediate 
(r=-0.56, p < 0.01) and delayed recall (r=-0.55, p < 0.05), and recognition scores 
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(r=-0.49, p < 0.05) (Figure 5). After correcting for multiple comparisons, associations 
between precuneal connectivity and MMSE score, and between precuneal 
connectivity and immediate recall score remained significant (p < 0.05) (Figure 5). 
No associations were found between variability in the hippocampus or cingulate 
cortex (ACC/ PCC) and neuropsychological test performance.
 
Figure 4. Subject-specific variability in functional connectivity in hubs of the DMN. Individual 
data-points per subjects are depicted on the X-axis whereas the length of the coloured 
rectangle corresponds with the degree of variability in a certain region of interest (longer 
rectangle = more variability between diferent data-points). Absolute differences between 
the first and the last time point (scansession) are depicted on the Y-axis.
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Figure 5. Associations between variability in functional connectivity in hubs of the default 
mode network and neuropsychological performance. (A) Higher variability in precuneal 
connectivity was associated with a decrease in MMSE score (B= -0.18 ± 0.06; p=0.012), (B) 
lower immediate recall scores (B= -2.42 ± 0.86 ; p=0.012), (C) lower delayed recall scores (B= 
-0.71 ± 0.27 ; p=.019) and (D) lower recognition scores (B= -0.71 ± 0.30; p=.032). 
* p-values significant after correction for multiple comparisons.
DISCUSSION
The present study evaluated the potential of RSNs as a biomarker for disease, by 
investigating its test-retest reliability in healthy aging. To the best of our knowledge, 
this is the first study assessing the stability of 8 RSNs over time in both HO and HY 
subjects by means of rs-fMRI. Thus far studies mainly focused on HO [23, 24] or 
HY subjects [25, 26], compared both groups cross-sectionally [27] or investigated 
the stability of resting state networks (RSNs) by means of other imaging modalities 
(e.g. PET) [28]. Test-retest reliability in the present study was investigated both on 
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a voxel-wise basis and by means of intraclass correlation coefficients. Second, we 
correlated regional DMN instability in older individuals with neuropsychological 
test performance in order to identify people who might carry an increased risk for 
future cognitive impairment.
Age-effects
A decrease in FC with aging was found in the auditory system and the DMN. Even after 
correction for GM atrophy and education, decreases in FC in HO subjects remained 
significant, indicating that age-related changes in connectivity are not solely due 
to reductions in gray matter volume or cognitive reserve. Previous studies show 
similar results, viz., a negative association between age and FC of the DMN [29, 30]. 
Small clusters of increased FC in older subjects were found in the sensory-motor 
system. These differences were mainly found in the precentral gyrus which forms 
the posterior border of the frontal lobe, and could possibly be explained by the 
posterior-anterior shift in aging [31]. Normal aging seems to induce a connectivity 
disruption within the DMN, more specifically along the anterior-posterior axis of 
this network [32], showing reduced deactivations in occipitotemporal areas and 
increased deactivations in bilateral frontal areas (e.g. precentral gyrus) in HO 
compared to HY [33].
In line with our findings, an age-related FC reduction has been reported within 
superior and middle frontal PCC/precuneus, middle temporal, superior parietal, and 
medial areas such as medial prefrontal, anterior cingulate, and hippocampal regions 
[34]. On the other hand, older subjects were also found to show greater activity at 
rest, or greater deactivations, mainly in anterior brain areas. This increased activity 
at rest in frontal DMN regions of elderly adults has been interpreted as an attempt 
to compensate for the decrease of resting-state activity in posterior DMN areas 
[33]. 
Stability of resting state networks over time
No significant differences in FC over time were found in each of the eight investigated 
networks for the total group of healthy subjects. Furthermore, intraclass correlation 
coefficients between different time points mainly showed good to excellent 
reproducibility. Previous studies with a different design (e.g. one age group) report 
similar results, in particular in the DMN. One study in HO subjects showed a relative 
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stability of rest-specific activity over time in regions commonly associated with 
the default-mode [28]. Other studies found that DMN coactivation patterns are 
reproducible in HY subjects (Meindl, et al., 2010; Shehzad, et al., 2009). The findings 
above indicate, in line with previous studies, that RSNs can be reliably reproduced 
over time. 
Relevance for early memory impairment
As known from the literature, posterior parietal regions are important nodes for 
memory encoding and retrieval and show strong FC [35]. The vulnerability of 
these nodes for AD pathology is related to their extensive connections with other 
AD signature regions (e.g. hippocampus) and high metabolic activity compared to 
other regions of the DMN [36].
A number of studies found a reduction in connectivity between both the hippocampus 
[37, 38] and precuneus [6, 7, 39-41] and several other brain regions in (amnestic) 
MCI or AD. The present study found that in HO subjects, instability of FC between 
the precuneus and the rest of the DMN was linked with subtle alterations in global 
cognitive impairment and immediate recall, even after correction for multiple 
comparisons. This finding is of particular relevance since structural and functional 
alterations in precuneal regions are a consistent finding in various diseases such as 
AD. The precuneus, acting a hub, has extensive connections with other brain regions, 
increasing its sensitivity for metabolic and pathological influences. Abnormal 
connectivity patterns were also found within PCC regions in patients suffering from 
early AD [42, 43].  In this study, however, no associations were found between 
instability of FC in hippocampal/posterior cingulate regions and neuropsychological 
test performance. Besides the fact that our study population comprises of healthy 
subjects, this finding could also be due to the fact that no spatial memory task was 
administered which would have possibly been more sensitive to subtle hippocampal 
or PCC dysfunction. Recent evidence pointed out that stable RSNs may represent 
healthy aging, whereas decreased RSN reliability may indicate progressive neuro-
functional alterations before the actual manifestation of clinical symptoms [23]. In 
order to strengthen our conclusion that instability in precuneal connectivity is a 
precursor of cognitive problems, this hypothesis requires testing in subjects with 
subjective and/or mild cognitive impairment. Associations between other nodes of 
the DMN and neuropsychology may possibly become apparent in later stages of the 
disease process.
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Limitations and future perspectives
The present study has several limitations. First, a predefined template was used 
instead of a data-driven independent component analysis (ICA) approach. It may 
be argued that predefined networks limit the scope of observations by restricting 
the criterion of connectivity to temporal similarity within a given network. 
These networks were however chosen on the basis of previous studies that 
had reproduced them in entirely different populations [14, 44]. An advantage is 
that typical ambiguities associated with ICA are avoided (e.g. specificity of the 
investigated group, model order). Second, older subjects with memory problems 
were not included in this study. Future studies could additionally include subjects 
with memory problems for discriminant analysis or longitudinally follow groups of 
healthy subjects in order to re-evaluate their cognitive status after a number of 
years. Third, it is known that certain mechanisms related to BOLD-variability might 
have an influence on BOLD-reactivity differences between old and young subjects 
[45]. One study found that there is substantial variability in responses collected 
across subjects and that differences between multiple scans sessions within a single 
subject seem to be less variable [46]. Another study suggests including an estimate 
of hemodynamic response function in order to solve some of the variability isssues 
across subjects [47]. It is also known that other factors such as caffeine intake [48], 
physiological factors [49] and sleep during scanning might have an influence on the 
BOLD-response [50]. In the present study, we did not control for caffeine intake nor 
for respiratory factors by means of external recordings of physiology. We however 
corrected for the influence of noise by using methods inherent to the ICA-approach, 
e.g. correction for head motion and low frequency artefacts. Regarding sleep and 
vigilance, we did not measure EEG-activity during fMRI, which would have been 
the most sensitive technique. However, a questionnaire was administered in which 
subjects, after scanning, reported their sleepiness during scanning and whether 
they had fallen asleep. From the total group of subjects, over all scanning sessions, 
one subject fell asleep during one of the three scanning sessions. Fourth, stability 
was assessed at one-month interval. Neuronal changes due to the process of 
aging possibly require longer intervals. On the other hand, short intervals form the 
optimal paradigm for evaluation of the resting state technique and to validate FC 
measurements as such. Fifth, previous studies showed that resting-state FC changes 
overlap with structural connectivity alterations and that combining these modalities 
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can enrich our understanding of underlying brain networks [51]. Future studies 
could include techniques such as diffusion tensor imaging to extensively investigate 
the process of healthy aging or disease, both on a functional and structural level. 
Finally, recent evidence points out that healthy subjects with amyloid plaque 
deposition in the brain (investigated by means of Positron Emission Tomography 
(PET)) show patterns of decreased FC at rest [52]. A recent study was unable to 
replicate these findings in diagnostic groups [53]. To investigate whether amyloid 
depositions precedes aberrant FC in the DMN, and to explore the diagnostic value 
of each of these techniques, future studies could combine resting state modalities 
together with PET. A major strength of this study is the correction for gray matter 
atrophy and education. A large fraction of previous rs-fMRI studies did not correct 
for gray matter atrophy nor for cognitive reserve, which both play a prominent 
role in the process of aging.  Furthermore, the present study used dual regression 
techniques to evaluate differences in FC between groups and time points. Hence, 
rater time is limited with the majority of the analysis being automated.
  
Clinical implications
The exploration of FC in RSNs by means of rs-fMRI has the advantage of being 
noninvasive, readily available, and does not require complex subject interaction [54]. 
This is essential in older patients and especially when working with patients suffering 
from AD. From a research perspective, RSNs can be used for the investigation of 
disease progression over time, and for monitoring of healthy older subjects. From a 
clinical point of view, RSNs can be used to select patients for clinical trials or to aid 
the early diagnostic process. A recent study found high diagnostic accuracy rates for 
the investigation of the DMN by means of rs-fMRI, ranging from 64-97%, depending 
on the method of analysis used [55].
CONCLUSION
The present study provides important insights into the reproducibility of RSNs in 
healthy aging. Measurements of FC in RSNs, investigated by means of rs-fMRI were 
stable over different time points, showing good to excellent reproducibility, both 
in healthy old and healthy young subjects. Age-effects were identified, indicating a 
decrease in FC in the DMN and in the auditory system, associated with aging. Loss 
of stability of FC in vulnerable regions of the DMN (e.g. precuneus) could become a 
predictor for future memory problems on an individual level. 
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Rationale 
The main objective of this thesis was to expand insight into the use of novel 
magnetic resonance imaging (MRI) techniques for the early detection, diagnosis 
and prognosis of Alzheimer’s disease (AD). The clinical value of both conventional 
and novel imaging markers was evaluated for their possible contribution to patient 
management. 
Added value of MRI in clinical practice
Current clinical practice in most Memory Clinics consists of a cognitive examination 
of patients by means of a neuropsychological test battery, together with a physical 
and neurological investigation, (hetero)anamnesis, a blood test and a brain scan. 
Based on the results of all these tests a diagnosis is made, treatment is initiated, 
and a follow-up trajectory is defined. Given the limited resources in health care, an 
efficient use of diagnostic tests with a minimum of costs per diagnosis together with 
a maximum accuracy is important. A first question that automatically arises from 
this clinical approach formed the starting point of the thesis: ‘What	 is	the	added	
value	of	MRI	to	general	diagnostics,	and	more	specific:	to	neuropsychological	test	
performance?’.  
First of all, by means of MRI one can exclude other underlying diseases or possible 
causes of cognitive impairment [1, 2], and assess the presence of vascular (i.e. white 
matter lesions, lacunes, infarcts) and treatable diseases (i.e. subdural hematoma, 
tumors). Second, structural MR images allow an evaluation of atrophy in medial 
temporal lobe (MTL) regions, a key marker for AD, by means of a qualitative visual 
rating scale [3]. In most memory clinics, MRI investigation is actually limited to 
these assessments.
In Chapter	 2 we found that MRI hippocampal volume was the best predictor of 
conversion from mild cognitive impairment (MCI) to AD. Measuring hippocampal 
volume furthermore improved the accuracy over memory tests alone. In line 
with others was found that the delayed recall test is the best neuropsychological 
predictor for AD in subjects with MCI. We pointed out that when MRI-assessment is 
available, that adding a measurement of hippocampal volume to neuropsychological 
test performance is preferred. We also found that the added value of performing 
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a visual rating scale on top of neuropsychological testing is limited in terms of 
sensitivity and specificity. Assessing disease progression by means of episodic 
memory tests (delayed recall) and MMSE-score is an alternative at the cost of a 
lower sensitivity and specificity. In line with the results in Chapter	3, we concluded 
that the likelihood to identify MCI patients at risk for AD-conversion is highest for 
volumetric measurements. Assessment of hippocampal volume together with 
a delayed recall test may be sufficient for short-term prognostic purposes (e.g. 
follow-up of MCI-patients). Recent evidence pointed out that MTL atrophy is not 
completely specific for AD since it can also be found in other forms of dementia [4]. 
It is furthermore known that AD pathology is not restricted to the MTL. Chapter	4 
therefore explored differences between healthy controls, MCI and AD-patients in 
and outside the MTL. We evaluated if four techniques assessing gray matter (GM) 
atrophy differences in the brain show the same pattern of abnormalities throughout 
the same dataset. We found that the sensitivity of each method to detect group 
differences was region-specific. Manual volumetric measurements together with 
voxel based morphometry are preferred techniques for assessing GM differences 
showing abnormalities in most of the investigated regions, with a predominance 
of the MTL in the early phase. Automated FreeSurfer volumetric measurements 
show similar performances in the early phase, displaying group differences in the 
posterior parietal cortex (PPC) but not in MTL regions. Measurements of cortical 
thickness are less sensitive in the MCI stage and its sensitivity is restricted to the 
MTL and PPC regions in later stages of the disease (AD). 
Taken together, the results of the studies described in chapters	 2	 to	 4 allow us 
to draw three major conclusions. First, MRI has indeed an added value on top of 
neuropsychological assessment, both in the field of diagnosis and prognosis (disease 
tracking). Second, we confirmed the early involvement of the MTL (Chapter 2 to 
4) and its clinical importance in predicting conversion to AD in subjects with MCI 
(Chapter 2 and 3). We also showed that atrophy of the MTL is related to cognitive 
decline (Chapter 3). Third, our findings add to the existing body of knowledge that 
the diagnostic value of MR imaging in AD is not limited to qualitative assessments 
in MTL regions (Chapter 4). Quantitative, volumetric measurements show higher 
predictive accuracy rates than visual rating scales (Chapter 3) and the sensitivity 
of volumetric markers for (early) AD is not restricted to MTL regions since also 
posterior parietal and prefrontal regions show macroscopic alterations throughout 
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the disease process (Chapter 4). However, a major pitfall for implementing 
volumetric measurements in clinical practice is access to an infrastructure which 
allows quantitative assessments (see discussion below).
Gray matter atrophy or white matter connectivity?
Besides GM atrophy as a key hallmark of AD, white matter (WM) integrity is 
decreased in MCI and AD suggesting a potential diagnostic value that may possibly 
help to improve the diagnostic accuracy of GM atrophy measurements [5, 6]. In 
Chapter	5 we evaluated the potential of DTI as an early marker for AD, in relation 
to MTL atrophy measurements, by using a meta-analysis approach. We concluded 
that in general, effect sizes of volumetric MTL atrophy measurements were equal 
or larger than effect sizes of DTI. However, in the early stages (controls vs. MCI), 
hippocampal mean diffusivity showed larger effect sizes than hippocampal volume. 
Despite studies stating that DTI measurements seem to be more sensitive than 
volumetric measurements [7] our meta-analysis did not clearly support the notion 
that DTI is superior to structural MTL assessment in detecting early stage AD. In 
chapter 6, we tried to replicate the findings of chapter 5 by means of a case-control 
study. Cross-sectionally, we found a constrained pattern of GM differences in left 
parahippocampal gyrus (healthy controls versus subjects with MCI and AD) and 
left posterior cingulate regions (controls versus AD). This in contrast with  previous 
findings that show a widespread pattern of GM atrophy in AD and a more restricted 
GM atrophy pattern in MCI patients [8]. In addition, diffusivity metrics were 
more sensitive for group differences than atrophy measurements, and were less 
influenced by the effects of aging, gender and scan parameters in a priori selected 
ROIs. Diffusivity differences were found in all the investigated structures, whereas 
changes in absolute diffusivity (mean diffusivity (MD), radial diffusivity (DR) and 
axial diffusivity (DA)) were more pronounced than changes in anisotropy (FA).
Since longitudinal cognitive and behavioral data were available, we additionally 
investigated the value of these markers for predicting decline at 2 years follow-
up. We found that diffusivity differences in the genu of the corpus callosum but 
not volumetric measures predicted decline in a group of MCI-subjects. Important 
to note is that, in contrast to our meta-analysis in chapter 5, automated atrophy 
measurements (FreeSurfer) were evaluated here, both in and outside the MTL. 
The novelty of this study was that the pattern of gray and white matter alterations 
in both MCI and AD-patients was investigated in a multicenter setting, and that 
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diagnosis was based on expert panel judgements.
From the results in chapter 5 and 6 we can conclude that DTI is a sensitive method 
to detect white matter changes in subjects with MCI and AD. In widespread brain 
regions diffusivity is already impaired early in the disease process, with more severe 
white matter disruptions with increasing disease severity. Diffusivity measurements 
show higher effect sizes than volumetric measurements in discriminating healthy 
controls from MCI and AD and are less influenced by the effects of aging, gender and 
center in apriori selected ROIs. DTI metrics in medial temporal, posterior parietal 
and callosal regions may therefore serve as an early marker for degeneration, even 
before atrophy is detectable. Diffusivity metrics in the genu of the corpus callosum 
can predict decline in a group of MCI-subjects. 
Robustness of structural atrophy and functional connectivity measurements
In the search for new imaging markers for disease, we must be well aware that 
techniques may be influenced by internal (e.g. patients age) and external (e.g. 
software, hardware) factors. In order to explore some of these influences, we 
carried out a number of methodological evaluations in the third and last part of the 
thesis.
Automated segmentation techniques become more and more popular nowadays 
due to the time-intensive nature of manual volumetry. The question therefore arises 
if processing conditions such as workstation type, operating system and software 
version affect automated segmentation results and thus influence group differences. 
Chapter	 7 investigated the robustness of FreeSurfer to capture morphological 
changes in the brain against varying processing variables and in comparison to 
manual measurements. We concluded that later versions of FreeSurfer were more 
accurate than earlier versions, especially in medial temporal and posterior parietal 
regions. A lot of research in the last decade has pointed out resting state functional 
connectivity as a marker for AD [9]. The first step toward a biomarker is assuring 
that age-effects do not influence the reliability of RSNs. Chapter	 8 investigated 
whether functional connectivity patterns can be reliably reproduced over time in 
healthy old and young subjects.  It was found that measurements of functional 
connectivity, investigated by means of resting state functional MRI were stable over 
different time points, showing good to excellent reproducibility, both in healthy old 
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and healthy young subjects. Age-effects were furthermore identified, indicating a 
decrease in FC in the DMN and in the auditory system, associated with aging.
From the findings in chapter 7 and 8 we can conclude that both FreeSurfer 
automated volumetry and resting state functional connectivity are reliable 
measurements to study the process of aging and disease. Prior work of our group 
has shown that mixing up versions, workstations or operating systems might lead 
to significant differences in cortical thickness or volumetry in schizophrenic patients 
[10]. The findings in chapter	7 were much more positive, but we however agree 
with the software developers that it is advised to keep the research environment 
stable. The necessity to control for age-effects in dementia research is furthermore 
quite evident as age might cover or lead to an overestimation of group-specific 
differences [11]. 
Underlying mechanisms of gray and white matter pathology in AD
Alterations in gray and white matter are independent pathological mechanisms 
in AD [12-14]. GM atrophy essentially results from neurodegeneration by 
the accumulation of aggregated hyperphosphorylated tau protein (‘tangles’), 
deposition of amyloid-beta (‘plaques’), oligodendrocyte death and reactive gliosis 
[15, 16]. The exact neurobiological substrate of diffusion changes still remains 
unresolved. Alterations of anisotropy (FA) have been suggested to correlate 
primarily with the integrity of the axonal membrane [17]. An increase in mean 
diffusivity (MD) is thought to reflect enlargement in the extracellular space due 
to altered cytoarchitecture (i.e. loss of neurons, axons, and dendrites), suggesting 
immaturity or degeneration of the tissue leading to elevated water diffusivity 
within these regions [18, 19]. Intra-axonal structures are thought to determine 
the diffusion parallel to the axonal fibers (DA) [20], whereas the changes in 
myelin sheats and axonal membranes underline diffusion perpendicular to the 
axonal fibers (DR) [21].  In Chapter	6 was found that the discriminative value of 
diffusivity metrics is higher than that of GM atrophy suggesting that in most regions 
microstructural changes in WM precede macrostructural atrophy. The pattern 
of decreased WM integrity in Chapter	 6 was consistent with the retrogenesis 
model of WM degeneration in AD, which shows that myelin breakdown follows 
a pattern that is the reverse of myelogenesis, thus first affecting late-myelinating 
fibers [22-24]. This retrogenesis model of WM change is furthermore consistent 
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with the pattern of functional changes in early AD where memory, language and 
executive problems are present in the absence of sensory and motor problems [25]. 
Apart from retrogenesis, also Wallerian degeneration plays a role in WM pathology 
in AD. In the Wallerian degeneration model, degradation of microstructure occurs 
secondary to GM pathology [26, 27]. The genu, splenium and cingulum fiber 
pathways investigated in Chapter	6 all share connections to MTL structures (e.g. 
hippocampus) known to be affected early in the course of AD  [28] and changes 
in these structures (e.g. atrophy) could lead to Wallerian degeneration [29]. 
The results of Chapter	 6 did not change when analyses were corrected for GM 
volume, suggesting that WM diffusivity differences were independent of GM 
atrophy patterns and that Wallerian degeneration is not the primary mechanism 
of WM change in AD. The lack of a significant correlation between diffusivity and 
volumetric measurements in regions outside the hippocampus strengthens the 
idea that DTI and MR-based volumetry measure different aspects of underlying 
pathology [30]. Since the data in chapter	6 was mainly cross-sectional we cannot 
adjudicate about causality. However, our findings suggest that WM changes in 
AD are primary related to alterations in the integrity of myelin[21] rather than to 
Wallerian degeneration secondary to distal GM atrophy. These findings are in line 
with previous work [24, 31] and neuropathological evidence indicating that WM 
changes in AD are not solely due to Wallerian degeneration [32].
Scientific implications
The results described in this thesis have several implications for future studies 
into the pathogenesis of early AD. In line with other studies, we showed that both 
GM atrophy and WM diffusivity play an important role in discriminating between 
healthy controls and (early) AD, predicting AD-conversion in subjects with MCI 
or predicting decline after 2 years [13, 33-37]. Associations with genetic, CSF and 
neuropsychological markers were investigated and techniques were validated both 
in single center and multi-center settings.
Relation	with	other	(non-imaging)	AD-biomarkers
In chapter	 3 we found, in line with the literature, that hippocampal volume 
significantly correlated with CSF t-tau and p-tau but not with Ab1-42 [38-40]. These 
findings may be explained by the obervation that antemortem hippocampal volume 
significantly correlates with the density of neurofibrillary tangles at autopsy [41, 42] 
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but not with amyloid beta plaque load [41]. The qualitative MTA-score and lateral 
ventricle volume correlated with CSF Ab1-42. This correlation may indicate that 
these MTL measures in part reflect generalised brain atrophy as previous studies 
showed that lower Ab1-42 levels but not t-tau levels were associated with total 
brain atrophy and ventricular volume [43]. Automated hippocampal volume at 
baseline was furthermore associated with APOE-e4 allele status in chapter	3.	
Multi-center	effects
Besides the above mentioned differences in software and hardware during pre-
processing and analysis, also scanners (e.g. manufacturer, type, field strength) 
or scanparameters often vary in multi-center studies and may influence imaging 
results or group differences. Since the data used in chapter	3 consisted of scanners 
with different field strengths (1T and 1.5T), we investigated the possible effects 
of these differences on hippocampal volume measurements. First, we identified 
a study from one of our co-authors comparing hippocampal volumes of subjects 
scanned at both 1.5T and 3T scanners (Wolz 2013, in press). Hippocampal volume 
was measured by means of the LEAP method using data from the ADNI study. The 
correlation between the measurements on each type of scanner was very high 
(r=0.98). The volumes measured on 3T were on average 24.4 mm3 or 1.17% larger 
than on 1.5T. Important to note is that the volume was also about 1.5% larger if the 
hippocampus was measured the second time on a scanner with the same magnetic 
field strength (either 1.5T or 3T; Wolz 2013, in press). This indicates that for the 
LEAP method, even a difference of 1.5T in field strength has no significant impact 
on hippocampal volume. Secondly, we tested the effect of field strength on the 
volumetric measures. We compared the volumes of 127 subjects scanned on a 1T 
scanner with that of 201 subjects scanned on a 1.5T scanner with correction for 
age, gender, educational level, baseline MMSE score and follow-up diagnosis. The 
difference in volume between 1T and 1.5T scanners was only 0.2% for the LEAP 
method (p-value = 0.9 [44]), 0.9% for manual hippocampal volume (p-value = 0.6), 
and 1.5% for the lateral ventricle volume (p-value = 0.8). Third, we tested whether 
field strength modulated the effect of the volumetric measures on conversion to 
AD-type dementia. The interaction between field strength and volumetric measure 
was not statistically significant for any of the volumetric measures (p>0.15). These 
data indicate that the difference in field strength had no effect on hippocampal or 
ventricular volume. 
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In chapter	 7, we used multi-center DTI-data consisting of different scanners 
(manufacturers) and scan parameters with equal field strength (3T). One healthy 
volunteer (25 years old, male) was scanned twice at all centers to determine intra 
and inter center differences in DTI-values. In the hippocampal region we found 
variability values between 0.79-3.88% (depending on the DTI parameter) compared 
to 0.22-9.58% in the posterior cingulum. As expected, inter center variability was 
higher than intra center variability, and also region-dependent (hippocampus 2.07-
6.85% vs. posterior cingulum 7.12-16.45%). Our results are in line with recent 
evidence which reported a variation in FA across multiple scanners/field strengths 
both using a physical phantom and human brain scans [45].
The findings above indicate the importance of harmonization in the field of scanners, 
scan protocols, software versions, pre-processing steps and methods of analysis. 
These premonitions are not limited to the field of imaging since other markers (e.g. 
CSF, neuropsychology) also require standardisation of methods and validation of 
cut-offs. It is virtually impossible to correct for all sources and types of errors in 
research practice. It is however essential that we are aware of potential sources 
of error, that research protocols and analyses account for these factors and that 
corrections are performed, if possible.
MRI in clinical practice: necessity or option? 
At	 this	 point,	we	are	back	 to	where	we	 started	 in	 the	beginning	of	 this	 chapter:	
‘What	is	the	role	of	MRI	in	clinical	practice?’	and	‘Is	MRI	investigation	necessary	in	
clinical	practice	or	does	it	only	lead	to	additional	burden	from	a	patient’s	point	of	
view?’. Taken together all three parts of the thesis, and building upon the existing 
body of knowledge, we can conclude that MRI plays an important role both for 
diagnostic and prognostic purposes. However, despite the clinical relevance of 
certain imaging modalities (e.g. hippocampal volumetry, connectivity), many of 
these findings are not readily transferrable to clinical practice. Translation to clinical 
settings remains to be demonstrated due to restrictions inherent to the technique 
(e.g. no standardization, no longitudinal validation, no availability of cut-offs, no 
expertise), or due to the unavailability of software or hardware amenities. 
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For implementation in clinical practice, a marker requires that its dynamics are 
known at different disease stages and that its relationship with other imaging and 
biological markers is understood [46]. In chapter 3 was found that the predictive 
accuracy of both volumetric hippocampal measurements for AD-type dementia 
(manual and LEAP) was higher than that of the qualitative rating and lateral ventricle 
measure. Both measures of hippocampal volume significantly correlated with CSF 
t-tau and p-tau but not with Ab1-42. LEAP hippocampal volume at baseline was 
furthermore associated with APOE-e4 allele status (lower LEAP volumes in APOE-e4 
carriers compared to APOE-e4 non-carriers). For the limited rater time (four minutes 
control time on a standard computer), LEAP automated hippocampal measurement 
may be preferred for clinical implementation.
A lot of effort has been made to point out the best biomarker (or combination of 
markers) for diagnosing early AD [47]. To date, indirect evidence has indicated that 
amyloid markers (assessed through PET-imaging or CSF) show more substantial 
abnormalities than structural MRI in the asymptomatic to MCI stage, and that 
CSF-levels are overall more sensitive as diagnostic tool [48]. Atrophy markers on 
the other hand are more sensitive to change (disease tracking) than CSF-markers 
[49, 50]. However, a lot of inconsistencies are found regarding the initiator and 
accelerator roles of certain pathological events and thus markers for different 
disease stages [48, 51, 52]. According to recent findings one might consider all CSF 
and neuroimaging biomarkers (together with the presence of cognitive impairment) 
to the same degree whereas the presence of each factor increases the risk of 
underlying AD pathology [53]. Despite the high diagnostic accuracy rates of CSF 
biomarkers, lumbar puncture is feared by many patients due to the risk of severe 
complications and post-LP heaches in 2-4 percent of cases [54]. From a patients 
perspective, an MRI scan is a more feasible and less intrusive diagnostic alternative 
in clinical practice.
Future	research	directions
The restrictions mentioned above should be thoroughly investigated and resolved 
before quantitative measurements (structural atrophy or connectivity) can be 
succesfully implemented in everyday clinical practice. In order to implement ‘MRI-
beyond-MTA’ as a biomarker for AD, future studies need to standardise automated 
techniques for use in clinical practice, and establish and validate cut-offs in studies 
with large sample sizes. Such cut-offs are needed to achieve the ultimate goal of 
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an MRI-biomarker, namely a reliable diagnosis on a subject-level based on a single 
cross-sectional MRI scan.
Future studies need to assess the clinical relevance of the above mentioned 
techniques in large-scale clinical trials which aim to examine the diagnostic and 
prognostic value of certain techniques. Furthermore, treatment effects need to 
be mapped with different multimodal imaging modalities. The latter is even more 
important if disease modifying treatments become available that require easy 
accessible, cost-effective and non-invasive techniques to diagnose AD in its earliest 
stages. 
A	necessary	stopover…	to	know	or	not	to	know?
The research area of early biomarkers for AD is highly motivated by the on-going 
development of disease-modifying treatment. However, to date there is no cure 
available for AD yet, so there is no direct benefit from an early diagnosis. The 
question therefore arises if preclinical persons need to be informed about their 
status in clinical routine? 
In short, early diagnosis may also negatively affect health and daily life of an early-
stage AD patient. A few of the possible implications are feelings of hopelessness 
and despair which may lead to depression, loss of job and/or driver’s license, and 
insurance issues. Besides an impact on the patient level, also the social system 
(relatives, employer) is concerned. On the contrary, even without treatment 
options, early diagnosis might be clarifying for the patient, facilitate access to tools 
which can help to cope with the progressive decline and enhance assistance from 
the health care system. 
Extended use of early diagnostic tools in research environments is furthermore 
essential since these developments may lead to increased enrollment of patients in 
clinical trials which can in turn lead to novel treatment approaches. 
Conclusion
In conclusion, this thesis expands insights into the added value of imaging markers 
as diagnostic tool for the early detection of AD. Atrophy of MTL structures is a 
candidate marker to assess change from MCI to moderate AD stages (prognosis). 
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We showed that relatively novel and thus less validated MRI markers such as DTI 
and resting state functional MRI are promising for diagnosing AD in an early stage 
but need to be evaluated empirically. Standardization of operating procedures 
(for e.g. volumetric and connectivity approaches) will further consolidate our 
understanding of AD-pathology, facilitate comparison and integration of results, 
enable the establishment of cut-offs and consequently pave the way to clinical 
implementation.
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SUMMARY
Worldwide, 115 million people are at the forefront of an Alzheimer’s tsunami. The 
baby boom generation is now entering their mid-sixties and many of them will 
suffer from Alzheimer’s disease (AD), which now already affects 1 in every 8 people 
over age 65. Early diagnosis and treatment may help to reduce both patient and 
health-cost burden. Before clinical or cognitive deficits become apparent, a distinct 
set of underlying brain abnormalities such as a decrease in cerebral connectivity 
are present. Early detection of these (often subtle) abnormalities is therefore an 
important public health goal. The research described in this thesis aimed to expand 
insight into the use of both conventional (e.g. hippocampal volumetry) and novel 
(e.g. diffusion tensor imaging) magnetic resonance imaging (MRI) markers for early 
detection, diagnosis and prognosis of AD. MRI provides more information than 
macrostructural atrophy and vascular abnormalities. However, the added value 
and exact position of novel imaging techniques in the diagnostic field of AD was 
still unclear. The principle question of the thesis was whether MRI investigation 
is necessary in the diagnostic process of AD and which MRI measurements can 
incrementally contribute to the early and specific diagnosis of Alzheimer disease.
The clinical value of novel imaging markers for AD was evaluated in relation to current 
(gold standard) methods (i.e. hippocampal volumetry, visual rating scale). In the 
first part of the thesis (Chapter 2 to 4) we evaluated well-known imaging techniques 
which assess gray matter atrophy in the brain. In the second part (Chapter 5-6) we 
examined the discriminative and predictive value of a novel imaging marker for AD: 
Diffusion Tensor Imaging (DTI). In the third part (Chapter 7-8) we investigated the 
robustness of structural and functional abnormalities in AD.
In	chapter	2 we investigated in a multicenter setting (n=184) if MR imaging markers 
increased predictive accuracy for AD relative to a model which only included 
demographical and neuropsychological information. We found that hippocampal 
volume is the best predictor of conversion from mild cognitive impairment (MCI) 
to AD. Measuring hippocampal volume furthermore improved the accuracy over 
memory tests alone. In line with others was found that the delayed recall test is 
the best neuropsychological predictor for AD in subjects with MCI. We concluded 
that when MRI-assessment is available, that adding a measurement of hippocampal 
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volume to neuropsychological test performance is preferred. Additionaly, it 
was found that the added value of performing a visual rating scale on top of 
neuropsychological testing is limited in terms of sensitivity and specificity. Since the 
MTL still receives a lot of attention in diagnosing AD, discriminating converters from 
non-converters and AD from non-AD, chapter	3	compared the predictive value of 
4 different MTL measurements in a multicenter (n=328) and single-center setting 
(n=172). Results showed that volumetric hippocampal measurements are the best 
predictors of conversion to AD-type dementia in subjects with MCI after 2 years 
follow-up (manual and LEAP hippocampal volume). Both volumetric measurements 
strongly correlate with cerebrospinal fluid (CSF) markers of neuronal injury (CSF 
t-tau and p-tau), are able to predict cognitive decline, and show consistent cut-
off values between different cohorts. LEAP hippocampal volume has the advantage 
over manual volumetry that it needs much less rater time and shows no interrater 
variability effects. In addition, LEAP has a low technical failure rate. 
Recent evidence pointed out that MTL atrophy is not completely specific for AD 
since it can also be found in other forms of dementia. It is furthermore known 
that AD pathology is not restricted to the MTL. Since the contribution of brain 
areas outside the MTL has become more evident, in chapter	4 we evaluated the 
discriminative value of several techniques measuring GM atrophy in the brain, 
both in and outside MTL regions. It was investigated if four techniques assessing 
gray matter (GM) atrophy differences in the brain show the same pattern of 
abnormalities throughout the same dataset. We found that the sensitivity of each 
method to detect group differences was region-specific. Results showed that 
manual volumetric measurements together with voxel based morphometry are 
preferred techniques for assessing GM differences showing abnormalities in most 
of the investigated regions, with a predominance of the MTL in the early phase. 
Automated FreeSurfer volumetric measurements showed similar performances in 
the early phase, displaying group differences in the posterior parietal cortex but not 
in MTL regions. Measurements of cortical thickness are less sensitive in the MCI 
stage and its sensitivity is restricted to the MTL and PPC regions in later stages of 
the disease (AD). 
Chapter	5 describes a meta-analysis which was conducted to evaluate the discrim-
inative value of DTI in a group of controls subjects, patients with MCI and AD-pa-
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tients. We included seventy-six studies on MTL atrophy including 8122 subjects and 
fifty-five DTI studies including 2791 subjects. Effect sizes (ES) were calculated for 
several regions of interest known to be altered by pathophysiological mechanisms 
of AD, and were compared with ES of medial temporal lobe measurements. Results 
showed that DTI is a sensitive method to detect white matter changes in subjects 
with MCI and AD. It seems that in widespread brain regions diffusivity is already 
impaired early in the disease process, with more severe white matter disruptions 
with increasing disease severity. DTI abnormalities were found in many different 
regions. FA and MD changes seem to follow a slightly different anatomical pattern 
whereas highest ES (relative to controls) for DTI-FA were typically seen in cingulate 
and callosal areas (total cingulum, posterior cingulum, parahippocampal cingulum, 
splenium CC and uncinate fasciculus). For DTI-MD the largest differences were seen 
in the hippocampus, followed by the parietal lobe, splenium CC and temporal lobe. 
It was furthermore found that the discriminative power of DTI-MD is slightly higher 
than for DTI-FA.
Chapter	6 aimed to validate the findings of chapter 5 by means of a case control 
study. Cross-sectionally, we found a constrained pattern of GM differences in 
left parahippocampal gyrus (healthy controls versus subjects with MCI and AD) 
and left posterior cingulate regions (controls versus AD). This in contrast with 
previous findings that show a widespread pattern of GM atrophy in AD and a more 
restricted GM atrophy pattern in MCI patients. In addition, diffusivity metrics were 
more sensitive for group differences than atrophy measurements, and were less 
influenced by the effects of aging, gender and scan parameters in a priori selected 
ROIs. Diffusivity differences were found in all the investigated structures, whereas 
changes in absolute diffusivity (mean diffusivity (MD), radial diffusivity (DR) and 
axial diffusivity (DA)) were more pronounced than changes in anisotropy (FA). We 
furthermore found that diffusivity differences in the genu of the corpus callosum but 
not volumetric measures predicted decline in a group of MCI-subjects. Due to the 
time-intensive nature of manual volumetry, automated segmentation techniques 
become more and more popular nowadays. As a result, the question arises if 
processing conditions such as workstation type, operating system and software 
version affect segmentation results and thus influence group differences. In chapter	
7	we investigated the robustness of FreeSurfer to capture morphological changes 
in the brain against varying processing variables and in comparison to manual 
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measurements. We concluded that later versions of FreeSurfer were more accurate 
than earlier versions, especially in medial temporal and posterior parietal regions. 
A lot of research in the last decade has pointed out resting state functional 
connectivity as a marker for AD. The first step toward a biomarker is assuring that 
age-effects do not influence the reliability of RSNs. 
In chapter	 8	 we investigated whether functional connectivity patterns can be 
reliably reproduced over time in healthy old and young subjects.  It was found that 
measurements of functional connectivity, investigated by means of resting state 
functional MRI were stable over different time points, showing good to excellent 
reproducibility, both in healthy old and healthy young subjects. Age-effects were 
furthermore identified, indicating a decrease in functional connectivity in the DMN 
and in the auditory system, associated with aging. 
Chapter	9 provides a general overview of the findings described in this thesis. Clinical 
and research implications resulting from the presented studies are discussed.
In conclusion, this thesis expands insights into the added value of imaging markers 
as diagnostic tool for the early detection of AD. Atrophy of MTL structures is a 
candidate marker to assess change from MCI to moderate AD stages (prognosis). 
We showed that relatively novel and thus less validated MRI markers such as DTI 
and resting state functional MRI are promising for diagnosing AD in an early stage 
but need to be evaluated empirically. Standardization of operating procedures 
(for e.g. volumetric and connectivity approaches) will further consolidate our 
understanding of AD-pathology, facilitate comparison and integration of results, 
enable the establishment of cut-offs and consequently pave the way to clinical 
implementation.
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NEDERLANDSE SAMENVATTING
De ziekte van Alzheimer (ZvA) is de meest voorkomende vorm van dementie die 
wereldwijd ongeveer 34 miljoen mensen treft. Onderzoekers voorspellen een 
tsunami van dementie, waarbij de prevalentie van de ziekte zal verdriedubbelen 
als gevolg van de vergrijzing van de bevolking. Dit leidt tot een toenemende nood 
aan vroegdiagnostiek van deze ziekte om behandeling in een vroege fase mogelijk 
te kunnen maken. Een vroege diagnose en behandeling kan immers naast een 
toename van levenskwaliteit ook een kostenbesparing teweegbrengen, zowel 
op het niveau van de patiënt als van de gezondheidszorg. Vooraleer klinische of 
cognitieve afwijkingen daadwerkelijk objectiveerbaar worden, is er reeds sprake 
van onderliggende abnormaliteiten op hersenniveau, waarbij volumeverlies in 
bepaalde regio’s en een afname van cerebrale connectiviteit een voorbeeld zijn. 
Beeldvorming met magnetische resonantie (NMR of MRI) biedt een kader om 
de structurele en functionele veranderingen geassocieerd met het proces van 
neurodegeneratie te visualiseren.
Het onderzoek beschreven in dit proefschrift kadert binnen het eerder aangehaalde 
onderzoeksveld van vroegdiagnostiek en heeft primair als doel de inzichten in het 
gebruik van zowel de traditionele (bijv. volumebepaling van de hippocampus) 
als de meer recente (bijv. diffusiviteit in de witte stof) beeldvormingstechnieken 
te vergroten. Deze technieken werden geëvalueerd zowel op het vlak van 
vroegdetectie, diagnose, als prognose van de ziekte van Alzheimer. De huidige 
aanpak in de meeste Nederlandse geheugenpoli’s vertrekt van een interview met 
patiënt en zijn naaste, gevolgd door een neurologisch onderzoek. Hierna wordt 
een neuropsychologische test batterij afgenomen en vindt er een bloedtest en 
een hersenscan plaats. Aangezien MRI beelden ons meer informatie kunnen 
verschaffen dan zuiver macroscopische (bv. tumor) of vasculaire afwijkingen, is het 
gebruik van hersenscans in de kliniek van exclusie van andere ziekten (bv. tumoren, 
infarcten) uitgebreid naar vroegdetectie (bv. ZvA versus gezonde veroudering) 
en differentiaaldiagnostiek (bv. ZvA versus Fronto-temporale dementie). Echter, 
de toegevoegde waarde en exacte rol van de nieuwe beeldvormingstechnieken 
voor de vroegdiagnostiek van de ZvA is nog steeds onduidelijk. De vraag of MRI 
onderzoek überhaupt noodzakelijk is in het diagnostisch proces van de ZvA en welke 
MRI technieken potentieel zinvol zijn vormde het startpunt van dit proefschrift. 
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De klinische waarde van nieuwe beeldvormingstechnieken voor de ZvA werd 
geëvalueerd in relatie tot de meer traditionele (‘gouden standaard’) methoden 
(bv. volumemeting van de hippocampus en een visuele beoordelingsschaal voor 
volumeverlies van de mediale temporaalkwab).
In het eerste deel van dit proefschrift (Hoofdstuk 2-4) werden technieken die 
volumeverlies in de grijze stof van het brein meten geëvalueerd. Het tweede deel 
(Hoofdstuk 5-6) beschrijft het onderscheidend en voorspellend vermogen van een 
nieuwe beeldvormingstechniek: Diffusie-gewogen beeldvorming (‘diffusion tensor 
imaging’ of DTI). Het derde en laatste deel van dit proefschrift (Hoofdstuk 7-8) heeft 
zich gericht op het evalueren van de robuustheid van structurele en functionele 
afwijkingen bij de ZvA.
In hoofdstuk	2 hebben we in een multicenter setting onderzocht (n=184) of het 
toevoegen van MRI-beelden de voorspellende waarde voor de ZvA verhoogd 
ten opzichte van een model dat enkel demografische en neuropsychologische 
informatie bevat. Hippocampaal volume (gemeten op MRI-beelden) bleek de beste 
voorspeller te zijn voor conversie van milde cognitieve klachten (MCI) naar de 
ZvA. Het toevoegen van het volume van de hippocampus verbeterde bovendien 
de voorspellende waarde van een episodische geheugentaak. In lijn met eerder 
onderzoek werd gevonden dat een test voor uitgestelde reproductie van een 
woordenlijst de beste voorspeller is voor de ZvA op neuropsychologisch vlak. 
We concludeerden dat wanneer MRI-onderzoek mogelijk is (oa. infrastructuur 
en expertise aanwezig, patiënt MRI-compatibel), dat een volumemeting van de 
hippocampus naast neuropsychologisch onderzoek wenselijk is. Verder bleek dat 
de toegevoegde waarde van een visuele beoordelingsschaal (MTA-score) beperkt 
was in termen van sensitiviteit en specificiteit.
Het evalueren van volumeverlies in de mediale temporaalkwab is tot op heden nog 
steeds een belangrijk onderdeel van de diagnostiek bij de ZvA. Volumeverlies in 
deze regio kan bovendien converters van non-converters onderscheiden en mensen 
die lijden aan de ZvA onderscheiden van mensen met een ander type dementie. In 
hoofdstuk	3 hebben we de voorspellende waarde van 4 verschillende maten die 
volumeverlies van de mediale temporaalkwab meten onderzocht in een multicenter 
(n=328) en single center (n=172) setting. Resultaten hebben aangetoond dat een 
volumemeting van de hippocampus de beste voorspeller is voor conversie naar 
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de ZvA bij mensen met MCI (zowel de manuele als automatische meting van 
hippocampaal volume (LEAP methode)). Beide maten toonden bovendien een 
sterke samenhang met markers in hersenvocht (CSF) die schade aan de hersencellen 
meten (CSF t-tau en p-tau). Er werden consistente afkapwaarden gevonden tussen 
verschillende cohorten en beide maten voorspelden cognitieve achteruitgang na 
2 jaar. De LEAP volume meting heeft als voordeel ten opzichte van de manuele 
methode dat deze minder tijdsintensief is en geen variabiliteit tussen beoordelaars 
laat zien. Bovendien heeft LEAP een erg lage technische foutenmarge.
Recent onderzoek heeft aangetoond dat volumeverlies in de mediale 
temporaalkwab niet geheel specifiek is voor de ZvA en dat we dit ook terugvinden 
bij andere vormen van dementie. Uit eerder onderzoek is bovendien gebleken dat 
Alzheimer pathologie zich niet beperkt tot deze gebieden. Aangezien ook andere 
regio’s aangetast zijn bij de ZvA hebben we in hoofdstuk	4 onderzocht welke de 
onderscheidende waarde is van verschillende technieken die volumeverlies in de 
grijze stof van de hersenen meten, zowel in de mediale temporale gebieden als 
daarbuiten. We hebben onderzocht of 4 verschillende technieken die grijze stof 
atrofie in het brein meten dezelfde resultaten laten zien binnen eenzelfde dataset. De 
sensitiviteit of gevoeligheid van elke methode bleek afhankelijk van de onderzochte 
regio. Resultaten toonden aan dat een manuele volumemeting en VBM (voxel based 
morphometry) de voorkeur genieten voor het in kaart brengen van volumeverlies 
in de grijze stof. De meeste regio’s lieten groepsverschillen zien met een duidelijk 
overwicht in mediaal temporale gebieden. Automatische volumetrische methodes 
(FreeSurfer) toonden gelijkaardige prestaties waarbij verschillen in de posterieure 
delen van de parietaalkwab (en dus niet in de mediaal temporaalkwab) het meest 
uitgesproken waren in de vroege fase van de ziekte. Het meten van de dikte van de 
hersenschors (‘cortical thickness’) bleek minder gevoelig in het vroege stadium van 
de ziekte.
In hoofdstuk	5 hebben we een meta-analyse gepresenteerd die primair als doel had 
de diagnostische waarde van een nieuwe beeldvormingstechniek (DTI of diffusie 
tensor beeldvorming) te evalueren in een groep van gezonde controles, patiënten 
met MCI en patiënten met de ZvA.  Naast 76 studies die volumeverlies in de medi-
ale temporaalkwab onderzochten (8122 subjecten) werden er ook 55 DTI studies 
(2791 subjecten) geïncludeerd. Voor verschillende regio’s in het brein werden ef-
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fectgroottes berekend die op hun beurt vergeleken werden met effectgroottes van 
technieken die atrofie van de mediale temporaalkwab meten. Resultaten toonden 
aan dat in wijdverspreide regio’s van het brein de beweging van watermoleculen 
(diffusie) reeds in een vroege fase van de ziekte verstoord is, waarbij we meer in-
grijpende witte stof veranderingen zien bij progressie van de ziekte. Abnormaliteit-
en op het vlak van fractionele anisotropie en gemiddelde diffusiviteit toonden een 
verschillend anatomisch patroon. De maat van anisotropie was het meest gevoelig 
voor verschillen in cingulate en callosale regio’s. De gemiddelde diffusiviteit daar-
entegen was het meest sensitief voor verschillen in de hippocampus, gevolgd door 
de parietaalkwab, het splenium van het corpus callosum en de temporaalkwab. 
Over het algemeen genomen was de fractionele anisotropie index even gevoelig 
als de gemiddelde diffusiviteit. Een lagere gevoeligheid van fractionele anisotropie 
ten opzichte van gemiddelde diffusiviteit was het meest opmerkelijk in de corticale 
gebieden. 
In hoofdstuk	6 hebben we gepoogd de bevindingen van hoofdstuk 5 te valideren 
door middel van een case control studie. Onze resultaten toonden aan dat het 
patroon van grijze stof afwijkingen in deze studie beperkt was tot de linker 
parahippocampale gyrus (controles versus subjecten met MCI en ZvA) en de linker 
posterior cingulate (controles versus subjecten met ZvA). Dit is deels in tegenstelling 
met eerdere bevindingen die een wijdverspreid patroon van afwijkingen laten zien 
bij patiënten met de ZvA en een meer beperkt patroon van grijze stof afwijkingen 
bij MCI-patiënten. Er werd daarenboven gevonden dat diffusiviteitsmaten meer 
gevoelig zijn voor groepsverschillen dan metingen van volumeverlies en dat deze 
minder beïnvloed worden door leeftijdseffecten, effecten van geslacht en scanner 
instellingen. Verschillen qua diffusiviteit werden gevonden in alle onderzochte 
structuren waarbij veranderingen in absolute diffusiviteit (gemiddelde diffusiviteit 
(MD), radiale diffusiviteit (DR)  en axiale diffusiviteit (DA)) meer uitgesproken 
waren dan veranderingen in anisotropie (FA). Verder werd gevonden dat niet het 
volumeverlies maar de verschillen in diffusiviteit in de genu van het corpus callosum 
achteruitgang voorspelden in een groep van MCI-patiënten. Door het tijdsintensieve 
karakter van manuele volumemetingen hebben automatische metingen meer 
en meer aan belang gewonnen. De potentiële invloed van hardware en software 
instellingen op de resultaten van dergelijke technieken en dus ook het indirecte 
effect op groepsverschillen is tot nog toe vrij onderbelicht gebleven. In hoofdstuk	7 
onderzochten we of FreeSurfer resistent is tegen deze verschillen. Om hierbij een 
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zuivere vergelijkingsbasis te hebben werd deze techniek rechtstreeks vergeleken 
met de manuele segmentatie. Onze bevindingen toonden aan dat het effect van 
hardware (workstation) kleiner is dan van software (FreeSurfer versie) en dat latere 
versies van FreeSurfer meer accuraat zijn dan eerdere versies, vooral in posterieur 
pariëtale gebieden.
Recent onderzoek heeft aangetoond dat ‘resting state’ functionele MRI (rsfMRI), 
een techniek die de hersenactiviteit in een taakvrije omgeving meet, een belangrijk 
marker is voor de ZvA. De eerste stap richting ontwikkeling en validatie van een 
zogeheten ‘biomarker’ is onderzoeken of leefijdseffecten de betrouwbaarheid van 
deze ‘resting state’ netwerken niet beïnvloeden. In hoofdstuk	8 werd onderzocht 
of patronen van functionele connectiviteit stabiel zijn over de tijd bij gezonde 
ouderen en jongeren. Resultaten toonden aan dat metingen van functionele 
connectiviteit, onderzocht door middel van rsfMRI, stabiel waren over verschillende 
tijdsmomenten, en een goede tot uitstekende reproduceerbaarheid laten zien. 
Leeftijdseffecten werden geïdentificeerd en er werd een afname in functionele 
connectiviteit gevonden in het ‘default mode netwerk’ (DMN) en het auditieve 
systeem, welke in verband staan met veroudering.
In hoofdstuk	9	wordt een algemene discussie van onze bevindingen beschreven. 
Klinische en wetenschappelijke implicaties worden hier uitgebreid toegelicht en 
suggesties voor verder onderzoek worden gegeven.
We kunnen besluiten dat volumeverlies in de mediale temporaalkwab een kandidaat-
marker is voor het meten van progressie van een milde cognitieve stoornis naar 
de ZvA (prognostische waarde). Het onderzoek hier beschreven toont bovendien 
aan dat relatief nieuwe en dus minder gevalideerde MRI technieken (DTI en resting 
state fMRI) veelbelovend zijn voor de toekomstige vroegdiagnostiek maar dat deze 
nog uitgebreid empirisch getest en gevalideerd moeten worden. Standaardisatie 
van de procedures (voor bijv. volumetrische maten en maten van structurele en 
functionele connectiviteit) zullen onze kennis wat betreft onderliggende Alzheimer 
pathologie verder uitbreiden en ervoor zorgen dat we resultaten kunnen vergelijken 
en integreren. Bovendien kunnen we op die manier stabiele afkappunten gaan 
ontwikkelen dewelke de weg naar klinische implementatie verder kunnen faciliteren. 
Het ultieme einddoel van een MRI-biomarker is immers een betrouwbare diagnose 
op subjectniveau, gebaseerd op een enkele MRI-scan.
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DANKWOORD
Beste (ex)collega, vriend, familie, verdwaalde lezer,
Meer dan vier jaar geleden, op een regenachtige lentedag (uiteraard in België) 
kreeg ik onderweg van Leuven naar huis telefoon. Een nummer uit NL... Zou het? Ik 
durfde amper te antwoorden: “Hallo Lies, Pauline Aalten uit Maastricht, stoor ik?” 
“Euh nee hoor” *slik* “Wij hebben besloten dat jij de ideale kandidaat bent voor de 
MRI onderzoeksplek binnen het LeARN project...” *say whaaaaat* “...dus als jij het 
ook ziet zitten verwelkomen we jou graag binnenkort in Maastricht”. Hoe graag ik 
ook “Jaaaaa natuuuurrrllliiijjk” wou schreeuwen… toch probeerde ik de rustige Lies 
te zijn (bestaat-die-dan?) en antwoordde ik “Ja hoor, heel graag” ...
Het enthousiasme wat er was op dat moment en de zin om ‘erin te vliegen’ is sedert 
dien alleen maar gegroeid. Nooit gedacht dat ik op 4 jaar tijd zoveel zou ontdekken, 
verwezenlijken, bijleren. Dit promotietraject was voor mij een verrijking op alle 
vlakken.
4 jaar en minstens evenveel life-events later kijk ik terug op een heerlijke tijd. Een 
tocht naar de bouw van dit proefschrift die mede mogelijk werd gemaakt door een 
aantal mensen die er elk op hun manier voor gezorgd hebben dat ik -in de meest 
optimale omstandigheden- deze promotie tot een goed einde kon brengen. Ik 
neem dan ook graag de tijd om iedereen uitgebreid te bedanken, “voor die ene 
keer dat het eens kan en mag gezegd worden, en dat er geen beperking op het 
aantal woorden zit”.
Allereerst wil ik graag alle patiënten, hun mantelzorgers en de gezonde 
proefpersonen bedanken. Zonder jullie was dit onderzoek niet mogelijk geweest 
en dankzij jullie deelname en het beschikbaar stellen van de klinische gegevens 
staan wij onderzoekers elke dag een stapje dichter bij het oplossen van het 
Alzheimervraagstuk. Bedankt voor uw tijd en vertrouwen.
Mijn	promotieteam:
Frans, het feit dat je promotor bent van minstens evenveel promovendi als dat 
er dagen in een maand zijn (parallel gezien dan) belette je niet om telkens actief 
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mee te denken over nieuwe projecten en om me er steeds aan te herinneren wat 
het uiteindelijke doel van dit ganse traject was. Je probeerde me telkens op het 
juiste pad te houden wanneer ik er vanaf dreigde te dwalen. Bedankt voor het 
vertrouwen en de autonomie om zelf richting te mogen geven aan mijn verschillende 
onderzoekslijnen! En dank je wel om steeds de tijd de nemen om te peilen ‘of het 
met de kindjes thuis wel allemaal goed te combineren viel’.
Pieter-Jelle: van jou leerde ik dat er voor alles een syntax bestaat, dat alles te 
verklaren valt, dat iemand zowel K3 als klassieke muziek kan waarderen en dat 
iemand tegelijk verstrooid en perfectionistisch kan zijn. Deze laatste combinatie 
leidt blijkbaar zelfs tot onderzoek op topniveau! Bedankt dat ik mee mocht genieten 
van jouw kennis en kunde, en bedankt om steeds voor mij de tijd te nemen ondanks 
jouw ontelbare andere taken/verantwoordelijkheden/AIO’s.
Pauline, bij de start van mijn promotie slaagde jij er meteen in mij op mijn gemak 
te doen voelen en daarnaast toch ook de nodige professionaliteit uit te stralen om 
een goede dagelijkse begeleider te kunnen zijn. Fijn trouwens om grote zusjes en 
kleine broertjes ervaringen te kunnen uitwisselen! Bedankt dat jouw deur steeds 
open stond voor werk en wat-minder-werkgerelateerde vragen en bedenkingen. 
Heidi, mijn niet-officiële maar daarom niet minder waardevolle co-promotor: 
waar moet ik beginnen? Ik ga voor Heidelberg! Van toen af hebben wij het heel 
erg met elkaar kunnen vinden, op alle vlakken. Heerlijk hoe jij altijd weer energie 
en zin hebt om mee te denken over allerlei dingen. Ik heb het gevoel dat ik met 
jou volledig op 1 lijn zit. Mede dankzij jou heb ik een ongelofelijk leuke tijd gehad 
tijdens mijn stage in Jülich en is mijn kennis op het vlak van MRI op tijd en stond 
serieus uitgebreid (nerdtime that is!). Ik heb enorm veel bewondering voor alles 
wat je verwezenlijkt hebt en datgene waar je nog elke dag naar streeft (en liefst 
zoveel mogelijk tegelijkertijd). Ik wil je graag bedanken voor alles. Graag samen 
ook nog veel california maki’s met een cola light/zero (en smashed apples ;-)) en ik 
zorg ervoor dat ML en M nog veel tekeningen voor jou (en Joost) zullen maken ;-) 
Bedankt om er altijd te zijn en om altijd tijd voor me te willen maken! 
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I would gratefully like to thank the members of my reading committee for their time 
and involvement in evaluating my work: Prof. Dr. Yasin Temel, Prof. Dr. Stefan Teipel, 
Prof. Dr. Mathieu Vandenbulcke, Dr. Paul Hofman and Dr. Inez Ramakers.
Mijn	MRI-buddies:	
Saar, ik bewonder jouw vastberadenheid en doorzettingsvermogen en wens je 
nog veel succes in je verdere onderzoekscarriere! Verder hoop ik ook dat we -als 
mama’s- nog veel kunnen kletsen over onze kleine supermannen-en vrouw(en)!
Ed-gouden-raket, soms tovenaar altijd expert! Is er iets wat jij niet kan? Ja! ik 
weet het: water drinken! :) Bedankt voor alle hulp, door jou leek niks onmogelijk. 
Misschien moeten wij samen de DTI-bijbel schrijven? Daar kan je straks vast de tijd 
voor vinden! Of toch niet?! :) Ik wens je het allerbeste toe samen met je geweldige 
vrouwtje en ik hoop dat ik nog heel vaak centimeters lange emails van jouw mag 
ontvangen! (en niet met blessures of issues aub!).
Harm, ookal zitten er wat (kilo?)meters tussen onze werkplekken toch kreeg ik het 
gevoel dat wij altijd erg efficiënt en snel konden communiceren. Nog veel succes 
met je verdere promotie.
Mijn	‘oude’	kamergenootjes: 
Ron, ik heb nooit iemand van onze leeftijd zo serieus en gewetensvol geweten als jij. 
En toch was er bij jou ook steeds plaats voor grapjes en grollen als een Nederlands-
Vlaams woordenboek – waar is dat trouwens gebleven? Jij slaagt er bovendien in 
voor alles een lijstje te maken en alles te automatiseren. Petje af! Bedankt voor de 
interessante discussies en jouw heldere kijk op het hele LeARN gebeuren. Ik ben 
benieuwd hoe Papa-Ron zich verder zal ontplooien, graag af en toe een (pamper)
update! :)
Syenna, jij prettig gestoorde kip tandoori. Jij bent zo iemand waarmee je na 5 min 
het gevoel krijgt je al een gans leven te kennen. Ik wil je nog veel succes de komende 
tijd! En als je graag nog eens een make-over van je huis hebt, gewoon even bellen 
en ik kom langs met de (b)engeltjes! ;)
Steph, lieve Steph, wat hebben wij een leuke tijd gehad samen daar aan die dubbele 
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bureau in de glazen kamer! Geen koekje of thee-tje wat we op die jaren niet 
geproefd hebben en geen doctoraatsdipje wat we niet met elkaar hebben gedeeld. 
Zelfs een transfer naar de Albert Heijn zou destijds geen straf geweest zijn als ik met 
jou mocht samenwerken. Blij dat jij er telkens was tijdens de ontdekkingstocht van 
onze promotie en blij dat jij mijn paranimf bent op deze ‘grote dag’... Ik hoop dat we 
in de toekomst nog vaak tegenover elkaar zullen zitten!
Renske, jij kwam er later bij (zoals zovelen) maar toch slaagde jij er vrijwel meteen 
in om actief mee te varen in het ‘LeARN clubschuitje’. Fijn dat onze mannen het ook 
zo goed met elkaar kunnen vinden zodat onze contacten zich niet enkel beperken 
tot Maastrichtse bodem. Waar gaan we de volgende keer dineren en degusteren? 
Leuk dat jij eveneens dicht bij me bent tijdens mijn verdediging!
Gisela, mama Gis.. onze kamers lagen de afgelopen jaren ‘ver’ uit elkaar maar toch 
vonden we ieder om beurt de tijd om lekker even bij te kletsen (en voor nu: leve 
whatsapp!). Fijn om samen met jou dikke buik en andere kindergerelateerde pret 
te kunnen delen.
Sanne, Peggy en Ieke, mijn ex-buurvrouwen: leuk dat jullie de witte en andere 
chocotoffs met mij wilden delen en tegelijk ook steeds into een leuke babbel waren! 
Ieke: jouw gouden tip van M&Ms eten in de auto en dan het pakje naar achter 
gooien – ik pas hem regelmatig toe! Dank je wel daarvoor ;)  S&P: veel succes nog 
met het afronden van jullie boekje!
Nico en Ron M., wat mij betreft zijn jullie de levende versie van de Rescue Rangers: 
geen karwei te groot, geen klus te zwaar, die 2 staan altijd klaar! De verdeling van 
wie knabbel en wie babbel is laat ik aan de lezer over. Bedankt voor jullie IT-hulp-
in-nood!
Elsa, “la mama” van de afdeling! Voor alles kunnen we bij jou terecht – en we 
worden bovendien nog ontvangen met een brede glimlach ook. Bedankt voor alle 
hulp tijdens mijn promotie en voor het extra-tandje-erbij bij de afronding!
Astrid, bedankt voor jouw logistieke en andere hulp bij het organiseren van NPO’s, 
huisbezoeken, scansessies enz.!
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Tanja en Carla: bedankt voor jullie ondersteuning en harde werk tijdens de vele 
patiëntencontacten! 
Claire, bedankt voor de leuke samenwerking binnen PSI/LeARN!
 
Marjolein H., we hebben elkaar niet zo vaak ‘in person’ gezien de afgelopen jaren 
maar we hebben samen wel een erg leuke tijd gehad in Riga (oa. in die Amerikaanse 
eettent haha) en gelukkig bestaat er social media die veel mogelijk maakt! Veel 
succes met de opleiding verder!
Alle andere collega’s van divisie 1 wil ik eveneens bedanken voor de leuke tijd 
samen!
I would also like to thank my German colleagues: Eckart, we had some nice low-level 
conversations im Seecasino, thanks for your daily help in choosing the right sausage 
for lunch. Kim and Niels (and later: Boris), we had a great time together in the 
summer of 2012! I enjoyed our FSL-discussions and the little course we organized. 
Ozgur, our contact is limited but however valuable. It’s nice to have little boys who 
share the same age. Juraj, thank you for giving me the opportunity to work on the 
RIMCAD data.
Uiteraard en niet in het minst zijn er ook een heleboel mensen buiten Maastricht 
die het verdienen om hier vernoemd te worden:
Lieve Anneke, Moorsie, my BFF! Zo leuk dat we ineens terug in elkaars leven zijn 
gekomen - it was meant to be! Heerlijk om samen ADA te zijn en uren met jou te 
messagen, bellen of chatten. YOLO! Elkaar in het echt zien is natuurlijk nog veel 
beter maar dan lukt het ongeneerd praten niet zo goed door die 4 kleine varkentjes 
van ons. Ik hoop dat ik nog vaak spreuken mag sturen omdat je overtijd gaat.. en 
dat jij nog vaak (kuch) als eerste op de materniteit kan staan. Voor de geur alleen al, 
toch? :) (ps: wa IS dees?!).
Lieve Ellen S. aka foefie, we kennen elkaar nu zo’n 13 jaar (say whaaaat?) en ik 
herinner me nog heel goed wat een leuke tijd we hebben gehad op de PHL. Fully 
open, samen met Mie. Ik ben blij dat we nog steeds contact hebben en dat we 
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elkaar bij leuke en minder leuke dingen altijd weten te vinden. 2014 kan niet meer 
stuk, jullie wens mag eindelijk uitkomen… en die van Fre en mijzelf dus ook een 
beetje! Muchos besos voor jou en Steve-man!
Lieve Ellebelle, hoe krijgen we het toch voor elkaar om telkens weer dezelfde keuzes 
te maken in het leven? Zo fijn om een blond kopietje van mezelf te hebben! Tha 
blond and tha brunette! Foreva! Ik kan heel wat wist-je-datjes gaan bedenken maar 
eentje blijft essentieel: groene fluostift + tranen = gele fluostift (ik WIST van bij het 
ontstaan van die spreuk dat deze ooit gepubliceerd ging worden: bij deze!) ;) Keep 
on shining Miss van Criekinge! En jij ook nog veel succes met afrondingsmanoeuvres 
– ik zal er zijn he! ;)
Lieve Stephanie T., Celine, Ann. R., Nathalie, Sylvie, Katrien V., Vroni - bedankt voor 
jullie oprechte interesse in mijn doen en laten van de afgelopen 4 jaar. Een mens 
kan zich geen betere vriendinnen wensen!
Graag wil ik ook mijn bredere familie en schoonfamilie bedanken voor hun interesse 
in de ongetwijfeld vaak abstracte inhoud van mijn job. Fijn dat jullie vanuit de 
kantlijn zo enthousiast wilden mee supporteren!
Steven, dank je wel voor het prachtige ontwerp van de kaft! Een half uurtje hebben 
we hiervoor samen gezeten – ik probeerde mijn vage ideeën zo goed mogelijk over 
te brengen en jij noteerde HELEMAAL NIETS. Ik wachtte rustig (en toch ook wat 
sceptisch) af tot ik enkele weken later een knaller van een cover toegestuurd kreeg 
- ongelofelijk! PAL EROP! Exact wat ik wou en dat zonder enige voorkennis en met 
een schamele uitleg – dat kan alleen een echte professional. 
Kristof, lieve schoonbroer (of is het schoonboer???), fijn dat we op tijd en stond 
eens nuchter (?) kunnen kletsen over het reilen en zeilen binnen onze beide jobs. 
Hoewel erg uiteenlopend weten we allebei wat het is om gebeten te zijn door ons 
vak, hard te werken en een heel klein beetje veel work-a-holic te zijn. Ik vind het 
heerlijk om zo een leuke schoonboer te hebben! Bedankt om bovendien zo’n leuke 
peter/nonkel te zijn voor onze kids!
Nico, je suis heureuse que tu fasses partie de la famille. Tu es l’homme grâce à qui 
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ma petite soeur n’a pas mal tourné! :) Et n’oublie jamais: kleine t**** and dikke 
p***! :)
Elisabeth, lieve schoonzus, wat heerlijk dat jij er plots bijkwam. Eindelijk iemand 
waarmee ik ongegeneerd kon kletsen, shoppen en chocola eten. Een lieve tante Bee 
voor ML, een uitmuntende metie voor Maurice en een geweldige vriendin voor mij. 
Ik hoop dat we samen nog veel stukken chocola kunnen kraken, voor-, tijdens en na 
onze shoppinguitjes!
Sonia, lieve zus, we kennen elkaar ondertussen iets minder dan 30 jaar en hoewel 
we 400km uit elkaar wonen, toch slagen we er telkens in om bij belangrijke 
gebeurtenissen bij elkaar op de 1e rij te staan. Mijn jeugd had er heel anders uit 
gezien zonder jou erbij, dank je voor alle leuke momenten en ook om ze allemaal 
te onthouden zodat we ze nu elke keer weer opnieuw kunnen beleven. A demain, 
portemonnaie vous bien.. En dan? :) Ma das de wiiinnnddd! :p ML kan zich geen 
betere meter wensen en ik geen betere zus. Sokke, you rock BIG time! 
Marc en Monique: schoonouders krijg je er gratis bij - Wel, voor jullie had ik gerust 
heel wat willen bijbetalen! Ongelofelijk hoe goed het tussen ons allemaal klikt en 
wat voor een prettig gestoorde bende we samen zijn. Ik hoop dat we nog vaak 
samen kunnen ‘zakdoek leggen’ op Italiaanse (of andere) bodem. Marc, bedankt 
om ons telkens op culinair en ander vlak in de watten te leggen, geen zalm is veilig 
in jouw buurt! Monique, mémé, mijn respect voor jou is eindeloos. Ondanks het 
ziek zijn, de pijn en de moeilijke periodes sta je toch altijd klaar om ons te helpen 
als dat nodig is. 100km rijden om mijn achterstallige berg strijk te komen doen 
geschiedt met de glimlach, ML en M opvangen, een luisterend oor bieden en een 
flinke dosis amusement voorzien; niets is teveel gevraagd. Mede dankzij jou (jullie) 
is dit doctoraat geworden wat het vandaag is en daar kan ik je niet genoeg voor 
bedanken!
Mijn rotsen in de branding: mama en papa! Eerst en vooral sorry voor het bloed, het 
zweet en de tranen die ik jullie gekost heb tijdens mijn kleuter-, tiener- en puber-tijd. 
Vechten om niet naar het oudercontact te moeten gaan, moedeloos thuiskomen 
en ontvangen worden door een kind dat blijft volhouden dat ‘alles goed komt’. 
Maar hey, had ik gelijk of had ik gelijk? Duizend maal dank om me bij te sturen 
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waar nodig, maar toch ook vrij te laten in de keuzes die ik wou maken en uiteraard 
om mij alle kansen te geven! Bedankt om er altijd te zijn voor ML en M, om bij te 
springen waar nodig en om urenlang mijn klaagzangen te aanhoren (vooral tijdens 
mijn Leuven-tijd: ‘Ik ga effe wenen he, maar eet gerust verder ge moet ni naar mij 
kijken’). Papa, bedankt voor je bescheiden maar steeds übernuchtere kijk. Ik ben 
er zeker van dat er niemand is die met nog minder woorden zoveel duidelijk kan 
maken. Het is er gewoon altijd ‘boenk op’! Ookal zijn het vaak niet de zaken die ik 
op dat moment wil horen. Ik heb enorm veel bewondering voor alles wat je bereikt 
hebt in je leven en ook voor alles waar je tot op de dag van vandaag nog voor gaat. 
Hoezo maar ene keer per verlof de Ventoux doen?! Mijn superpapa! Mama, er zijn 
maar weinig dochters die het geluk hebben dat hun moeder EN een moeder EN een 
beste vriendin is. Er is niets waarmee ik bij jou niet terecht kan. Wellicht kunnen 
we vaak met veel minder woorden iets aan elkaar duidelijk maken maar hey wat 
hindert dat, happytime nemen wij gewoon heel letterlijk. Ik kan nog pagina’s vullen 
maar het boekje is uiteindelijk al dik genoeg dus het volstaat om hier af te ronden 
met een welgemeende dankjulliewel en een ‘ikziejullieongelofelijk graag’! 
Fre, schattie, hubbie, ondertussen zijn wij al meer dan 6 jaar samen en ik kan me 
niet herinneren dat ik mij ooit 1 seconde verveeld heb. Sinds april 2008 staat de 
funmode in mijn leven permanent aan. Het dagelijks leven met jou en de kids 
is gewoon DE MAX! Ik hoop dat wij, 2 prettig gestoorde psychologen, nog veel 
crazy avonturen samen kunnen beleven. Soms (heel soms dan wel) zijn woorden 
overbodig: Ik hou zielsveel van je!
En dan nu de aller aller aller allerbelangrijkste persoontjes in mijn leven: DE KIDS! 
Lieve	Marie-Lou	en	Maurice,	
Zonder	jullie	…	was	het	zéééér	zéker	OOK	gelukt…	haha!	Grapje!
Marie-Lou,	Louke,	Louisie,	pippi	langkous,	mijn	mooie	lieve	prinses:	jij	bezorgt	papa	
en	mij	al	meer	dan	3	jaar	topentertainment	van	de	bovenste	plank.	Mijn	liefde	voor	
jou	en	broer	is	grenzeloos.	Ik	hoop	dat	we	nog	vaak	samen	kunnen	shaken	op	K3	en	
dat	ik	nog	vaak	voor	jou	slaapwel	verhaaltjes	mag	verzinnen.	Lieve	meid,	ik	kijk	uit	
naar	alles	wat	nog	komt	en	ben	superfier	elke	dag	opnieuw	jouw	mama	te	mogen	
zijn.	Love	you	van	hier	tot	aan	de	maan	en	terug!
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Maurice,	Mr.	Mau,	Maurizio,	 broeder	 Tuc,	 stoere	man	 van	me:	 vanaf	 de	 eerste	
minuut	was	 ik	totaal	aan	jou	verhangen.	Jouw	grote	donkere	deugenieten-kijkers	
doen	me	elke	dag	opnieuw	beseffen	wat	écht	belangrijk	 is.	 Ik	hoop	dat	 jij	en	zus	
nog	 vaak	 apenkuren	 gaan	uithalen	 en	 ons	 huis	 overhoop	gaan	 zetten	 -	 gooi	 die	
dvd’s	 maar	 allemaal	 door	 de	 kamer,	 haal	 die	 kasten	 maar	 leeg!	 Ik	 kijk	 er	 naar	
uit	om	ook	dan	weer	 samen	met	papa	de	uitdaging	aan	 te	gaan	 in	het	heerlijke	
opvoedingsavontuur.	Want	sinds	jij	in	onze	leven	bent	is	die	uitdaging	wel	minimaal	
verdriedubbeld!!!	Love	you!

